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Summary 
Immune surveillance by T cells is an important component of body’s defense against infection 
and disease, whereas the peripheral immune tolerance is important for defense against self-
reactive T cells. The fine balance between the two is skewed in cancer, whereby the tumors 
exploit the immune tolerance mechanisms to escape recognition and elimination by the 
cytotoxic T lymphocytes (CTLs). One of the major routes of immune resistance of tumor cells 
is mediated by cell surface bound ligands that engage immune-inhibitory receptors on T cells. 
Targeting these immune-checkpoint ligands that inhibit immune rejection, e.g. via blocking 
antibodies, can restore immune surveillance and increase the efficacy of cancer 
immunotherapy. However, only a few such targets have been identified so far.  
The aim of this thesis was to establish a high-throughput screening assay that enables a rapid 
and comprehensive identification of cell surface genes with immune modulatory function in 
selected tumors. To this end, a tumor cell-T cell co-culture assay was established which 
combines siRNA-based gene knockdown with a luciferase-based assessment of T cell-
mediated tumor cell killing. Applied to three independent parallel screens, this study 
uncovered a repertoire of novel and robust immune modulatory ligands on breast cancer cells 
that are also abundantly expressed by other cancer types. Amongst them, CCR9 was 
functionally validated as a strong inhibitor of T cell function and suppressor of T cell 
reactivity against breast cancer, malignant melanoma and pancreatic cancer. Knockdown of 
CCR9 resulted in increased tumor susceptibility towards immune lysis by antigen-
experienced T cells along with the increased production of effector cytokines and cytolytic 
enzymes. CCR9-induced gene expression changes in the encountering T cells were consistent 
with an enhanced effector T cell phenotype. Mechanistically, CCR9 regulated T cell effector 
function through differential activation of the STAT signaling pathways, thereby representing 
a unique example of an alternative, TCR-independent route for effective immune suppression 
induced by a cell surface molecule. Additionally, the in vivo relevance of targeting CCR9 for 
adoptive cancer immunotherapy was explored in this study. 
Taken together, this study describes a rapid, high-throughput, siRNA-based screening 
approach that allows a comprehensive identification of immune-modulatory genes which, as 
an entity, represents the ‘immune modulatome’ of cancer. Screening additional tumor types 
for their immune modulatory signatures would help in uncovering additional targets for 
therapeutic inhibition. 
  
Zusammenfassung 
T-Zellen spielen eine wichtige Rolle bei der Abwehr von Pathogenen und Krankheiten, die 
periphere Toleranz hingegen schützt vor selbst-reaktiven T-Zellen. Das Gleichgewicht 
zwischen diesen beiden Mechanismen ist bei Krebserkrankungen gestört und der Tumor nutzt 
die Mechanismen der peripheren Toleranz, um der Erkennung und Eliminierung durch 
zytotoxische T-Zellen zu entgehen. Einen der wichtigsten Mechanismen stellen dabei 
Liganden auf der Zelloberfläche der Tumorzellen dar, die inhibitorische Rezeptoren auf T-
Zellen binden. Ein Blocken dieser immune-checkpoint- Liganden, zum Beispiel mittels 
Antikörpern, kann das Erkennen des Tumors durch das Immunsystem wiederherstellen und 
die Effizienz von Immuntherapien erhöhen. Bisher wurden nur wenige dieser Liganden 
identifiziert. 
Das Ziel dieser Doktorarbeit war die Entwicklung eines Hochdurchsatz-Screens zur schnellen 
und umfassenden Identifizierung von Molekülen mit immunmodulierender Wirkung auf der 
Oberfläche von Krebszellen. Zu diesem Zweck wurde die Kokultur von Tumorzellen und T-
Zellen mit einem siRNA basiertem knockdown kombiniert. Das Töten der Tumorzellen durch 
die T-Zellen wurde dabei mit einem Luciferase-Assay gemessen. Mit Hilfe dieser Methode 
wurden in drei voneinander unabhängigen Screens neue immunmodulierende Liganden auf 
Brustkrebs-Zellen gefunden, die jedoch auch auf anderen Tumorentitäten überexprimiert sind. 
Von den Liganden wurde CCR9 als ein starker Inhibitor der T-Zell Antwort gegen Zellen aus 
Brustkrebs, malignem Melanom und Pankreaskarzinom funktional validiert. Der knockdown 
von CCR9 führt zu einer größeren Empfänglichkeit der Tumorzellen gegenüber einer Lyse 
durch Antigen-erfahrene T-Zellen sowie zu einer erhöhten Produktion von Effektor-
Zytokinen und lytischen Enzymen der T-Zellen. Eine Genexpressions-Analyse der T-Zellen 
zeigt einen verstärkten Effektor-Phänotyp nach knockdown von CCR9 in den Krebszellen. 
Mechanistisch reguliert CCR9 die T-Zell Effektor-Funktionen über die differenzielle 
Aktivierung von STAT-Signalwegen. Dies stellt einen alternativen, von 
Oberflächenmolekülen aktivierten Suppressions-Mechanismus dar, der vom Signalweg des T-
Zellrezeptors unabhängig ist. Zusätzlich wurde die Relevanz von CCR9 für eine adoptive 
Immuntherapie in vivo untersucht. 
Diese Arbeit beschreibt einen Hochdurchsatz-Screen zur umfassenden Identifikation von 
immunmodulierenden Molekülen, die in ihrer Gesamtheit das „Immun-Modulatom“ von 
Krebs darstellen. Die Untersuchung der immunmodulierenden Signatur weiterer 
Tumorentitäten kann zusätzliche Ziele für eine verbesserte Immuntherapie hervorbringe.
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1. Introduction 
1.1 Cancer  
In the present day world where at least one out of every 5 person suffers from cancer, cancer 
is a household subject that requires little introduction. More than 8.2 million deaths were 
accorded to cancer in 2012 worldwide (1). Amongst this, breast cancer, which results from the 
neoplasm arising from the inner linings of the milk ducts or lobules of the healthy breast 
tissue, has been the most frequently diagnosed form of cancer in women and the leading cause 
of cancer-related mortality with 522,000 deaths reported in 2012 (1). But cancer is more than 
just this mere representation of staggering statistics. Sun Tzu, an ancient military general and 
strategist, in his book titled ‘The Art of War’ said: “If you know neither the enemy nor 
yourself, you will succumb in every battle”. This age-old wisdom for successful combat also 
applies to our current fight against cancer where ‘knowing thy enemy’ would be the first 
milestone towards successful cancer therapy.  
 
Cancer is the malignant transformation of a normal cell to a state of uncontrolled proliferation 
that is capable of propagating throughout the body, infringing on the normal functioning of 
healthy organs and thereby endangering the survival of the host. In 2000, Douglas Hanahan 
and Robert Weinberg (2) fittingly summarized the complexity of cancer to six key hallmark 
signatures according to which cancer cells: i) stimulate their own growth; ii) resist anti-growth 
signals; iii) inhibit their programmed cell death (apoptosis); iv) stimulate the growth of blood 
vessels in order to fetch nutrients (angiogenesis); v) multiply uncontrollably; and vi) can 
invade to local and distant sites (metastasis). Their oversight of the role of the immune system 
in shaping tumor progression was rectified in a follow-up publication a decade later (3), 
whereby they added two new additional hallmarks of cancer as: vii) evading the immune 
system; and viii) deregulating the metabolic circuitry.  
 
Despite the fact that considerable progress has been made over the last decade in dissecting 
the molecular basis of cancer, a great deal of knowledge still remains to be acquired regarding 
the complex interplay between the tumor and the host, as well as its regulation thereof. In a 
broader sense, this thesis is focused on knowing thy enemy in which I attempt to further 
characterize cancer to the next level by defining its immune modulatory properties. But before 
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going into that, it is important to understand how the immune system plays a role in cancer 
development. 
1.2 Anti-tumor immunity 
The theory of immunosurveillance, put forward by Burnet and Thomas way back in the 
1950s, underlines the fact that the host immune system is capable of recognizing the 
transformed self-cells right at the early stage of tumor development (4). Over time this theory 
has found increased experimental validation and reinforcement, with both the innate and the 
adaptive arms of the immune system being shown to play a role in controlling tumor 
outgrowth. In fact the occurrence of tumor antigen-specific T cells in the tumor 
microenvironment is a predictive biomarker for improved survival in cancer patients, 
especially for melanoma and colorectal cancer patients (5, 6). Generation of anti-tumor 
immunity, however, is a multi-step process described in the so-called ‘Cancer Immunity 
Cycle’ (Figure I) (7): 
 
i. For mounting an effective immune response, first the tumor-associated neo-antigens 
have to be released so that they can be captured, processed and presented by the 
professional antigen presenting cells (APC), such as dendritic cells (DC), present in 
the tumor bed. Immunogenic cell death inducers, such as certain chemotherapeutic 
agents and radiotherapy, aid in this antigen release process (8). Tumor-associated 
antigens (TAAs) that are recognized by the immune system can be broadly classified 
into six categories: overexpressed self antigens (such as EpCAM, survivin), cancer 
testis antigens (such as MAGEA1), tissue differentiation antigens (melanosome-
related antigens such as MART1), chromosomal breakpoint antigens (such as BCR-
ABL), mutated self-antigen (such as mutated KRAS or p53) and finally oncogenic 
virurs-encoded antigens (such as HPV-16 virus encoded E6 and E7). Whole genome 
exome sequencing has revealed that the success of generating high frequency antigen-
specific anti-tumor immune response is correlative to the mutational frequency of 
certain tumors, especially in case of melanoma, colon and lung cancer (9, 10) which 
have been shown to harbor higher mutations per megabase (11). 
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ii. Following the uptake of antigen, DCs undergo maturation, receiving stimulatory 
signals from the proinflammatory cytokines and co-signaling receptors (such as TNF-
a, IFN-a, ATP from dying tumor cells, CD40/CD40L interaction). This results in 
mature DCs that are capable of processing and presenting the antigenic peptides on 
their surface bound to the MHC-I or MHC-II molecules. 
 
iii. MHC receptor-bound peptides are then presented by DCs to the naïve T cells in the 
lymph nodes to prime the T cell response against the presented antigen. The nature of 
the immune response is determined at this stage depending on whether immune 
tolerance is induced towards the presented antigen (mediated by regulatory T cell 
priming and expansion) or anti-tumor immunity is induced (leading to effector T cell 
generation). 
 
iv. Effector CD8+ T cells primed in the above stage then migrates to the tumor site by 
virtue of chemokine and chemokine receptors, such as CXCL9 and CXCL10 (ligands 
for CXCR3) or CCL5 (ligand for CCR5) among others (12).  
 
v. The next challenge for the immune cells is to infiltrate the tumor bed by crossing 
through the endothelial barrier, which is achieved via the virtue of adhesion molecules 
such as LFA1, ICAM1, selectins etc.  
 
vi. Once in the tumor microenvironment, the effector T cells then have to recognize and 
bind to their tumor targets through interaction between its antigen-specific T cell 
receptor (TCR) and the MHC-I bound cognate antigen on the tumor cell surface.  
 
vii. Finally, antigen-recognition and binding activates the downstream TCR signaling in 
these antigen-specific cytotoxic T lymphocytes (CTLs), leading to the release of 
effector cytokines such as interferon-gamma (IFN-γ), interleukin-2 (IL-2) and 
cytolytic granules containing enzymes such as granzyme-B and perforin. These 
effector mechanisms not only bring about the tumor lysis, but also result in the release 
of fresh antigens that can be taken up by surrounding APCs for re-initiating the 
immune response cycle.  
Introduction 
Page 4 
 
 
 
Figure I. Cancer immunity cycle detailing the seven-step process involved in the generation of an anti-tumor 
immune response. Individual steps are detailed in the text above. Adapted from Chen et al, 2013 (7).  
1.3 Cancer despite immunosurveillance: the 3E’s of cancer immune-editing  
Given that the immune system can recognize and eliminate malignant self-cells in a specific 
manner, early immunotherapists anticipated distinct clinical responses in tumor patients upon 
adoptive cellular transfer of high numbers of autologous, tumor-reactive T cells. However, 
early clinical studies involving adoptive immune cell-based therapies produced mediocre 
results at the very best, driving the clinicians back to benchside to look for the answers to 
explain the lackluster performance of T cell-based therapies (13). It soon became apparent 
that immune surveillance in patients runs in parallel with tumor-mediated immune evasion 
and that the relatively transient equilibrium between these two now forms the basis of the 
modified theory of ‘immune-editing’ (14). The principle of immune-editing recognizes the 
fact that tumor development and progression is a process guided and molded by the host 
immune system right from the early stage, involving the 3E-phases: elimination, equilibrium 
and escape. Nascent transformed cells are under attack by the host’s innate defense 
mechanisms involving NK cells, macrophages and neutrophils; all of which are capable of 
recognizing and eliminating the transformed host cells to maintain cellular homeostasis. 
Following this, in the equilibrium stage the transformed cancerous cells recognize and adapt 
to the immune selection pressure leading to the loss of MHC molecules, downregulation of 
surface antigens, defects in the antigen-presentation machinery, all in order to avoid the 
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immune attack. If the tumor cells succeed in tilting the balance in their favour during this 
equilibrium stage, immune-escape variants of the tumor emerge that are further equipped to 
escape immune surveillance. Therefore, targeting these immune escape mechanisms in 
conjunction with conventional immunotherapeutic approaches to reactivate the immune 
system would be crucial for realizing the full potential of cancer immunotherapy in clinics. 
But in order to achieve that, elucidation of the tumor-mediated immune escape pathways is 
imperative. 
1.4 Immune-escape pathways 
Peripheral immune tolerance is an integral component of a healthy body’s defense program 
against self-reactive immune cells. However, in diseased state, these pathways are hijacked by 
the cancer cells to thwart and escape the immune response. Basically, every step in the cancer 
immunity cycle, described above in Figure I, is susceptible to escape routes mediated by the 
tumor. The means of tumor-mediated immune escape are as varied and complex as the anti-
tumor immunity itself and are described here in some detail. 
1.4.1 Impairment of antigen-presentation by tumors 
CD8 effector T cells recognize their tumor targets for clearance only in context of the peptide-
bound MHC (pMHC) complex. This therefore requires the appropriate processing of the 
tumor antigens to relevant epitope-harboring peptides which can be presented on the cell 
surface in MHC-I grooves for recognition by CTLs. In this regard, tumors can escape 
recognition by CTLs via two possible routes (Figure II): 
• Down-regulation or loss of antigen: Occurs via genetic deletions or frequent mutations 
to alter the immune-dominant epitopes on the antigen, leading to immune-escape 
tumor variants that can evade immune surveillance (15). 
 
• Defects in the antigen-presentation machinery: Not only can tumor cells loose or 
mutate their immunogenic peptides, but they can also downregulate the MHC-I 
molecule, via deletion or frame-shift mutations in the beta 2-microglobulin gene 
(β2m), so that the antigen is not even presented on the tumor cell surface for 
recognition by antigen-specific effector T cells (16). Loss of HLA alleles has also 
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been reported in multiple cancers, including colorectal carcinoma and melanoma, 
aiding in immune escape (17). Furthermore, cellular components of the antigen-
processing machinery and of the immunoproteasome (such as transporter-associated 
with antigen processing: TAP or LMP2, LMP7) can be mutated leading to defective 
antigen presentation by the tumor cells (18). 
 
 
 
Figure II. Mutations in the cellular proteins responsible for antigen processing and presentation (β2m, MHC, 
TAP) may result in the failure of target antigen’s presentation by the tumor cells, thereby leading to an inhibition 
of T cell’s reactivity against their tumor targets. Adapted from Hinrichs et al, 2013 (19). 
1.4.2 Elaboration of soluble immune-suppressive mediators 
Tumor and the stromal cells in the tumor microenvironment secrete a plethora of immune-
suppressive cytokines, growth factors and metabolites that are capable of actively silencing an 
effector anti-tumor T cell response, or creating an immune-suppressive environment around 
the tumor bed for maintaining immunological anergy against the developing tumor. These 
soluble mediators and their role in immune suppression are summarized below in Table I. 
Agents Role in immune suppression 
TGF- β Inhibits T-cell activation, proliferation and differentiation (20) 
VEGF Suppresses T-cell adhesion to tumor endothelium and prevents homing to tumors (21) 
IL-10 
Reduces antigen presentation by downregulating TAP1 and TAP2, reduces Th1 
cytokine secretion, induces regulatory T cells (Treg) and impairs DC function (22) 
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Prostaglandin E2 
(PGE2) 
Impairs the ability of DCs to attract and activate naive T cells, induces accumulation 
and function of regulatory immune cells and impairs CTL activation (23) 
Indoleamine 2,3-
dioxygenase (IDO) 
and Arginase 
Involved in the catabolic degradation of tryptophan and L-arginine respectively, 
depletion of which in the tumor surrounding leads to an inhibition of T cell 
proliferation (24, 25). 
 
Table I. Soluble immunosuppressive mediators released by the tumor cells and their role in immune escape. 
 
1.4.3 Specific recruitment of the immune-regulatory cell populations 
Besides active subversion of the effector T cell responses via secretion of immunosuppressive 
mediators, tumors can also enrich their microenvironment by deploying cell populations to the 
tumor bed that promote tumor progression, along with maintaining immunogenic anergy and 
suppression. Such cell populations mostly include regulatory T cells (Tregs), immature and 
plasmacytoid dendritic cells (iDCs, pDCs), myeloid-derived suppressor cells (MDSCs), 
mesenchymal stem cells (MSCs) and tumor-associated macrophages (TAMs). 
• Regulatory T cells (Tregs): These subset of CD4 T lymphocytes are marked by 
CD25hi FOXP3hi expression and are typically involved in maintaining immune 
homeostasis and peripheral tolerance against self-antigens. However, in the case of 
tumor progression, they are preferentially recruited to the tumor microenvironment 
over effector T cells to suppress effector T cell function and maintain immune 
tolerance against the tumor antigens. Local accumulation of Tregs has been correlated 
to poor survival in many cancer types including gastric, esophagus, breast and ovarian 
cancer (26-29). They can suppress anti-tumor immunity through plethora of 
mechanisms (briefed in Figure III), for example via immune-inhibitory surface 
molecules like CTLA4, LAG3 (detailed in 1.4.4), or via soluble mediators such as 
TGF- β and adenosine (30). 
 
 
 
Figure III. Potential modes of Treg-mediated immune suppression which includes: DC impairment via 
inhibitory receptor engagement, cytokine deprivation, competitive inhibition of the effector T cells, inhibitory 
cytokine and metabolite production (IL-10, IDO, adenosine) and direct cytolysis of the effector T cells. Adapted 
from Caridade et al, 2013 (31). 
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• Immature and plasmacytoid dendritic cells (iDCs and pDCs): iDCs are those dendritic 
cells that leave the bone marrow and express very low levels of the co-stimulatory 
molecules CD80 or CD86 that results in poor maturation of the DCs and subsequent 
impairment of T cell activation. They produce little or no amount of IL-12 which is 
required to support T cell proliferation. As a result, accumulation of these immature 
DCs in the tumor microenvironment leads to immune escape (32, 33). Plasmacytoid 
DCs (pDCs) on the other hand are a small subset of dendritic cells that are believed to 
actively suppress T cell response in the tumor tissues (34). They induce the expression 
of the immunosuppressive mediators IL-10 and IDO that inhibits the clonal expansion 
of effector T cells and promotes T cell apoptosis. Besides, they also favor the growth 
and expansion of Tregs, adding to their immunosuppressive profile (35). Overall, the 
lack of proper costimulatory signal in these defective DCs induces tolerance towards 
the recognized tumor antigen, leading to T cell anergy rather than anti-tumor T cell 
response. 
 
• Myeloid-derived suppressor cells (MDSCs): These are immature myeloid cells with a 
heterogeneous hierarchy and often found to be elevated in inflammation and cancer. 
Tumor associated growth factors and cytokines, such as CCL2, CXCL12, and 
CXCL5, support the recruitment and proliferation of MDSCs in the tumor bed, while 
in return MDSCs suppress the host immune system via production of arginase, 
inducible nitric oxide synthase (iNOS), IDO and immunosuppressive cytokines that 
negate CTL function (36). Elevated levels of MDSCs have been shown to correlate 
with poor survival in many tumor types (37). 
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• Mesenchymal stem cells (29): These are immuneprivileged, multipotent stem cells 
found in adult connective tissues and bone marrow with the capability of 
differentiating into any cell type of mesodermal lineage (38). Injection of human 
MSCs into the tumor-bearing BALB/c mice have shown that MSCs exert immune-
protection by inhibiting DC maturation as well as T cell proliferation, promoting 
apoptosis of effector CTLs, secreting immunosuppressive factors like PGE2, IDO and 
by increasing Treg proportion (39, 40). 
 
• Tumor-associated macrophages (TAM): Macrophages are mononuclear phagocytic 
cells of the myeloid lineage which are characterized by their phenotypic plasticity 
depending on the microenvironment. Classically activated (M1) macrophages are anti-
tumoral in nature, whereas alternatively activated (M2) macrophages support tumor 
growth and immune-suppression (41). TAMs are an integral cellular component of the 
inflamed, heterogeneous tumor microenvironment where they acquire an M2-like 
phenotype. Besides secreting tumor promoting growth factors, they also actively 
suppress anti-tumor immunity by secreting immunosuppressive mediators such as 
iNOS, arginase, IL-10, as well as by defective antigen presentation and inhibition of T 
cell proliferation (42). 
1.4.4 Activation of negative co-stimulatory signals on the immune cells – the case of 
immune modulatory ligands 
Tumors can engage the T cells directly via their immune-modulatory receptors and ligands on 
the cell surface, which provide negative co-stimulatory signal to the interacting T cells. This 
subsequently leads to the inhibition of TCR activation and downstream signaling and 
sometimes even apoptosis of the reactive T lymphocytes. In a healthy state, these immune-
inhibitory switches serve as fail-safe mechanisms of immune-modulation that control over-
activation of T cell responses and limit autoimmunity. However, in the diseased state of tumor 
progression, these immune-checkpoint nodes are exploited by the malignant cells to shut 
down and inactivate the anti-tumor immune response. Of such inhibitory pathways, CTLA4- 
CD80/CD86 and PD1-PDL1 axis have gained major prominence in the last decade for 
elucidating the immunosuppressive potential of such negative interactions. Therapeutic 
blocking of these immune-checkpoint entities now represents one of the most attractive 
paradigms of cancer immunotherapy (43). 
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1.4.4.1 CTLA4-CD80/CD86 axis 
Biology and the functional role: 
Cytotoxic T lymphocyte antigen 4 (CTLA4, also known as CD152), expressed on the 
activated T cells, is a cell surface receptor belonging to the immunoglobulin superfamily. 
Structurally, it is a homolog of the T cell co-activation receptor CD28, even binding to the 
same ligands - B7-1 (CD80) and B7-2 (CD86) which are expressed on the specialized APCs - 
but with higher affinity (44, 45). However, functionally it is an exact opposite. It possesses a 
cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM) domain which, upon 
successful engagement with its respective ligand on the APCs, recruits SHP family of 
phosphatases to reverse TCR activation-induced phosphorylation of signaling molecules and 
thereby serves to limit the T cell response. Role of CTLA4 in immune inhibition is further 
exemplified by Ctla4-/- mice that develop fatal multi-organ destruction due to uncontrolled 
lymphocyte proliferation and infiltration (46, 47). 
 
Role in tumor immune biology: 
Even though tumours can present antigens in the context of MHC molecules, they still elicit 
insufficient immune response. One of the reasons for this was believed to be the lack of co-
stimulatory signals provided by B7-CD28 interaction, as the expression of B7 ligands are 
restricted to specialized APCs. However, it is now known that even tumors that express B7 
ligands elicit only partial immune response (48). Work from James P. Allison’s group using 
B7+ve and B7-ve murine colon carcinoma cells has shown that the expression of immune 
inhibitory CTLA4 on tumors can explain the lack of immune reactivity against B7-positive 
tumors. Furthermore, inhibition of CTLA4-mediated negative stimulatory pathway could not 
only lead to tumor regression, but also result in immunological memory (49). Targeting 
CTLA4 therefore lowers the threshold of T cell activation and promotes expansion and 
maintenance of activated T cells. Moreover, Treg-specific CTLA4 deficiency leads to 
systemic lymphoproliferative disorder, indicating that CTLA4 is also crucial for the 
suppressive function of natural Tregs (50) and that targeting CTLA4 using antibody therapy 
might further aid in clinical immune response (Figure IV). 
 
Blocking antibodies and clinical success: 
Based on the above rationale, clinical trials have been conducted with ipilimumab, a human 
IgG1 anti-CTLA4 blocking antibody, whereby an overall response rate of 10.9 % has been 
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noted in patients with advanced melanoma (51). It is the only treatment to date for advanced 
metastatic melanoma patients whereby 46% of the treated patients are disease-free after 1 
year, as opposed to the 1-year survival rate of 25% with alternative treatment modalities (52). 
Encouraged by these durable responses, FDA approved ipilimumab in 2011 as a first-in-line 
treatment option for advanced melanoma (53). Notably, about 80% of the patients treated with 
ipilimumab presented adverse toxicity-related events which could be traced back to the 
serious autoimmune phenotype of Ctla4-/- mice, highlighting the central role of CTLA4 in 
immune tolerance. Interestingly, treatment-related adverse events in some of these patients 
were found to be correlated with improved patient outcome, underscoring the need for 
modified treatment-evaluation parameters for immunotherapy trials (54, 55). 
 
 
 
Figure IV. (A) The interaction between the B7 ligands, on the surface of APCs, and CTLA4, on the surface of T 
cells, leads to the inhibition of TCR signaling in activated T cells. (B) Blocking this interaction by using the anti-
CTLA4 antibody (ipilimumab) allows for enhanced T cell stimulation and anti-tumor response. Adapted from 
Mellman et al, 2011 (56). 
 
1.4.4.2 PD1-PDL1 axis 
Biology and the functional role: 
Programmed death receptor 1 (PD-1, also known as CD279) is an inhibitory co-signaling 
receptor which also belongs to the CD28-B7 family of proteins. It is induced only upon 
activation on the surface of T cells, B cells, natural killer T cells, monocytes and dendritic 
cells (57). It pre-dominantly binds to its ligands PD-L1 (also known as B7-H1 or CD274) and 
to some extent to PD-L2 (also known as B7-DC or CD273), both of which are cell surface 
proteins that are constitutively expressed on the APCs and inducible on epithelial and 
endothelial cells upon inflammation (58). Besides the ITIM motif, PD-1 also contains a 
cytoplasmic immunoreceptor tyrosine-based switch motif (ITSM) domain, which recruits the 
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SHP2 phosphatase to dephosphorylate the TCR-induced phosphorylation event. Ligation of 
PD-1 with PD-L1 (or PD-L2) therefore transmits an inhibitory signal into the T cell, which 
reduces cytokine production, T-cell proliferation and promotes apoptosis of effector T cells, 
ultimately leading to the T cell ‘exhaustion’ (59, 60).  
 
Role in tumor immune biology: 
Tumors exploit this immune-inhibitory capacity of the PD-1/PD-L1 signaling axis by 
upregulating PD-L1 expression via the loss of tumor suppressor protein PTEN (61). 
Additionally, IFN-γ released by the activated T cells could also upregulate the expression of 
PD-L1 on tumor cells (62). Overexpression of PD-L1 has been demonstrated in many 
different cancer types (eg, melanoma: 40%-100%, non-small cell lung cancer: 35%-95%, 
breast cancer: 30-50%, pancreatic cancer: 40% and multiple myeloma: 93%), and high levels 
of PD-L1 expression have been correlated to poor clinical outcomes (63-66). Besides active 
inhibition of the T cell response, PD1-PDL1 signaling between the T cells and DCs can also 
polarize the nature of the immune response to a Treg phenotype (67), thereby further 
suppressing the anti-tumor immune response (Figure V).  
 
 
 
Figure V. PD-1 receptor, expressed on the activated T cells, binds to the ligands PD-L1 (or PD-L2) expressed on 
the tumor cells. PD-L1’s expression is induced by IFN-γ secreted by the activated T cells. PD1-PDL1 ligation 
inhibits the TCR-induced downstream signaling events in effector T cells, creating a phenotype known as T-cell 
exhaustion. PD1-PDL1 signaling in other immune subsets could also lead to pro-tumor immune escape. 
Illustration by Sznol et al. 2013 (66). 
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Blocking antibodies and clinical success: 
Given its critical role in immune suppression, cancer immunotherapy based on the targeted 
inhibition of PD-1 or PD-L1 is currently been explored in the clinics. In vitro studies with 
blocking antibodies against PD-1 or PD-L1 demonstrated higher cytokine production by the 
effector T cells, prolonged survival and proliferation, as well as higher cytolytic activity (68). 
Nivolumab, a humanized IgG4 monoclonal antibody against PD-1, was the first antibody to 
demonstrate broad and encouraging results in the phase I clinical trials with objective, and 
most importantly durable response rates, observed in 31% of metastatic melanoma patients, 
16% of non small cell lung cancer patients and 29% of metastatic renal cell carcinoma 
patients (69). These impressive preliminary results in previously-treated, late-stage cancer 
patients have ushered the PD-1 and PD-L1 based therapeutics for a fast track FDA approval 
that is anticipated this year.  
 
Combinatorial therapy: 
Adverse events associated with the PD-1 antibody therapy were less severe than those 
observed with anti-CTLA4 therapy and this can be explained in view of the distinct roles that 
CTLA4 and PD-1 play in immune regulation.  CTLA4 dampens the activation signal in T 
cells during the initial activation stage and fine-tunes the magnitude of early activation of 
naïve and memory T cells, while PD-1 functions to limit the activity of already activated T 
cells in the periphery in order to limit autoimmunity. Therefore, CTLA4 is more critical in 
establishing a central tolerance threshold for T cells activation, whereas PD-1 checks upon the 
activation status of already activated T cells (66). In light of these complementary pathways 
of immune regulation which are temporally and spatially distinct, combinatorial trials with 
nivolumab and ipilimumab are currently underway in advanced melanoma patients to exploit 
any potential synergistic effect that might result from co-inhibition of PD-1 and CTLA4. 
Early results report an objective response rate of 40% in these patients with rapid and deep 
tumor regression observed in many patients (70). 
1.4.4.3 Other immune modulatory ligands 
• FasL: Fas ligand (FasL or CD95L) is a type-II transmembrane protein belonging to 
the TNF family that interacts with its receptor Fas (CD95), triggering a cascade of 
subcellular events leading to the induction of apoptotic cell death of sensitive target 
cells (71). Fas/FasL interaction plays an important role in the activation-induced cell 
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death (AICD) of cytotoxic T cells. FasL-expressing tumors exploit this pathway for 
clearing effector T cells by inducing T cell apoptosis (72).  
 
• Galectins: Galectins are evolutionarily conserved glycan-binding proteins that bind to 
N-acetyllactosamine sequences on both N- and O-glycans on the cell surface (73). 
Galectins are expressed by multiple tumor types as well as by tumor stromal cells (73). 
Few of the galectin members have exhibited immunosuppressive function. Galectin-1 
has been shown to sensitize T cells towards FasL-induced apoptosis and suppression 
of Th1 responses (74). Tumor-associated galectin-3 has been shown to promote tumor 
growth and suppress tumor-reactive CD8+ T cells in mice receiving adoptive T cell 
transfer (75). Multimeric complexes of galectin-3 have also been shown to impose 
steric hindrance to TCR complex and restrain the TCR-induced activation signaling 
(76). Galectin-9, on the other hand, is believed to be the ligand for T cell 
immunoglobulin (Ig) domain and mucin domain 3 (Tim-3), a Th1-specific type 1 
membrane protein expressed on the cell surface of fully differentiated CD4+ Th1 cells 
(77). Binding of galectin-9 to Tim-3 results in an inhibitory signaling cascade 
downstream of Tim-3 leading to apoptosis of Tim-3 expressing Th1 cells. Tim-3 
expression on T cell surface has therefore been correlated with an exhausted immune 
status. Notably, recent evidences have emerged that suggest galectin-9 is not the 
ligand for Tim-3, leaving this field of investigation open for further in depth analysis 
(78). 
 
• LAG-3: Lymphocyte activation gene-3 (LAG-3) is a cell surface molecule expressed 
on a subset of immune cells. It has been shown to be important for the immune-
suppressive function of CD4+CD25+ Tregs (79). It has also been shown to be 
expressed on antigen-specific CD8+ T cells, restraining its accumulation and effector 
function at the tumor site. Antibody blockade of LAG-3 has been shown to alleviate 
the proliferative capacity and the effector function of antigen-specific CD8+ T cells, 
indicating its role in immune tolerance (80). Recently, it has been shown that LAG-3 
and PD-1 pathway act synergistically in maintaining tolerance towards both self and 
tumor antigens, providing strong rationale for co-inhibition in clinical studies (81). 
 
• CEACAMs: Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) 
are a part of the immunoglobulin superfamily which are characterized by their 
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involvement in cell-to-cell adhesion (82). Multiple members of the CEACAM family 
have been implicated in tumor progression and metastasis, including CEACAM-1 and 
CEACAM-6. CEACAM-1, which contains a cytoplasmic immunoreceptor tyrosine-
based inhibitory motif (ITIM), is expressed on T cells upon activation and inhibits 
TCR signaling, thereby modulating immune response (83). Recently, the host 
laboratory has shown the novel involvement of CEACAM-6 expression on multiple 
myeloma in suppressing the anti-tumor function and reactivity of T cells. Inhibiting 
CEACAM-6 with blocking antibody could effectively rescue the anti-tumor reactivity 
of patient-derived T cells (84).  
 
• RCAS-1: Breast cancer cells have been shown to express RCAS1 (receptor-binding 
cancer antigen expressed on Siso cells), which induces cell cycle arrest and apoptosis 
of activated T-cells via interaction through a putative RCAS1 receptor (85). 
 
Nevertheless, the immune-inhibitory interactions presented above do not necessarily represent 
an exhaustive list of pathways that tumor cells exploit to antagonize the anti-tumor T cell 
response. Treatment unresponsiveness has been noted in a good proportion of patients 
undergoing PD-1/PD-L1 or CTLA4 blockade therapy (51, 68, 69, 86). For example, about 
50% of the PD-L1-positive tumors failed to respond to treatment with MPDL3280A, an anti-
PD-L1 blocking antibody, in Genentech’s ongoing clinical study (87). Moreover, it has been 
shown that targeting PD1-PDL1 pathway alone does not always result in a complete 
restoration of T cell functionality (88), hinting at the involvement of other undefined immune 
regulators. Given that the tumors are inherently heterogeneous, probably even in their 
expression of immunosuppressive entities, there is a strong rationale to believe that other 
immune-checkpoint pathways may be active besides the ones that are being currently targeted 
in the clinics.  
 
Therefore, successful cancer immunotherapy in the future would require a systematic 
dissection of the entire immune-modulatory circuitry that regulates the magnitude of anti-
tumor immunity. However, such an approach towards a systematic and high-throughput 
delineation of novel immune regulators has been largely missing in the field.  
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1.5 High-throughput RNAi-based screen 
Genetic screens based on the principle of RNA interference (RNAi) have become a standard 
practice to uncover modifiers of biological phenomena in a high-throughput and systematic 
fashion (89). RNAi is an intracellular defense mechanism whereby messenger RNA is 
targeted for destruction by double-stranded RNA (dsRNA) which contains sequence 
homology to the targeted gene, leading to a block in translation of the transcribed mRNA and 
thereby resulting in gene silencing (90). Since its discovery in nematode worms 
Caenorhabditis elegans in 1998, it has become a powerful tool for experimentally-induced 
gene silencing protocols with an extended use in therapeutics (91).  
1.5.1 RNAi: principle and formats 
Small interfering RNAs (siRNAs) are the main effector molecules of the RNAi pathway that 
bring about the sequence-specific gene silencing (Figure VI). These are 21-28 nucleotide long 
RNA duplexes with 2-nucleotide long 3’-overhangs which are generated upon the cleavage of 
long dsRNA by RNase-III-type enzyme termed Dicer. These siRNA duplexes are then 
recognized by the RNA-induced silencing complex (RISC) which incorporates the anti-sense 
strand of the duplex into the complex and guides it to the complementary sequence on the 
target mRNA. Perfect complementarity between the target mRNA and the antisense strand of 
siRNA duplex leads to the cleavage and degradation of the mRNA by the RISC complex. 
Imperfect complementarity however results in a steric inhibition of the RNA translation 
machinery. Ultimately, both lead to posttranscriptional gene silencing of the targeted gene 
(92). Cellular source of an siRNA can be endogenous (endo-siRNAs) or processed from long 
dsRNAs of viral origin or can be introduced synthetically in an experimental set-up. On the 
other hand, microRNAs (miRNAs) are endogenously synthesized double stranded RNA 
molecules that are transcribed as a RNA-hairpin loop structure (pri-miRNA) initially that gets 
processed into 22-nt long miRNA duplex to mediate gene silencing in a similar fashion as 
siRNA (92). Exogenously introduced short-hairpin RNAs (shRNAs) or dsRNAs undergo 
similar processing by cellular machinery to get converted into direct effectors of gene 
silencing. 
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Figure VI. RNA interference (RNAi), mediated by siRNA or miRNA effector molecules, basically involves a 
RNA duplexes, one strand of which is complementary to the mRNA of the target gene (guide or antisense 
strand). The guide strand is imported into the RNAi-induced silencing complex (RISC) which consists of the 
Argonaute protein (AGO2). AGO2 cleaves the target mRNA upon perfect complementarity or inhibits the 
translation in case of partial complementarity. In both cases, expression of the target mRNA is inhibited leading 
to the gene knockdown phenotype. miRNAs differ from siRNAs in that they are produced endogenously as 
primary miRNAs (pri-miRNAs) which subsequently gets processed by cellular machinery into the mature 
miRNA duplex. Illustration by Fougerolles et al, 2007 (93). 
 
High-throughput RNAi-based genetic screens in mammalian cells have largely employed 
either synthetic siRNAs or vector-based expression of shRNAs to create gene knockdown 
phenotypes in target cells and assess their role in context of a particular biological process 
defined by the readout assay. RNAi screening based on siRNA library involves the delivery of 
artificially synthesized siRNA duplexes with desired sequence specificity to target cells, 
typically via liposomal transfection or electroporation, for transient knockdown of target gene. 
Whereas in shRNA-based RNAi screens, shRNA-expressing plasmids carried by lenti-, retro 
or adenoviral particles are used to transduce mammalian cells to mediate transient or stable 
gene knockdowns. Both these formats have their own set of salient features. Formats based on 
siRNA offer ease of production and transfection, generally high transfection efficiency as well 
as greater control over the amount of siRNAs transfected, which in turn means greater control 
over concentration-based non-specific side effects. In comparison, shRNA-based libraries are 
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advantageous for transducing non-transfectable cell types and for stable as well as inducible 
expression that could allow for long duration-based readout assays (91). Based on individual 
experimental needs, both these formats have been widely employed by the scientific 
community in cancer genetics to find modifiers of tumor growth, metastasis, drug 
susceptibility/resistance, synthetic lethality (94-96). 
1.5.2 Cell-based assays and workflow for an RNAi screen 
One of the key steps involved in a large scale RNAi screen is the design of an assay that is 
suited for reading out the exact biological question under investigation and its scale up to a 
high-throughput level. In addition, the screen would require the selection and optimization of 
a high-throughput-compatible gene knockdown strategy in the desired cell culture system, 
data acquisition, normalization and analysis to reveal the primary hit list. Once a primary hit 
list of candidate genes is generated, potential hits are re-validated in re-runs, creating a 
secondary hit list of reproducible hits that are then followed up in secondary and tertiary 
assays. These are designed independently of the primary assay used in the screening 
methodology to rule out false-positive hits. The basic workflow of an RNAi screen and the 
associated hit validation strategy is outlined in Figure VII. 
 
“The end of the screen is the beginning of the experiment”89 
 
 
Figure VII. siRNA-based RNAi screen involves the transfection of double-stranded siRNAs, either in individual 
wells or delivered as pools, into cell cultures to induce gene silencing. Gene silencing-induced phenotype is then 
readout using the appropriate assay creating a primary hit-list of candidate genes which is subjected to further 
validations as outlined in the flow-chart on the right. Adapted from Boutros et al. 2008 (89). 
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1.5.3 Data analysis from RNAi screen experiments 
Depending on the complexity of the readout assay (image-based or value-based), large scale 
RNAi screens can be data intensive, requiring dedicated statistical analysis and computational 
resources. Software packages that integrate data analysis pipeline (such as cellHTS (97), 
RNAither (98), GUItars (99) among others) have been developed to streamline the data 
analysis part of RNAi screen approaches. Numerical datasets, such as luciferase intensity 
from the assay readout, could be imported into these software packages for normalization, 
quality metrics calculation and finally for setting filtering parameters for hit identification 
(100). 
Normalization of the raw data is usually performed to account for and remove systematic 
technical errors that can vary from plate to plate, even within the same experimental setting, 
thereby allowing for data comparison and summation across the different plates in a screen. 
Various methods of data normalization, including control-based or sample-based 
normalization exist and are chosen depending on the data distribution parametric of the 
involved study. In the more commonly used plate-based median normalization method, signal 
intensity of each well in a plate is calculated relative to the plate’s median intensity to scale 
plate-to-plate differences. The data is then deemed ready for further processing, but before 
that one must ensure the quality of the produced data meets the quality control requirements. 
Firstly, the performance of the replicates can be compared to each other to ensure 
reproducibility. Technical errors resulting from faulty pipetting or robotics, edge effects or 
spatial effects on plates could be further normalized to a certain extent at this stage using 
specialized normalization methods such as B-score or local regression (loess)-based 
normalization techniques (101). A clear dynamic range, defined as the degree and clarity of 
separation between the positive and negative controls, is desirable to ease the complexity of 
high-confidence hit calling and this can be mathematically deduced using the geometric 
means of the respective controls. For final generation of the hit-list, strength of individual 
siRNAs can be ranked based on their z-score, defined as the number of standard deviations 
from the mean of the sample distribution. User-defined threshold parameters, which can be 
control-based or quartile-based, are then employed to deduce meaningful hits from the ranked 
list. Nevertheless, it remains to be said that algorithms for hit identification are seldom 
absolute and are rather largely dependent on the biological significance of the gathered 
phenotypes compared to the relevant positive or negative controls (89). 
Introduction 
Page 20 
 
In the field of cancer immunity, RNAi screens have been very recently employed to 
investigate genes that modify antigen-presentation by dendritic cells (102) or impair tumor 
susceptibility to NK cells (103). It is worthwhile to note that the success of any high-
throughput screen largely depends on the careful design of the screening assay. Systematic 
discovery of tumor-associated immune-checkpoint molecules has proven to be challenging for 
the same reason, since a reliable high-throughput scale–compatible immune assay that 
measures the impact of tumor-specific gene expression on anti-tumor capacity of T cells has 
been largely lacking.  
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1.6 Aims and objectives of the thesis 
Immunotherapy has emerged as a new pillar of cancer treatment over the last decade, but its 
clinical efficacy requires further optimization and tweaking. One of the major limitations to 
cancer immunotherapy is posed by the immunosuppressive ligands present on the tumor cell 
surface that inhibit an effector anti-tumor T cell response. Targeting these immune-checkpoint 
nodes is considered as the next paradigm shift in the realms of cancer immunotherapy. 
However, the current knowledge about the repertoire of such immunosuppressive ligands that 
are presented by the tumor is rather limited due to the lack of systematic, high-throughput 
studies that are devoted to the discovery of immune modulators. 
 
Therefore, the major aim of this thesis was to establish and to functionally validate a high-
throughput and robust screening assay which could uncover novel tumor-associated immune 
modulators. To achieve this aim, the following objectives were laid out: 
 
i. An immune assay will be established which combines gene knockdown via RNAi in 
tumor cells with the assessment of T cell-mediated tumor cell death in order to 
quantify the influence of individual cell surface-associated genes in cancer on the 
cytotoxic potential of effector T cells. 
 
ii. The above-mentioned immune-based screening assay will be employed at a high-
throughput level to systematically screen for potential immune modulators expressed 
by the cancer cells. The robustness and the feasibility of such a screening strategy 
under various biological parameters would also be tested.  
 
iii. Validity of the screening approach to yield meaningful immunosuppressive candidates 
will be verified by functional characterization of the identified hits. For this, the effect 
of candidate gene knockdown on the function and anti-tumor reactivity of antigen-
specific T cells in multiple tumor settings will be investigated. Potential route of 
mediating immune suppression by the candidate gene will be additionally explored. 
 
Materials 
Page 22 
 
2. Materials 
2.1 Chemicals, reagents and consumables 
Product 
 
Supplier 
 
1 kb DNA Ladder (GeneRuler) Thermo Fisher Scientific 
100 bp DNA Ladder (TrackIt) Life Technologies 
  
AB human serum Valley 
Agar Fluka 
Agarose Life Technologies 
AMP Sigma-Aldrich 
Ampicillin Sigma-Aldrich 
Aqua ad iniectabilia B. Braun 
ATP Roche 
  
Benzonase Merck 
Beta-mercaptoethanol Gibco 
Biocoll solution (density 1.077 g/ml) Biochrom 
Bovine serum albumin (BSA), fraction V Sigma-Aldrich 
Bromphenol blue Merck 
  
Cell culture dishes TPP 
Cell strainers (40 and 100 µm-pores) Falcon, BD 
Conical centrifuge tubes TPP 
Cryogenic vials (2 ml) Corning 
  
DharmaFECT1, 2 and 4 transfection reagents Dharmacon, GE 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich 
Disposable needles (0.4 x 20 mm) Henke Sass Wolf 
Disposable syringes (1 ml) Henke Sass Wolf 
Disposable syringes (50 ml) BD 
Dithiothreitol (DTT) Gerbu 
D-luciferin (for Luc-CTL assay) Biosynth 
D-luciferin potassium salt (for in vivo injection) Synchem 
dNTP mix (10mM) Invitrogen 
Dulbecco's PBS powder without Ca2+, Mg2+ (for 10 L) Biochrom 
Dulbecco's PBS without Ca2+, MgCl2 (1X) Sigma-Aldrich 
Dynabeads CD3/CD28 T cell expander, human Dynal 
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Dynabeads Pan-Mouse IgG kit Invitrogen 
  
EDTA 1% (w/v) without Mg2+ Biochrom 
Enhanced chemiluminescence (ECL) detection reagents GE Healthcare 
Ethanol absolute Sigma-Aldrich 
Ethidium bromide Sigma-Aldrich 
  
Fetal bovine serum Biochrom 
Ficoll tubes - Leucosep (50 ml) Greiner Bio-one 
Flat-bottom plates (6, 12, 24, 48, 96 well) TPP 
Freezing container (Mr. Frosty) Nalgene, Thermo Scientific 
  
GeneJammer transfection reagent Agilent Technologies 
Geneticin sulfate (G418) Gibco 
Glycerol Carl Roth 
  
HEPES buffer (1 M) Sigma-Aldrich 
Hoechst dye Invitrogen 
  
IL-2 (human, recombinant) Novartis 
Isoflurane Baxter 
Isopropanol Fluka 
  
Library Efficieny DH5α competent cells Invitrogen 
Lipofectamin LTX/ PLUS reagent Life Technologies 
Lipofectamin RNAiMAX Life Technologies 
Loading dye solution (6X) Fermentas 
LumaPlates PerkinElmer 
Luminometer plates (white, 96 well, flat) PerkinElmer 
  
Magnetic particle concentrator Life Technologies 
Matrigel basement membrane matrix BD 
MES SDS running buffer (20X) Life Technologies 
Methanol VWR 
Milk powder Carl Roth 
Multichannel pipette (50µl) Thermo Scientific 
MultiScreen-HA filter plates (0.45 µm, clear, sterile) Merck 
  
Na2 51CrO4 (5 mCi, 185 MBq) Perkin-Elmer 
Negative control siRNA 1 and 2 Ambion 
Non-essential amino acids (100X) Sigma-Aldrich 
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Nuclease free water Ambion 
  
Oxalic acid Sigma-Aldrich 
  
PageRuler prestained protein ladder Thermo Fisher Scientific 
Pertussis toxin Sigma Aldrich 
Phenylacetic acid Sigma-Aldrich 
Pipette filter tips (10 µl -1000 µl) Starlab 
Plastic serum pipettes, sterile Greiner bio-one 
Polybrene (Hexadimethrine bromide) Sigma-Aldrich 
Polystyrene round bottom tubes with caps (5, 15 and 50 
ml) 
Falcon 
Polyvinylidene difluoride (PVDF) membrane Millipore 
PowerPac Basic Power Supply Bio-Rad 
Protease Inhibitor tablets (complete) Roche 
Puromycin (10 mg/ml) Gibco 
  
Recombinant human CCL25/TECK protein R&D Systems 
Recombinant human PD-L1 protein Life Technologies 
Round-bottom plate (96 well) TPP 
  
Safe-lock tubes (0.5, 1.5, 2 ml) Eppendorf 
SDS polyacrylamid gels (4-12% Bis/Tris) Life Technologies 
Shaver for mice (Exacta) Aesculap 
siGENOME set of 4 upgrade siRNAs against CCR9, 
CCL25, CCRL1, PTGER3 and GHSR. 
Dharmacon, GE 
siGENOME SMARTpool siRNAs against PD-L1, 
CEACAM-6, RCAS-1, GAL-3, UBC, PLK-1, R-Luc, Chk 
1, Elmo 2, FLuc and Control siRNA 
Dharmacon, GE 
Syringe filter units (0.22 and 0.45 µm-pores) Millipore 
  
Taq DNA polymerase, recombinant Invitrogen 
Tissue culture flask/filter cap (25, 75, 150 cm2) TPP 
TransIT-LTI transfection reagent MirusBio 
Transwell inserts; thin-certs 8µm pore size Greiner bio-one 
Triton X-100 Fluka 
Trypan blue solution (0.4%) Fluka 
Trypsin-EDTA (1X) (sterile filtered) Sigma-Aldrich 
TurboFectin OriGene 
Tween 20 Sigma-Aldrich 
  
Whatman 3 mm gel blot paper Sigma-Aldrich 
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2.2 Assay kits 
Kits Supplier 
5-Plex STAT Phosphoprotein kit, Milliplex MAP Millipore 
7-plex T Cell Receptor Signaling phosphoprotein kit, 
Milliplex MAP 
Millipore 
9-Plex Multi-Pathway Cell Signaling kit, Milliplex MAP Millipore 
Bight-Glo luciferase assay system Promega 
Bio-Plex Pro Assay kit Bio-Rad 
CCL25/TECK ELISA kit R&D systems 
CellTiter-Glo Luminescent Cell Viability Assay kit Promega 
Compensation Beads set (anti-mouse) BD 
Dynabeads FlowComp Mouse CD8 Kit Life Technologies 
EndoFree Plasmid Maxi Kit Qiagen 
IFN-γ ELISA kit BD 
Live/Dead fixable yellow dead cell stain kit Life Technologies 
QIAprep Spin Miniprep Kit Qiagen 
QuantiTect reverse transcription kit Qiagen 
RNeasy Mini Kit Qiagen 
2.3 Buffers 
• ACK lysis buffer for red blood cell lysis 
 
NH4Cl  8.3 g 
KHCO3  1.0 g 
EDTA  0.037 g 
ddH2O 1 L 
 
• Dulbecco's PBS without Ca2+, Mg2+ (10X) 
 
Dulbecco's PBS powder  95.5 g 
ddH2O 1 L 
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• ELISpot washing solution 
 
PBS (Sigma-Aldrich) 500 ml 
Tween-20  1.25 ml 
 
• ELISpot blocking solution 
 
RPMI (Sigma-Aldrich) 500 ml 
AB serum  25 ml 
 
• FACS buffer 
 
PBS (Sigma-Aldrich)  49.5 ml 
FCS  0.5 ml 
 
• MACS buffer 
 
EDTA 2.5 ml 
Filtered AB serum  250 µl 
PBS (Sigma-Aldrich) 47.5 ml 
 
• BL buffer 
 
ddH2O  84,8 ml 
HEPES (50mM Stock) 5 ml 
EDTA (0,5 mM Stock) 0,1 ml 
Phenylacetic acid (0,33 mM) 0,033 ml 
Oxalic acid (0,07 mM Stock)  0,07 ml 
 
pH adjusted to 7,6 and stored at 4°C for up to 4 weeks 
 
• Lysis buffer for Luc-CTL assay 
 
BL buffer                        48.5 mL 
10% TritonX-100          1.5  mL 
 
• B2 Buffer 
 
ddH2O  85 ml 
DTT (415 mM stock) 6,4 g 
ATP (33 mM stock) 1,82 g 
AMP (0,996 mM source) 0,035 g 
 
Aliquots were stored at -20°C. 
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• F-Luc mix for Luc-CTL assay 
 
ddH2O  8ml 
D_luciferin (35,7 mM stock) 0,1 g 
 
NaOH was added until the color changes. Aliquots were stored in dark eppendorf tubes at -
20°C. 
 
• FLuc buffer for Luc-CTL assay 
 
BL buffer                        44.35 mL 
Buffer B2                          5 mL 
D-Luc (10mg/mL)          0.65 mL 
1M MgSO4                       751 uL 
 
• Hoechst dye staining solution 
 
PBS  10 ml 
BSA 2.4 % 
Hoechst stain 1.25 µg/ml 
 
• SDS-PAGE running buffer 
 
MES SDS running buffer (20X)  50 ml 
ddH2O 950 ml 
 
• Immunoblot transfer buffer (10X) 
 
Tris base  30.3 g 
Glycine  144 g 
ddH2O 1 L 
 
• Immunoblot washing solution (PBS-T) 
 
PBS (10X) 100 ml 
ddH2O 900 ml 
Tween-20  1 ml 
 
• Immunoblot blocking solution 
 
WB washing solution  50 ml 
Milk powder 2.5 g 
 
• Whole cell protein extraction (WCE) buffer 
 
Tris-HCl (pH 7.4) 50 mM 
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NaCl 250 mM 
NP-40 0.5% 
Glycerol 10% 
EDTA 1 mM 
DTT 0.5 mM 
Protease inhibitor (added fresh each 
time) 
1X 
 
• Tris-acetate-EDTA (TAE) buffer (50X) 
 
Tris 242 g (2 M) 
Glacial acetic acid 57.1 ml 
0.5 M EDTA 100 ml 
ddH2O 1 L 
pH  8.5 
2.4 Media and supplements 
Product Supplier 
AB serum, human Pan Biotech 
AIM-V with L-glutamine, streptomycin sulfate, gentamycin 
sulfate 
Gibco 
Cell dissociation Buffer; enzyme-free PBS-based (1X) Gibco 
DMEM; high glucose (4.5 g/l), L-glutamine, sodium pyruvate, 
NaHCO3 
Sigma-Aldrich 
Dulbeco-PBS without Ca2+, MgCl2 (1X) Sigma-Aldrich 
Fetal calf serum (FCS) Biochrom 
Ham's F12 Nutrient Mixture  Gibco 
HEPES buffer (1M) PAA 
Human rIL-2 (for TIL expansion) Novartis 
Human rIL-2 (Proleukin; for T cell culture) Chiron 
LB broth Carl Roth 
LB-Agar Carl Roth 
L-Glutamine (200 mM) BioWhittaker, Lonza 
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Non-essential amino acids (NEAA; 100X) BioWhittaker, Lonza 
OPTI-MEM (1X) with HEPES buffer, Lglutamine, NaHCO3 Gibco 
Penicillin/Streptomycin (P/S; 100X) PAA 
RPMI 1640 with L-glutamine  Gibco 
RPMI 1640 with L-glutamine, NaHCO3  Sigma-Aldrich 
S.O.C. medium Invitrogen 
Trypsin/EDTA (1X) Sigma-Aldrich 
X-VIVO 20 (serum free)  Lonza 
 
FCS and AB serum were heat-inactivated and filtered through 0.22 µm pore-sized filters 
before being used as media supplements. Penicillin/Streptomycin (P/S) mix was also filtered 
through 0.22 µm filters before use. 
 
• Complete melanoma medium (CMM) 
 
DMEM  300 ml 
RPMI  100 ml 
Ham's F12 Nutrient Mixture  100 ml 
HEPES buffer  5 ml 
FCS  50 ml 
P/S  5 ml 
 
• Complete lymphocyte medium (CLM) 
 
RPMI 500 ml 
AB serum 50 ml 
HEPES 5 ml 
P/S 5 ml 
2-mercaptoethanol 50 µl 
 
• Freezing medium 
 
FCS 9 ml 
DMSO 1 ml 
 
• LB-Amp medium 
 
LB broth 25g 
dH2O 1L 
Ampicillin 100 µg/ml 
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• LB agar medium 
 
LB-Agar 40g 
dH2O 1L 
 
• TIL expansion medium with feeder cells 
 
CLM  50% 
AIM-V  50% 
Feeder cells  1x106/ml 
IL-2  6,000 U/ml 
OKT-3  30 ng/ml 
 
 
• TIL expansion medium without feeder cells 
 
CLM  50% 
AIM-V  50% 
IL-2  6,000 U/ml 
 
• T cell medium (for short-term culture) 
 
X-VIVO 20 50 ml 
Human rIL-2 (Proleukin) 100U/ml 
2.5 Cell lines 
All cell lines were of human origin: 
 
Cell lines Type (derived from) Culture medium 
HEK 293T Embryonic kidney DMEM, 10% FCS, 1% P/S 
M579 
Melanoma patient-derived 
primary cell culture 
Complete melanoma medium 
MCF7 Breast adenocarcinoma DMEM, 10% FCS, 1% P/S 
MCF7-luc Breast adenocarcinoma 
DMEM, 10% FCS, 1% P/S, 550 
µg/ml G418 
MDA-MB-231 Breast adenocarcinoma DMEM, 10% FCS, 1% P/S 
PANC-1 Pancreatic adenocarcinoma DMEM, 10% FCS, 1% P/S 
PANC-1-luc Pancreatic adenocarcinoma 
DMEM, 10% FCS, 1% P/S, 1 
mg/ml G418 
Phoenix ampho Embryonic kidney DMEM, 10% FCS, 1% P/S 
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Cells Type (derived from) Culture medium 
Polyclonal CD8+ T 
cells 
Leukocyte concentrates 
(Buffy coat) from healthy 
donors 
X-VIVO 20 
Survivin antigen-
specific T cells 
Peripheral blood of breast 
cancer patient 
X-VIVO 20 
SW480 Colorectal adenocarcinoma RPMI, 10% FCS, 1% P/S 
TIL 412 Melanoma patient-derived Complete lymphocyte medium 
TIL 53, and TIL 34 
Pancreatic cancer patient-
derived 
Complete lymphocyte medium 
2.6 Antibodies 
All antibodies used were reactive against human epitopes, unless otherwise stated. 
2.6.1 Flow cytometry 
Specificity Species Isotype Conjugate Clone Company Application 
CD69 mouse IgG1 PE FN50 BD 5 µl in 50µl volume 
CD8 mouse IgG2a FITC G42-8 BD 5 µl in 50µl  volume 
CD4 mouse IgG1 PerCP-Cy5.5 RPA-T4 BD 2.5 µl in 50µl volume 
CD8 mouse IgG1 V450 RPA-T8 BD 2.5 µl in 50µl volume 
CD3 mouse IgG2A APC HIT3a BD 2.5 µl in 50µl volume 
CD45 mouse IgG2A FITC 5B1 
Miltenyi 
biotec 
2.5 µl in 50µl volume 
PD-1 mouse IgG1 PE/Cy7 EH12.2H7 BioLegend 5µl in 100µl volume 
TIM-3 rat IgG2A PE 344823 R&D Systems 20µl in 100µl volume 
CCR9 mouse IgG2A 
Alexa-Fluor 
647 
112509 BD 5 µl in 50µl volume 
Isotype 
control 
mouse IgG2A APC S43.10 
Miltenyi 
biotec 
2.5 µl in 50µl volume 
Isotype 
control 
mouse IgG2A,k 
Alexa-Fluor 
647 
G155-178 BD 5 µl in 50µl volume 
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2.6.2 Immunoblot 
Specificity Species Isotype Clone Provider Application 
CCR9 rabbit IgG E99 Abgent 1:1000 
CEACAM-6 mouse IgG1 GM8G5 Axxora (Enzo) 1:1000 
Beta-actin mouse IgG1 AC-15 Abcam 1:3000 
PD-L1 mouse IgG1 130021 R&D Systems 1:1000 
Phospho-STAT1 
(Tyr701) rabbit IgG 58D6 Cell Signaling 1:1000 
Anti-mouse IgG- 
HRP goat IgG sc2005 Santa Cruz 1:2000 
Anti-rabbit IgG- 
HRP goat IgG sc2004 Santa Cruz 1:2000 
2.6.3 Cell-based assays 
Specificity Species Isotype Clone Provider 
Application and 
concentration 
CCR9 mouse IgG2A 112509 R&D Systems 
Blocking assays 
(BA): 30 or 60 
µg/ml 
CCR9 rabbit IgG ab38564 Abcam BA: 30 µg/ml 
CEACAM-6 mouse IgG1 GM8G5 Axxora (Enzo) BA: 30 µg/ml 
Isotype mouse IgG1 MG1-45 BioLegend BA: 30 µg/ml 
Isotype mouse IgG2A 20102 R&D Systems BA: 30 or 60 µg/ml 
PD-L1 mouse IgG1 130021 R&D Systems BA: 30 µg/ml 
CCL25 mouse IgG2B 52513 R&D Systems BA: 30 µg/ml 
CD3 mouse IgG2A OKT3 Dr. G. Moldenhauer 
TC activation, as 
indicated in methods 
CD28 mouse IgG1 15E8 Dr. G. Moldenhauer 
TC activation, as 
indicated in methods 
CD3 x EpCAM 
bsAb 
mouse  
OKT3 x 
HEA125 
Dr. G. Moldenhauer 
Cytotoxicity assays: 
5 µg/ml 
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2.7 Mice 
Non-obese diabetic (NOD)-severe combined immunedeficient (SCID) Il2rg-/-gamma (NSG) 
mice were used in this study. Original mouse strain was obtained from the Jackson Laboratory 
(strain name: NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) and were bred in-house at the DKFZ 
Animal Facility. Animal experiments were approved by the regulatory authorities (Karlsruhe). 
Mice were housed in sterile, individually ventilated cages (IVC). Ethical guidelines were 
followed according to the local regulations. 
2.8 Equipments 
Instrument Associated software (version) and developer Manufacturer 
Acumen Explorer eX3, fluorescence 
microplate reader 
 TTP LabTech 
Axiovert 40 CFL 
microscope/AxioCam MRm 
AxioVision LE (4.4) Carl Zeiss 
Caliper (digital)  Carl Roth 
Casy cell counter  Innovatis 
CTL ImmunoSpot S5 UV analyzer ImmunoSpot (5.0 Pro DC) CTL 
FACS Canto II Flow cytometer FACS Diva software (6) BD 
Gamma Counter (Cobra Packard)  PerkinElmer 
Gammacell 1000  Best Theratronics 
Infinite M200 plate reader iControl (1.6) Tecan 
IVIS100 in vivo imaging system 
Living Image (2.50), Igor Pro 
(4.09A) 
Xenogen 
Luminex100 Bio-Plex System Bio-Plex Manager (4.1.1) Bio-Rad 
Mithras LB 940 microplate reader  Berthold 
Molecular Imager (ChemiDoc 
XRS+) 
ImageLab (5.0) Bio-Rad 
MultiDrop Combi I  Thermo Scientific 
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Instrument Associated software (version) and developer Manufacturer 
NanoDrop 2000c 
NanoDrop 2000c (1.3.1), 
Thermo 
Peqlab 
Thermal Cycler, Peltier PTC-200  MJ Research 
UV gel documentation system  Konrad Benda 
XCell SureLock Mini-Cell 
Electrophoresis System 
 Life Technologies 
2.9 Additional software 
Software (version) Developer 
Adobe Illustrator (CS5) Adobe systems 
cellHTS2 Boutros et al (101), Heidelberg 
Clone Manager Professional (9) Scientific and education software, Cary, NC, USA 
EndNote (X4)  Adept Scientific 
FlowJo (8.8)  Tree Star 
GraphPad Prism (6)  GraphPad Software 
ImageJ (1.44)  Wayne Rasband 
Microsoft Office 2007 Microsoft, USA 
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3. Methods 
3.1 Cell culture techniques 
3.1.1 Tumor cell lines 
MCF7, MDA-MB-231 (both breast cancer), HEK 293T (human embryonic kidney), PANC-1 
(pancreatic cancer) and SW480 (colorectal cancer) cell lines were acquired from the 
American Type Cell Culture (Wesel, Germany). Cell lines were authenticated using multiplex 
PCR at the DKFZ Genomics and Proteomics Core Facility. MCF7luc cells were generated by 
electroporation with pEGFP-Luc plasmid (kindly provided by Dr. Rudolf Haase, LMU, 
Munich) and sorted GFP-positive clones were expanded in selection medium containing 550 
µg/ml geneticin/G418 (Gibco, UK). M579-A2-luc melanoma culture, stably transfected with 
HLA-A2 expression construct and luciferase plasmid, was established from a patient as 
described before and were kindly provided by Dr. Michal Lotem, Hadassah Hebrew 
University Medical Center, Israel (104). PANC-1-luc cells were generated by Antonio 
Sorrentino in the laboratory via transfecting pEGFP-Luc plasmid using the TransIT 
transfection reagent (as described in section 3.2.6) and subsequently sorted for GFP 
expression using flow cytometry. After two rounds of sorting, more than 95% of the sorted 
PANC-1 cells maintained stable expression of GFP over time under the selection pressure of 
G418 (1 mg/ml). All cell lines were cultured in the described culture media (see section 2.5) 
and maintained at 37°C, 5% CO2, except for melanoma cell culture which was maintained at 
8% CO2. 
3.1.2 Generation of stable CCR9 knockdown cell lines 
For stable knockdown of CCR9 in tumor cell lines, a lentiviral vector expressing shRNA 
targeting CCR9 mRNA was produced according to the manufacturer’s instructions (Cellecta). 
Briefly, DNA sequence coding for shRNA hairpin loop structure targeting CCR9 were 
obtained from the DECIPHER module library database and corresponding oligonucleotides 
for the sense and antisense strand were synthesized (Sigma-Aldrich). Single stranded 
oligonucleotides were phosphorylated and annealed using a T4 polynucleotide kinase and 
ATP. Phosphorylated, double-stranded oligonucleotides were ligated into the linearized 
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backbone of the pRSI9-U6-sh-HTS3-UbiC-TagRFP-2APuro lentiviral shRNA expression 
vector (Cellecta). Successful ligation was confirmed using colony PCR and DNA sequencing. 
Plasmid containing non-targeting shRNA sequence (NTS) in place of CCR9-specific shRNA 
sequence was used as a control (Cellecta). Lentiviral particles bearing the shRNA-encoding 
plasmids were produced by Tobias Speck in the laboratory. For this, 1.2x106 of low-passage 
number HEK 293T cells were seeded in 75 cm2 tissue culture flasks and co-transfected the 
following day with the second generation lentiviral packaging plasmid psPAX2 (coding for 
gag and pol), the VSV-G envelope protein expressing plasmid pMD2.G (endcoding for env) 
and the pRSI9 transfer plasmids (encoding the NTS or CCR9 shRNAs), in a ratio of 2:1:2 (1 
= 1.5 µg DNA) using Lipofectamine LTX with PLUS as transfection reagent. Afterwards, 
cells were incubated at 37°C and supernatants containing the lentiviral particles were 
harvested after 48 h and 72 h. Cellular debris were removed by passing through a 0.45 µm 
filter. The produced lentiviral particles were used for transduction of tumor cells by seeding 
5x105 cells in 25 cm2 flasks in growth media. On the following day, growth media was 
replaced by 2 ml of lentiviral particle-containing media (diluted 1:20) along with 4 µg/ml 
polybrene. Cells were incubated at 37°C for 16 h and afterwards, lentiviral medium was 
removed and flasks were washed with PBS. Cells were incubated at 37°C for additional 48 h 
to allow stable integration and expression of plasmid encoded gene products. Cells were then 
transferred to 75 cm2 culture dishes in the presence of 1 µg/ml puromycin for positive 
selection of transduced cells. 
3.2 Molecular biology techniques 
3.2.1 RT-PCR 
To evaluate the gene knockdown efficacy of siRNAs, mRNA transcript levels were measured 
using RT-PCR. Tumor cells were harvested after siRNA transfection (described below) and 
total RNA was extracted from the cell pellets using the RNeasy Micro kit (Qiagen). 1 µg 
RNA from each sample was reverse transcribed to cDNA using the QuantiTect reverse 
transcription kit (Qiagen) as instructed by the manufacturer. Water blank, instead of template 
RNA, was used as control for the reverse transcription reaction. Transcribed cDNA were 
amplified using PCR. PCR reaction was set up in a 25 µl volume using the recombinant Taq 
DNA polymerase (Invitrogen) as detailed in the manufacturer’s protocol. Water blank, instead 
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of template cDNA, was used as control. Following primers were used for the detection and 
amplification of the respective target genes: 
  
Gene Primer sequences (5’- 3’) 
CCR9 
Forward: CAGTGAACCCCTGGACAACT 
Reverse: TGCCACTCAACAGAACAAGC 
PD-L1 Forward: GTACCTTGGCTTTGCCACAT 
Reverse: CCAACACCACAAGGAGGAGT 
GAPDH Forward: GAGTCAACGGATTTGGTCGT 
Reverse: TTGATTTTGGAGGGATCTCG 
 
The PCR reaction was carried out initially at 94°C for 2 min, followed by 35 cycles of 3-step 
process: denaturation (94°C for 30 s), annealing (55°C for 30 s) and extension (72°C for 30 
s); and finally once at 72°C for 7 min using the PTC-200 Peltier Thermal Cycler (MJ 
Research). 5 µl of the PCR product was mixed with equal volume of the DNA loading dye 
and separated on a 1.8% agarose gel using the gel electrophoresis unit. Separated DNA bands 
were visualized using the UV gel documentation system (Konrad Benda). 
3.2.2 Protein extraction 
Tumor cells were harvested and pelleted via centrifugation at 1600 rpm for 5 min and washed 
once with PBS to remove any traces of media. Depending on the pellet size, cells were 
resuspended in 30-50 µl of whole cell extract buffer containing the protease inhibitor cocktail 
(diluted 1:20). Cell lysates were incubated for 20 min, followed by centrifugation at 13,000 
rpm at 4°C for 20 min. Supernatants containing the protein lysates were transferred into fresh 
tubes and quantified using the NanoDrop analyzer (blanked with water). Protein lysates were 
stored at -80°C. 
3.2.3 Immunoblotting 
For immunoblotting analysis, 25 µg of protein lysates were separated on the 4-12% Bis/Tris 
SDS polyacrylamide gels (Invitrogen) under reduced condition. PAGE-separated protein 
bands were blotted onto the PVDF membrane using the 1X wet-transfer buffer at 400 mA for 
45 min at 4°C. Membranes were blocked with 5% milk powder in PBS-Tween (PBS-T) at 
4°C overnight to reduce unspecific binding of the antibody. On the following day, membranes 
were incubated with the primary and HRP-conjugated secondary antibody prepared in the 
blocking buffer at the dilutions indicated in section 2.6.2. Between incubation with each 
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antibody, the membranes were washed thrice with PBS-T for 10 min each. Protein bands were 
detected using the ECL developing solution containing luminol substrate which is catalyzed 
by the antibody-conjugated peroxidase (HRP) enzyme, resulting in the emission of low 
intensity light that can be detected at 428 nm. Chemiluminescent signal was acquired using 
the ChemiDoc XRS system. 
3.2.4 Bacterial transformation and plasmid extraction 
For plasmid DNA amplification, DH5α (E. coli) competent cells (Invitrogen) were 
transformed with 2 ng of plasmid DNA by heat-shock method as detailed by the 
manufacturer. Next, competent cells were plated onto the LB plates containing 100 µg/ml 
ampicillin and incubated at 37°C overnight to obtain successfully transformed antibiotic-
resistant bacterial clones. Isolated colonies were picked up on the following day and used to 
inoculate 100 ml of LB culture containing 100 µg/ml ampicillin for plasmid DNA isolation. 
Plasmid DNA from bacterial culture was isolated and purified using the EndoFree Plasmid 
Maxi Kit (Qiagen) as per the manufacturer’s instruction. Integrity of the purified DNA was 
analyzed via gel electrophoresis after enzymatic digestion. For glycerol stock preparation of 
bacterial clones, 500 µl of turbid bacterial culture was mixed with 500 µl of 50% glycerol, 
vortexed, placed on ice for 30 mins and then stored at -80°C in cryotubes.  
3.2.5 Reverse siRNA transfection 
To induce gene knockdown in tumor cells, 6-well plates were coated with 250 µl of 500 nM 
siRNA stock solution per well for 10 min at room temperature. 4 µl of RNAiMAX 
(Invitogen) transfection reagent was diluted in 200 µl final volume of OPTI-MEM and 
incubated for 10 min at RT. 400 µl of additional OPTI-MEM was then added and overlaid 
onto the siRNA coated wells for 30 min. 3x105 tumor cells were resuspended in 1,200 µl of 
antibiotic-free culture medium supplemented with 10% FCS and seeded onto the siRNA-
RNAiMAX wells for reverse transfection with the siRNAs and incubated for 72-96 h at 37°C, 
depending on the experimental requirements. For transfection in 96- or 384-well plate 
formats, the above protocol was proportionally scaled down keeping the final siRNA 
concentration to 50 nM. For testing the siRNA transfection efficacy, cells were reverse 
transfected with lethal or control siRNAs in 384-well plates and cell viability was determined 
after 72 h as described in section 3.2.8. 
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3.2.6 Plasmid Transfection 
For overexpression, codon-optimized CCR9 ORF encoded in the backbone of the pCMV6-
AC-His vector, which contains a C-terminal histidine tag, was obtained from Origene. For 
plasmid transfection, 3x105 HEK2393 or MCF7 cells were seeded in a 6-well plate and 
incubated in 37°C cell culture incubator overnight. On the following day, 6 µl of TransIT-
LT1 transfection reagent (Mirius Bio) was added in 200 µl final volume of OPTI-MEM 
solution, mixed gently and incubated for 10 min at room temperature. Simultaneously, 3 µg of 
pCMV6-AC-His-CCR9 encoding vector or pCMV6-AC-His control vector was diluted in 600 
µl OPTI-MEM and mixed gently. After 10 min incubation, 200 µl of OPTI-MEM/TransIT-
LT1 mix was added to the 600 µl of plasmid/OPTI-MEM mix and incubated for 30 min at 
room temperature. Normal growth media on the seeded cells was replaced with antibiotic-free 
media in the meanwhile and to this plasmid/TransIT mix was added. Cells were incubated at 
37°C for 48 h before use in other assays. For transient transfection of the pEGFP-Luc plasmid 
into the MCF7 and SW480 cell lines in 384-well plates, the above protocol was 
proportionately scaled down with 50 ng of plasmid DNA and 0.2 µl of individual transfection 
reagents used accordingly per well. 
3.2.7 Fluorescent microscopy 
GFP and phase contrast images of the MCF7luc cells were acquired using the inverted 
Axiovert 40 CFL microscope and analysed using the Axiovision 4.4 software. 
3.2.8 Cell viability assays 
To assess cell viability after siRNA transfection, growth media was removed from wells and 
cells were fixed in 50 µl of fixation buffer (PBS, 4% PFA) for 30 min at room temperature. 
Buffer was removed and 20 µl of the DNA-binding Hoechst dye staining solution was added 
per well and incubated for 1 h at room temperature. Following this, the staining solution was 
removed and wells were washed twice with 80 µl PBS to remove any unbound dye. Plates 
were read using the Acumen Reader at 460 nm. 
For screening viability-related genes, CellTiter-Glo (CTG) assay (Promega) was employed. It 
quantifies the level of ATP present in the culture based on the luminescence signal generated 
by oxidative catalysis of luciferin to oxyluciferin by recombinant luciferase already present in 
the reagent mix. Therefore, it is important to note that CTG assay can only be performed with 
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luciferase negative cell lines. For CTG assay, siRNA transfected 384-well plates were soaked 
off media and incubated with 20 µl of CTG solution per well which was pre-diluted 1:4 in 
media and kept for 15 min in the dark. Luminescence was measured with the Mithras reader 
using 0.1 sec as the acquisition time with no filter setting. 
3.2.9 Transwell migration assay 
To evaluate the migration of CCR9+ve cells towards the chemotactic stimulus of CCL25 and 
to assess the capacity of pertussis toxin in inhibiting this migration, transwell migration assay 
was performed in 24-well plates with 8 µm transwell inserts. The receiver well was cultivated 
with 500 µl of medium alone or medium supplemented with 3 µg/ml of rhCCL25 protein 
(R&D systems). Transwell inserts (Greiner bio-one) containing 1x105 MDA-MB-231 cells in 
200 µl DMEM medium, supplemented with or without pertussis toxin (2 µg/ml), were 
overlaid onto the receiver wells and incubated for 24 h. Cells that migrated into the lower 
chamber were carefully harvested after 24 h and quantified using the CTG assay, as described 
in section 3.2.8. Experiment was performed in triplicates per sample group. 
3.2.10 Global gene expression analysis 
For transcriptomic analysis, 2.5 x 105 MCF7 cells per group were reverse transfected with 
control or CCR9 s1 siRNA in 6-well plates as detailed in section 3.2.5. Transfection was set 
up in triplicates per knockdown. After 72 h, 5 x 106 survivin T cells were added to each well 
of siRNA-transfected MCF7 cells and co-incubated for 12 h in 37°C incubator. Following co-
incubation, supernatant from each well were harvested and wells were additionally rinsed 
with 1 ml of culture media and pooled with the remaining supernatant. Survivin TCs in the 
supernatant were separated from the MCF7 tumor cells using anti-EpCAM antibody-coated 
magnetic beads as detailed in section 3.4.7. Total RNA was isolated from the purified T cells 
using the RNeasy Mini kit (Qiagen) as instructed by the manufacturer and diluted to 40 ng/ml 
final concentration using the RNase free water. RNA hybridization onto the GeneChip Human 
Genome U133 Plus 2.0 Array (Affymetrix) was performed by the Genomics and Proteomics 
Core Facility (DKFZ, Heidelberg). Gene expression intensity was quantile normalized and 
significant differences in the log fold-change of gene expression between the CCR9hi versus 
the CCR9lo treated TCs was evaluated using the Welch’s t-test. Gene expression comparison 
between the two groups was represented using the volcano plot distribution and the top 
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differentially up and down regulated genes were plotted as heatmaps using heatmap.2 
function. Gene enrichment analysis based on the GO molecular functions terms was 
performed for the top differentially expressed genes using DAVID. The obtained gene 
expression profile was compared with a publically available gene expression dataset from a 
previous study (105), which compared CD8+ T cells from the peripheral blood of healthy 
donors before and after 24 h of activation with anti-CD3/CD28 antibody plus IL-2. The 
published dataset was retrieved from the Gene Expression Omnibus using the accession code 
GSE7572 and analyzed using standard methods in R. Data analysis was kindly performed by 
Ashwini Kumar Sharma (DKFZ, Heidelberg). 
3.3 Immune-RNAi screen  
3.3.1 Screen layout and the Luc-CTL assay 
GPCR-targeting sub-library of the genome-wide siRNA library siGENOME (Dharmacon, 
Thermo) containing 516 siRNA pools, each pool consisting of four synthetic siRNA duplexes, 
was prepared as described (106). Four RNAi screens were performed in duplicate wells. 
Positive and negative siRNA controls were distributed into empty wells prior to the screening. 
Reverse siRNA transfection was performed by delivering 0.05 µl of RNAiMAX in 15 µl 
RPMI (Invitrogen). After 30 min, 3000 MCF7 cells (screen 1 and 3: MCF7luc, screen 2 and 
4: MCF7) in 30 µl DMEM medium (Invitrogen) supplemented with 10% FBS (Invitrogen) 
were added. Plates were incubated at 37°C for 24 h and for screens 2 cells were transiently 
transfected with a luciferase expression plasmid using the TransIT-LT1 transfection reagent 
(Mirius Bio). 72 h post siRNA transfection cancer cells were either challenged with CTLs and 
anti-CD3 x anti-EpCAM bi-specific antibody (0.2 µg/well; screen 1 and 2) or survivin-
specific CTLs (screen 3) or left untreated (condition without addition of CTLs and screen 4). 
T cells were isolated and activated as described in section 3.4.1 for use in the screen. Screen 1 
contained CTLs from one single donor and screen 2 CTLs from two different donors; one for 
each technical replicate within the screen. Tumor lysis was quantified 18 h later by analysis of 
residual luciferase expression in tumor cells (107).  For screen 1-3, supernatant was removed 
using a 24-channel suction comb and cells were lysed by adding 20 µl of the Luc-CTL lysis 
buffer per well for 10 min at room temperature. After this, 30 µl of FLuc buffer was added per 
well and plates were read after 1 min using the Mithras reader with 0.1 sec counting time. 
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Viability measurements were performed for screen 4 using the CellTiter-Glo assay as 
described in section 3.2.8.  
3.3.2 Data analysis 
Plate reader data from RNAi screens were analyzed using the cellHTS2 package in 
R/Bioconductor (101). Scores from both conditions, i.e. addition of CTLs and without 
addition of CTLs, were quantile normalized against each other using the aroma.light package 
in R. Differential scores were calculated using a loess regression fitting. Given the 
biologically mixed setup used for the three different screens, unsupervised hierarchical 
clustering of differential score of all genes from all screens was performed using the loess 
score to assess inter-screen heterogeneity on a per gene basis. To derive the candidate hit list, 
firstly, preliminary thresholds for the toxicity and the viability scores were determined for 
each screen based on the quartile distribution of z-scores of the samples. For identifying 
negative immune modulators, genes in the 75% to 100% quartile of the toxicity score 
(representing elevated CTL-mediated lysis) and below 75% quartile for the viability scores 
(representing negligible impact on cell viability) were chosen as hits in each screen. For 
identifying positive immune modulators, range of the toxicity score was chosen as 0% to 25% 
(representing lowered CTL-mediated lysis) and viability score of 15% to 75% (corresponding 
to the normalized score of -1.5 to +1.5). Next, these statistical thresholds based on sample 
distribution parameters were individually adjusted for each screen based on the biological 
performance of the relevant controls within the individual screens with PD-L1, GAL-3, 
RCAS-1 used to determine the toxicity threshold; PLK-1, UBC used for viability thresholds 
and control siRNA 1 and 2 used for both the scores. Genes satisfying the above threshold 
criteria were identified individually for each screen and those which popped up in at least two 
screens were selected. Top positive and negative immune regulators (ordered by highest and 
lowest summed loess scores across screens) were plotted as heatmaps using value imputation 
for highlighting their relative immunomodulatory strength across the individual screen setups. 
Finally, genes scoring in a CellTiterGlo-based viability screen were filtered out from the 
candidate list (score <-1.5 and >1.5) to exclude any additional siRNAs affecting cell viability. 
Data analysis was kindly performed by Dr. Marco Breinig and Ashwini Kumar Sharma 
(DKFZ). 
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3.4 Immunological techniques 
3.4.1 T cell isolation and activation  
For RNAi screens, CD8+ T cells were isolated from leukocyte cell concentrates (buffy coat) 
obtained from IKTZ Blood Bank (Heidelberg). Ficoll density gradient centrifugation was 
performed to isolate peripheral blood mononuclear cells (PBMCs) from buffy coats of healthy 
donors. CD8 Flow Comp kit (Invitrogen; Karlsruhe, Germany) was used to isolate CD8+ T 
cells from the isolated PBMCs as detailed by the manufacturer. 1x106 CD8+ T cells/ml of X-
VIVO 20 medium (Lonza) were activated for 3 days using the Human T-Activator 
CD3/CD28 activation beads (Dynal, Invitrogen; bead:cell = 1:3) and 100 U/ml IL-2. On the 
day of the co-culture, activated T cells were magnetically separated from activation beads, 
washed twice in X-VIVO 20 and then used directly for the experiment. For alternate T cell 
activation protocols (section 4.3), purified 6x107 CD8+ T cells from PBMCs were cultured in 
30 ml complete RPMI media in 75 cm2 tissue culture flask which was pre-coated for 2 h at 
37°C with 100 µg of anti-CD3 antibody (OKT3 clone from G. Moldenhauer). To this, either 
150 µg anti-CD28 antibody (15E8 clone from G. Moldenhauer) was added or left alone in the 
presence 100 U/ml IL-2. T cells were used after 3 days for Cr-release assay and FACS 
staining. HLA-A0201 restricted survivin95-104 (clone SK-1) specific CTL clones were 
generated from the PBMC of healthy donors as described (108). Tumor-infiltrating 
lymphocyte 412 microculture (provided by Dr. Michal Lotem, Hadassah Hebrew University 
Medical Center, Israel) was expanded from an inguinal lymph node of a melanoma patient as 
described before (109). Similarly, TIL 34 and TIL 53 microcultures (provided by Dr. Isabel 
Poschke and Dr. Rienk Offringa, DKFZ) were established from two different male patients 
with poorly differentiated pancreatic adenocarcinoma (PDAC). Both melanoma and 
pancreatic TIL cultures were expanded using the Rapid Expansion Protocol described in 
section 3.4.2. 
3.4.2 Rapid expansion protocol (REP) for TILs 
Isolated TILs were ex vivo expanded using the modified Rosenberg’s REP protocol (110). 
Thawed TILs were treated with benzonase (500 U/ml) to avoid cell clumps and were diluted 
to 6x105 cells/ml in CLM supplemented with 6000 U/ml rhuIL-2. Cells were incubated for 48 
h at 37°C and 5% CO2. PBMCs from 3 different buffy coats (1:1:1) were irradiated with 60 
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Gray (Gammacell 1000) and used as feeder cells to support TIL expansion. 1x106 TILs were 
co-incubated with 1x106 feeder cells/ml in 150 ml of TIL expansion medium and incubated 
for 5 days without any disturbance. Afterwards, media was replenished with fresh TIL media 
containing IL-2. Henceforth, TILs were counted every second day and cell concentration was 
set to 6x105 TILs/ml. On 14th day of the expansion, TILs were counted and frozen in aliquots 
of 10 x106 cells/ml or depleted of IL-2 overnight and used fresh for experiments the next day. 
3.4.3 51Chromium-release Assay 
Tumor cells were transfected with described siRNAs or expression plasmids as detailed 
(section 3.2.5 and 3.2.6) and used for Cr-release assay after 72 h. For antibody-mediated 
inhibition of target protein, 106 tumor cells were harvested and incubated with 3 µg of 
blocking mAb or isotype control antibody (unless otherwise stated) for 30 min on ice before 
being used as target cells. For CCR9 blockade using pertussis toxin (PTX), 106 tumor cells 
were incubated with 250 ng/ml of PTX (Sigma Aldrich) for 1 h at 37°C. In either case, treated 
target cells were washed and labeled with 200µL 51Cr/106 target cells (Perkins-Elmer, 
Germany) for 45 mins at 37°C. After labeling, the cells were carefully washed thrice to 
remove cell-free chromium and 3000 target cells /well were co-cultured with survivin-specific 
T cells in 96 well plates at a T cell to target cell ratio of 1:1 to 100:1 for 4 h at 37°C. In 
experiments where polyclonal T cells were used, 5 µg/ml of anti-CD3 x anti-EpCAM bi-
specific antibody was added to each well of the cyotoxicity assay to induce tumor lysis. Non-
specific anti-CD3 x anti-CD19 bi-specific antibody was used at the same concentration as 
control. After 4 h of tumor and T cell co-incubation, plates were spun down and the 
supernatant was harvested for measuring the radioactivity released by dead cells using the 
Gamma counter (Cobra counter Packard, Perkin Elmer). As a control for spontaneous release, 
the labeled cells were co-incubated with media alone; and for maximum release, cells were 
incubated with 10% Triton X-100 instead of T cells. % specific lysis was then calculated 
using the formula given below: 
 %  !"#$%&%$  !"#$#   = (!"#!$%&!'()*  !"#"$%" − !"#$%&$'#(!  !"#"$%")(!"#$!%!  !"#"$%" − !"#$%&$'#(!  !"#"$%")   ×100 
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3.4.4 ELISpot Assays 
IFN-γ or granzyme B secretion from T lymphocytes was determined using the enzyme-linked 
immunosorbent spot (ELISpot) assay, as detailed by the manufacturer (Mabtech, Nacka 
Strand, Sweden). Briefly, CCR9 expression was inhibited in the tumor cell lines using 
specific siRNAs or antibodies, along with the necessary controls. siRNA transfected cells 
were harvested after 48 h, washed and then added to the IFN-γ or granzyme B antibody 
coated ELISpot wells (1 µg/well). For antibody blockade, 5x105 WT cells were pre-treated 
with 3 µg of anti-CCR9 antibody (R&D systems or Abcam) for 1 h on ice, washed and then 
co-incubated with T cells in the ELISpot wells. For co-culture, either survivin-specific T cells 
(5000 cells) or polyclonal CD8+ T cells (10,000 cells) along with anti-CD3 x anti-EpCAM 
bsAb were used in a ratio of 5:1 (T cell to tumor cell) for 24 h at 37°C. After this, plates were 
washed and incubated with the respective biotinylated antibodies (0.1 µg/well), followed by 
the addition of streptavidin-alkaline phosphatase conjugate. Secreted cytokines by T cells 
which are locally captured by the coated antibodies were developed as spots using the 
Mabtech kit and analysed using the ELISPOT software (CTL Europe). Experiment was 
performed in triplicate wells for statistical comparison using the two-sided student’s t-test. 
3.4.5 ELISA 
To measure the production of CCL25 in different tumor cell lines, sandwich ELISA was 
performed using the commercial CCL25 ELISA kit (R&D systems). Briefly 96-well 
microplate were coated with 100 µl of the anti-human CCL25 antibody (0.5 µg/ml) and 
incubated overnight at room temperature. Plates were carefully washed thrice and blocked for 
1 h at room temperature using the blocking buffer provided in the kit. CCL25 protein 
standards were used as positive control and rhPD-L1 protein (BioLegend) was used as a 
negative control to check for the unspecific binding of anti-CCL25 antibody coated plates. 25 
µg of protein lysates from the respective tumor cell lines were prepared in 100 µl of the PBS-
T and added to the washed wells for 2 h at room temperature. Afterwards, plates were 
washed, incubated with the detection antibody, followed by incubation with streptavidin-HRP 
solution, as indicated in the manufacturer’s protocol. Finally, plates were developed using the 
provided substrate solution (containing H2O2 and tetramethylbenzidine) for 20 min in dark at 
room temperature after which reaction was stopped using 2 N H2SO4 solution. Absorbance or 
optical density was measured at 450 nm using the Infinite M200 plate reader (Tecan). 
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Similarly, IFN-γ ELISA was performed using the IFN-γ ELISA kit as detailed in the 
manufacturer’s protocol (BD Biosciences). Experiments were performed in triplicate wells for 
statistical comparison. 
3.4.6 Cytokine measurements using luminex 
For simultaneous quantification of multiple analytes in the same sample, luminex xMAP 
technology was used (Bio-Rad). This utilizes distinctly colored miscrosphere beads that can 
be coated with specific antibody to capture the analyte of choice in the sample mix, which can 
then be quantified by excitation and subsequent emission of light from the colored beads. For 
luminex assay, MCF7 cells were transfected with CCR9-specifc or control siRNA for 48 h 
and then harvested and cocultured with 104 survivin-specific T cells at 1:5 ratio in 96-well 
plate for additional 24 h at 37°C. After incubation, the plates were spun down and 100 µl of 
the culture supernatant was collected from each test well and centrifuged at 1000 g for 15 min 
at 4°C. The clear supernatant was collected and used directly for cytokine measurement using 
the Luminex100 Bio-Plex System and the Bio-Plex Pro Assay kit, as described by the 
manufacturer (Bio-Rad). Data was analyzed using the Bio-Plex Manager software version 6.0. 
Individual measurements were acquired from three test wells per group. 
3.4.7 Phosphoprotein analysis 
MCF7 cells were transfected with either control or CCR9-specific siRNAs as described 
before. After 72 h, the cells were harvested and 8x104 cells in 100 µl of cytokine free X-
VIVO 20 medium were plated per well of a 96-well plate. To this 2x106 survivin-specific T 
cells, suspended in 100µl of X-VIVO 20 medium, were added. Tumor and T cells were co-
cultured for 1 min, 5 min and 20 min for T cell receptor complex analysis and for 20 min, 1 h 
and 2 h for phospho-STAT analysis. After respective co-incubation time points, each cell 
group was added to 100 µl of pan mouse IgG beads (Invitrogen) that were coated with 4 µg of 
anti-EpCAM antibody (clone HEA125, provided by G. Moldenhauer, DKFZ) for 30 min at 
4°C to separate EpCAM+ve MCF7 tumor cells from EpCAM-ve T cells. Bead-separated TCs 
were then lysed and total protein concentration was measured using the BSA Protein Assay 
kit (Thermo scientific) as detailed in the product manual. Protein concentration was 
normalized across all samples before phosphoprotein detection using the 7-plex T cell 
receptor signaling phosphoprotein kit or phospho-STAT 5-plex kit (Millipore, Billerica, U.S.), 
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as instructed by the manufacturer. For phospho-transcription factor analysis (section 4.19), 
5x105 MCF7 cells were transfected with control or CCR9 s1 siRNA for 72 h and protein 
lysates were used for phosphoprotein detection as above using the Multi-Pathway Cell 
Signaling kit (Millipore). Measurements were performed using the Luminex100 Bio-Plex 
System (Luminex) and all the data were analysed using the Bio-Rad Bio-Plex Manager 
software version 4.1.1 (Bio-Rad).  
3.4.8 Imprinting T cells with immunosuppressive tumor supernatants 
To assess whether CCR9 mediates suppression on T cells via soluble mediators, MCF7 tumor 
cells were reverse transfected with control or CCR9 s1 siRNA in 6-well plates as detailed in 
section 3.2.5. After 60 h, cell culture supernatants were harvested from both the knockdown 
conditions and used to culture 1x107 fresh survivin T cells, each with the respective 
supernatants overnight. On the following day, knocked down MCF7 tumor cells (CCR9hi and 
CCR9lo) were harvested and used as target cells, along with wild type MCF7 cells, and the 
respective supernatant treated T cells (CCR9hi and CCR9lo SSN treated TCs) were used as 
effector cells in the classical Cr-release assay. 
3.4.9 Flow cytometry 
For flow cytometric analysis of surface proteins, cells were harvested and washed in FACS 
buffer and set to 3x105 cells per sample. For harvesting adherent cells from tissue culture 
dishes, enzyme-free PBS-based Cell Dissociation Buffer (Gibco, Paisley, UK) was used 
instead of trypsin-EDTA, especially for CCR9 surface staining, as trypsinization resulted in 
the loss of surface expression when detected by flow cytometry. Fc receptors of the washed 
cells (human) were blocked with 166 µg of Kiovig (Baxter), a human immunoglobulin 
concentrate, in 100 µl FACS buffer for 20 min on ice to reduce unspecific antibody binding. 
For mouse samples, BD Fc Block (BD Biosciences) was used at 5% concentration in 50 µl 
FACS buffer for 20 min on ice. After blocking, cells were washed once in FACS buffer and 
then incubated with fluorophore-conjugated target-specific or isotype antibody at the 
concentrations indicated in section 2.6.1 for 20 min in dark on ice. After this, cells were 
thoroughly washed twice in FACS buffer to remove any unbound antibody. For human 
samples, 5 µl of 10 µg/ml propidium iodide (PI) solution was added to each sample just 
before acquiring as a dead cell marker. For mouse samples, cells were stained with Pacific 
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Orange viability dye (1:1000 in 50 µl FACS buffer) for 15 min on ice before Fc blocking. All 
samples were acquired with the FACS Canto II Cell analyzer machine (BD Biosciences) and 
data was analyzed using FlowJo software (Tree Star). 
3.5 Mouse work 
Approval for the animal work was obtained from the relevant regulatory authorities 
(Regierungspräsidium, Karlsruhe). Experiments were performed by Tobias Speck as a part of 
his M.Sc. thesis under my guidance. For assessing the in vivo effect of tumor-specific CCR9 
upon the anti-tumor cytotoxicity of T cells, xenograft mouse model based on immunodeficient 
NOD/SCID gamma (NSG) mice was used. Four-six weeks old female NSG mice were 
ordered from the Animal Core Facility at DKFZ, Heidelberg. CCR9-ve PANC-1-luc cells 
(transduced with the CCR9-specific shRNA plasmid) and CCR9+ve PANC-1-luc cells 
(transduced with the non-targeting shRNA control plasmid) were generated as described in 
section 3.1.2. Mice were shaved at the flank regions and subcutaneously injected with 4x105 
CCR9+ve tumor cells in the left flank and 4x105 CCR9-ve tumor cells in the right flank at day 
0. Cells were prepared in 100 µl of matrigel/injection and injected using the 0.4 mm x 20 mm 
needles. Following this, at d2 and d9, 5 out of the 8 tumor-bearing mice received adoptive 
transfer of expanded TIL 53 cells (described in section 3.4.2) intravenously into the tail vein 
(1x107 cells/100 µl PBS/mouse). The remaining three mice were left untreated. In vivo 
bioluminescent imaging using the IVIS1000 imaging system was used to monitor tumor 
growth. For this, mice were intraperitoneally injected with 100 µl of 30 mg/ml D-luciferin 
substrate and anaesthetized via inhalation of the isoflurane-O2 mixture (5 L/min). Mice were 
then placed onto the imaging platform of the IVIS system to acquire the emitted 
bioluminescence signal using the CCD camera. Signal intensity was quantified in 
photons/second/cm2/steradian. Mice were imaged twice a week with an exposure duration of 
10 sec.  
 
For the flow cytometric analysis, mice were sacrificed via cervical dislocation at the end of 
the experiment and spleens and tumors were removed and placed in ice-cold PBS. To obtain 
single cell suspension from spleens, they were pushed through 100 µm-pore strainers. For 
tumors, they were cut into small pieces and pushed through 100 µm-pore strainers. Cell 
suspensions were washed with ice cold PBS and centrifuged at 1700 rpm for 5 min at 4°C. 
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For spleens, cells were briefly resuspended in 2.5 ml of ACK buffer to lyse the erythrocytes. 
Following this, the cells were washed, centrifuged again and resuspended in 1 ml of FACS 
buffer. They were then filtered using a 40 µm-pore strainer and used for staining as described 
in section 3.4.9.  
3.6 Statistical evaluation 
Statistical differences between the test and the control groups were analyzed by the two-sided 
student’s t-test, unless indicated otherwise. In all statistical tests, a p-value ≤ 0.05 was 
considered significant with * = p<0.05, ** = p<0.01, *** = p<0.005. Pearson correlation test 
was used to ascertain the correlation between the replicates in the screen and for inter-screen 
comparisons of the overall cytotoxicity scores. Statistical analysis for the RNAi screen and 
gene expression datasets are detailed in the respective sections of the methods. 
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4. Results 
4.1 Establishment of the Luc-CTL cytotoxicity assay for immune-RNAi screen 
The primary aim of this thesis was to establish a large-scale-compatible, RNAi-based 
immunological assay which quantifies the effect of individual tumor genes on the cytotoxic 
ability of T cells. One of the attractive high-throughput approaches to quantify cell death in 
response to a treatment is the colorimetric measurement of release of either an exogenously 
introduced reporter enzyme or an endogenous enzyme released by the dying cells. In a tumor 
cell-T cell co-culture system, measurement of endogenous cellular metabolites as an indicator 
of tumor-specific cell death is invalid given the cross-contamination from metabolites 
released by the T cells themselves. Therefore, reporter enzymes, such as luciferase, could be 
employed to tag the tumor cells before the co-culture, making its detection in the co-culture 
supernatant a direct indicative of the T cell-mediated cytotoxicity. A typical immune-based 
kill assay requires the co-incubation of T cells and tumor cells for a minimum of 4 hours, but 
the half-life of the released luciferase enzyme from dying cells in the supernatant is 
approximately 20 minutes (111). Thus, rather than measuring the activity of the released 
enzyme, we aimed to measure the luciferase activity of the remaining live tumor cells that are 
left attached to the plate after treatment with T cells (112). Therefore, in this assay, termed as 
the Luc-CTL assay henceforth, lower the luciferase activity associated with the leftover tumor 
cells, higher is the T cell mediated cytotoxicity.  
To employ the Luc-CTL assay for immune-checkpoint discovery RNAi was performed in 
luciferase-tagged tumor cells and the CTL-mediated lysis of RNAi-transfected tumor cells 
was measured based on the luciferase signal (Figure 1A). In order to exclude genes whose 
knockdown in itself impacts on cell viability and hence luciferase activity, the Luc-CTL assay 
included a viability control per gene knockdown, to which no CTLs were added (Figure 1A). 
The difference in luciferase activity between the toxicity wells (containing CTLs) and the 
viability wells (without CTLs) was then calculated per gene to ascertain the immune-
modulatory hits (detailed in methods section 3.3.2). Importantly, the extent of tumor cell 
killing detected by the Luc-CTL assay was comparable to that obtained with a common test of 
T cell mediated cytotoxicity, the 51chromium-release assay (113), establishing the robustness 
and the reliability of the Luc-CTL assay (Fig. 1B). 
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Figure 1. Principle and performance of the Luc-CTL assay. (A) RNAi is performed with luciferase 
expressing cells that are challenged with or without CTLs. Before readout, cell supernatant is removed and the 
remaining intact cells are lysed to measure the residual cell-associated luciferase. To identify immune-
checkpoint regulators, the difference between normalized luciferase measurements for conditions with CTLs and 
without CTLs is calculated. siRNA enhancing CTL cytotoxicity will only reduce normalized luciferase levels 
under conditions with CTLs, hence the difference between luciferase measurements will be > 0. (B) Comparison 
between the Luc-CTL assay (■) and the classical chromium release assay (○) with MCF7 breast cancer cells as 
target cells and survivin-specific T cells as effector cells at varying effector to target (E:T) ratios. Error bars 
denote +/- SEM; n=3. 
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4.2 Optimization of RNAi screen parameters: cell line, cell density, siRNA 
transfection and luciferase expression 
Breast cancer was chosen as the model tumor type to implement the Luc-CTL assay-based 
screen for the discovery of novel immune modulators. This was not only because of its 
abundant prevalence, but also because its progression is marked with decreased 
immunocompetence, hinting at the involvement of putative immunosuppressive entities (114). 
To induce gene knockdown tumor cells were reverse transfected with siRNA pools, whereby 
four different siRNAs per target gene in a single pool were arrayed and coated onto the 
bottom of 384-well plates and overlaid with the transfection reagent and tumor cells. Since 
different cell lines exhibit different levels of susceptibility towards siRNA-based transfection, 
two different breast cancer cell lines, namely MCF7 and KS, were tested for their 
transfectibility with siRNAs. In parallel, different siRNA transfection reagents were tested to 
establish the most effective reagent that delivered the siRNAs to the cells. To achieve this, 
different lethal siRNAs targeting genes that are vital for cell growth and viability (described 
in Supplementary Table 1), such as ubiquitin C (UBC) or polo-like kinase 1 (PLK1), were 
used. Successful transfection of these siRNAs would lead to the loss of cell viability that can 
be read out via live/dead staining using the Hoechst dye. As shown in Figure 2A, MCF7 cells 
were found to be best transfectable with RNAiMAX and DharmaFECT2 in comparison to the 
other transfection reagents. However, DharmaFECT2 showed a mild cytotoxic impact on cells 
in comparison to RNAiMAX and therefore RNAiMAX was chosen as the desired transfection 
reagent for MCF7 cells for the high-throughput screen (Figure 2B). On the other hand, KS 
cells showed a strong resistance to siRNA-based transfection using the tested reagents (Figure 
2A).  
 
For the luciferase-based readout, MCF7 cells were tested for both transient and stable 
luciferase expression using a plasmid encoding a fusion protein of GFP and firefly luciferase 
(pEGFP-Luc). For stable cell line generation, MCF7 cells were electroporated with the GFP-
Luc plasmid, selected under antibiotic selection pressure and subsequently FACS sorted twice 
based on GFP expression to select cell populations stably expressing GFP-luc. The selected 
clones (MCF7luc) maintained high levels of GFP expression over time, monitored via 
fluorescent microscopy (Figure 2C), as well as exhibited high luciferase signal that could be 
silenced using firefly luciferase (FLuc)-targeting siRNA (Figure 2D). Moreover, a linear 
relationship was observed between the seeded MCF7luc cell numbers and the associated 
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luciferase activity (r2 = 0.99), whereby as low as 250 luc+ cells could be detected above the 
background (Figure 2E). Correlation between cell density and luciferase intensity was also 
used to determine the appropriate cell number for seeding in order to avoid overcrowding of 
the tumor cells in the small 384 wells which may lead to saturation of the luciferase signal. 
Since the generation of stable luciferase expressing clones can be tedious and time-intensive, 
transient luc expression in MCF7 cells for the Luc-CTL assay was next tested. Co-
transfection of wild-type MCF7 cells with siRNAs and the GFP-Luc plasmid was found to be 
efficient, with GFP expression being noted in more than 85% of control siRNA-treated cells 
compared to negligible signal in the UBC siRNA-treated cells (data not shown). This 
indicated that transient transfection of luciferase plasmid could be exploited for rapid 
screening in wild type tumor cells without creating stable clones. 
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Figure 2. Optimization of RNAi screen parameters. (A) MCF7 and KS breast cancer cells were reverse 
transfected with the described control (H2O blank, RLuc) or lethal (UBC, PLK1, COPB2) siRNAs in 384 well 
plates using different transfection reagents (DharmaFECT1,-2,-4 and RNAiMAX). Loss in cell viability was 
readout after 72 h using Hoechst staining with light green representing viable cells and dark green indicating loss 
in viability. Mean cell intensities + SEM are quantified for MCF7 cells with DharmaFect2 (red bars) and 
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RNAiMAX (blue bars) in B. n= 6. (C) Fluorescent microscopy showing GFP expression in MCF7luc stable cell 
line. Scale bar = 100µm. (D) Luciferase activity of the MCF7luc cell line upon transfection with mock, control 
siRNA, luciferase (FLuc)-targeting siRNA or UBC-specific siRNA using Trans-IT as the transfection reagent; 
n=4. (E) Linear relationship plotted between luciferase intensity versus cell number for MCF7luc cells seeded in 
384-well plate (r2= 0.9907; p<0.0001). Error bars denote +/- SEM. 
4.3 Antigen-restricted and antigen-unrestricted T cells for the high-throughput 
screen 
As effector T cells for the high-throughput screen, both options of using an antigen-
unrestricted as well as an antigen-restricted system were explored (Figure 3A). For the 
antigen-unrestricted system, polyclonal CD8+ T cells were purified from the peripheral blood 
lymphocytes of healthy donors and pre-activated in culture via triggering of the CD3-based 
primary and/or CD28-based co-stimulatory signals in the presence of interleukin 2 (IL-2). 
Degree of T cell activation using the three different activation protocols: anti-CD3 antibody + 
IL-2; soluble anti-CD3 and anti-CD28 antibody; or anti-CD3/CD28 antibody coated beads + 
IL-2, was compared using CD69 as an early T cell activation marker in flow cytometry based 
staining (115). As shown in Figure 3B, anti-CD3/CD28 antibody coated beads induced the 
highest level of activation of CD8+ T cells (72%) compared to the other activation protocols 
tested. Accordingly, it also induced a higher tumor lysis of MCF7 cells in comparison to the 
activation protocol using anti-CD3 antibody alone (Figure 3C) and was therefore chosen as 
the method of choice for polyclonal T cell activation. Tumor recognition and lysis by these 
pre-activated polyclonal T cells was induced by using anti-CD3 x anti-EpCAM bispecific 
antibody (bsAb). As shown in Figure 3A, one arm of this bsAb recognizes and binds to the 
EpCAM epithelial antigen, present on the MCF7 breast cancer cells, and the other arm binds 
to the CD3 receptor on the T cells, creating an artificial immune synapse which facilitates the 
lysis of target tumor cells in the proximity by pre-activated T cells (116). The specificity and 
effectiveness of the bsAb approach in mediating tumor lysis is shown in Figure 3D, whereby 
polyclonal T cells could induce tumor lysis in the Luc-CTL assay in the presence of anti-CD3 
x anti-EpCAM bsAb, but not in the presence of anti-CD3 x anti-CD19 bsAb, which binds to 
an unrelated B-cell antigen CD19 that is absent on the MCF7s. Bi-specific antibody-induced 
tumor lysis was also found to be dose dependent as shown in Figure 3E. For the antigen-
restricted system, survivin-specific CTLs (clone SK-1) were employed that recognize the 
HLA-A0201 restricted survivin(95-104) epitope expressed by the breast cancer cells, but fail to 
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recognize the T2 cells loaded with an unrelated HIV peptide (108). As shown in Figure 1B, 
survivin-specific CTLs recognize and lyse the MCF7 breast cancer cells in a dose-dependent 
manner. Both these systems have their own merits and limitations which are discussed in 
detail in section 5.1.3. Given that robust immune modifiers that extend beyond a single donor 
or setup were sought, the RNAi screen was performed in parallel under both the settings.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effector T cells for immune RNAi screen. (A) Scheme showing the antigen-unrestricted approach 
whereby pre-activated, polyclonal T cells are cross-linked to tumor cells using bi-specific antibody and the 
antigen-restricted approach, whereby antigen-specific CTL clones recognize tumor targets in context of peptide-
MHC I complex. (B) CD69 surface staining showing the activation of CD8+ T cells after 72h of stimulation with 
anti-CD3 antibody and IL-2, or with anti-CD3 and anti-CD28 soluble antibody, or with anti-CD3/CD28 antibody 
coated beads and IL-2. Gates were set based on the isotype control antibody. (C) Cr-release assay showing the 
cytotoxic capacity of polyclonal CD8+ T cells upon stimulation with either anti-CD3 antibody + IL-2 (○) or with 
anti-CD3/CD28 antibody coated beads (■) against MCF7 target cells. Lysis in both cases was induced by the 
addition of anti-CD3xEpCAM bi-specific antibody; n=3. (D) Luc-CTL assay performed at different T cell to 
MCF7 cell ratio with PBMC-derived CD8+ T cells and anti-CD3 x anti-EpCAM bi-specific antibody (○). Anti-
CD3 x anti-CD19 bi-specific Ab (■) was used as a specificity control since CD19 is a B-lymphocyte-specific 
antigen and therefore this bsAb fails to crosslink tumor to T cells. Lower luciferase intensity indicates higher 
lysis; n=8. (E) Cr-release assay showing % specific lysis of MCF7 tumor cells by polyclonal pre-activated CD8+ 
T cells at E:T of 50:1 in the presence of the indicated doses (x-axis) of bi-specific antibody. Error bars denote 
SEM. Experiments are representative of at least three independent repeats. 
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4.4 Immunosuppressive positive controls for the screen 
For a high-confidence hit calling from a data intensive RNAi screen, it is essential to have a 
clear distinction between the expected positive and negative phenotype. Therefore, as positive 
controls for the Luc-CTL assay, the reported immunosuppressive effects of PD-L1 (60), 
RCAS-1 (85) and CEACAM-6 (117) were validated in MCF7 cells. Knockdown of these 
immune-checkpoint molecules in MCF7 cells (Figure 4A) led to a varied but strong decrease 
in the luciferase activity of the remaining tumor cells upon co-culture with the pre-activated 
TCs and bsAb, indicating elevated immune-mediated tumor lysis under the knockdown 
conditions (Figure 4B). Downregulation of the respective immune-checkpoint molecules had 
no major impact on tumor cell viability per se, as determined in the CTG cell viability assay 
(Figure 4C). These were therefore chosen as the reference immunosuppressive controls for 
evaluating the screen efficacy, along with the scrambled control siRNA as the negative 
control. 
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Figure 4. Positive immunosuppressive controls for the RNAi screen. (A) MCF7 cells were reverse 
transfected with scrambled control, CEACAM-6 or PD-L1 specific siRNAs and harvested after 72 h for 
determining protein knockdown efficacy using western blot analysis. Immunoblots were probed with anti-beta-
actin antibody to verify equal protein loading. (B) Luc-CTL assay showing lysis of MCF7luc cells upon siRNA-
mediated knockdown of indicated immune-checkpoint molecules by polyclonal pre-activated CD8+ T cells and 
CD3xEpCAM bi-specific antibody. (C) CellTiter-Glo (CTG) cell viability assay showing the impact of immune-
checkpoint knockdown on the viability of MCF7 cells. siRNA against UBC, which is vital for cell viability, was 
used as a positive control. Error bars denote SEM. Experiments are representative of at least three independent 
repeats; n = 6. 
4.5 Workflow and performance of the high-throughput RNAi screen 
To translate the Luc-CTL assay to a high-throughput screening approach, a library of 516 
genes coding for transmembrane and cell surface proteins, involving many G-protein coupled 
receptors (GPCRs), was chosen as these are suitable targets for therapeutic function-blocking 
antibodies. The entire RNAi screen workflow and candidate identification procedure is 
outlined in Figure 5A. In brief, screen 1 and 2 were conducted with polyclonally-activated 
PBMC-derived CD8+ T cells in the presence of the bispecific antibody, whereas screen 3 was 
conducted with survivin-specific CTLs. T cells derived from a single donor were used for 
screen 1 and two different donors were used for each technical replicate in screen 2. 
Additionally, the screens were conducted with not only stably transfected MCF7luc cells 
(screen 1 and 3), but also with wild type MCF7 cells that were transiently transfected with the 
luciferase plasmid (screen 2). The latter approach can be easily and rapidly employed for 
screening of various tumor cell lines without the time-intensive generation of stable 
luciferase-positive clones. Finally, data from an additional screen (based on the CTG assay) in 
which cell viability was determined independent of the luciferase activity by measuring 
intracellular ATP levels (screen 4) was employed to exclude genes that impacted cell 
viability. Each screen (screen 1-3) was performed a set of 4 replicates, two of which were 
exposed to CTLs (toxicity set) and two were incubated without CTLs (viability set). The 
reproducibility of the replicates within each individual screen was satisfactory for both the 
toxicity set and the viability set. For example, the Pearson’s correlation coefficient for the 
replicates in the toxicity set in screen 2, which had two different donor-derived T cells per 
replicate, was 0.73 and for the viability set it was 0.94. 
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An overview of the results from the individual screens is depicted in Figure 5B-D, whereby 
each gene is plotted for its impact on cell viability (x-axis) and immune-susceptibility (y-
axis). Knockdown using the FLuc siRNA expectedly abrogated the luciferase signal under 
both conditions and served as an internal control for the luciferase-based readout. siRNAs 
targeting genes indispensable for cell survival (UBC, PLK-1) resulted in a clear loss of cell 
viability, thereby yielding high scores under non-treated condition (without CTLs; x-axis). In 
contrast, the negative control siRNAs (Ctrl1 and Ctrl 2) impacted neither the cell viability nor 
the immune susceptibility of tumor cells and therefore showed no effect on the luciferase 
intensity under both conditions (Figure 5B-D). In accordance with their reported immune 
regulatory function, silencing of PD-L1, GAL-3 and CEACAM-6 resulted in higher 
cytotoxicity scores, whereby PD-L1 showed a higher impact on tumor lysis. On the other 
hand, knockdown of caspase 3 (CASP3) and caspase 8 (CASP8), which are required for the T 
cell-mediated apoptosis of target cell (118, 119), resulted in decreased cytotoxicity score 
(Figure 5D). Independent assessment of all genes for their impact on cell viability was 
achieved using the CTG assay as shown in Figure 5E.  
 
 
 
 
 
 
 
Figure 5. Layout and analysis of the RNAi screen used to identify immune-modulatory tumor genes. (A) 
Workflow: RNAi screen was performed thrice, each time in duplicates, along with an additional CTG-based 
viability screen. Screen 1 and 2 were performed with polyclonal CD8+ T cells derived from three different 
donors along with bsAb, whereas screen 3 was performed with survivin-specific CTLs. MCF7luc stable cells 
wete used for RNAi in screen 1 and 3, while transient transfection of the luciferase plasmid was employed 24 h 
after siRNA transfection in screen 2. Luciferase intensity after CTL challenge was acquired and data was 
normalization and analyzed using the cellHTS2 package. (B-D) Graphical summary of gene function related to 
modification of T cell mediated tumor lysis and cell viability for screen 1, 2 and 3 respectively. Positive score = 
reduced cancer cell viability, negative score = increased viability. X axis: Influence on cell viability without 
addition of T cells. Y axis: Influence on cell viability with addition of T cells. Appropriate immune-modulatory 
(PD-L1, CEACAM-6, GAL-3 and CASP3) and lethality (UBC, PLK-1) controls and few positive and negative 
immune modulatory hits (CCR9, GRM4) are highlighted herein. (E) Normalized score for all the tested genes 
depicted for the CellTitre Glo (CTG) assay used for determining lethal genes that directly affect MCF7 cell 
viability upon knockdown. 
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4.6 Data analysis and hit-calling parameters 
For hit identification, loess-normalized differential score between the viability and toxicity 
values for all genes was calculated for each screen. As explained earlier in Figure 1A, a 
candidate immunosuppressive hit would reveal a positive differential score and a candidate 
immune-activating hit would exhibit a negative differential score. This is shown exemplarily 
for PD-L1 and CASP8 in Figure 6A, whereby the difference between without CTL and with 
CTL condition is positive for immunosuppressive control PD-L1, negative for immune-
activating control CASP3 and no difference is observed for the control siRNA. Based on these 
differential scores, unsupervised hierarchical clustering was performed for all genes across the 
three screens to identify robust immune modulators that regulated anti-tumor immune 
response in all the three screening formats (Figure 6B). Clustering analysis revealed 
heterogeneity in the immunomodulatory performance of certain genes across the three 
screens, which is represented by the overall correlations between the three screens (Figure 
6C). The observed heterogeneity was expected given the intentional assorted biological set-up 
used for the three different screens, including not only the source and format of effector T 
cells, but also the nature of tumor cell modification with regard to luciferase expression. 
Therefore, to identify only robust immune-regulatory genes that modified anti-tumor immune 
response irrespective of the T cell source or tumor modification, candidates were considered 
as hits if they popped up in at least two of the three screens. Notably, the loess differential 
score between the viability and cytotoxicity value can be high for even a non-
immunosuppressive candidate if its viability score is too low while the cytoxicity score is 
minimal. To account for this bias, clustered hits were filtered based on threshold values for 
both toxicity and viability scores that were set based on the performance of the controls and 
sample’s quartile distribution (detailed in the methods section). Filtered genes were then 
ranked based on the sum of their loess differential scores from all three screens, resulting in 
top immunomodulatory candidates that are represented in Supplementary Figure 1. Filtering 
based on the CTG screen data was additionally employed as a second layer to exclude hits 
that revealed viability effects. Taken together, the presented screening methodology could 
reliably confirm the already established immune modulatory ligands in breast cancer cells, 
thereby proving its efficacy to identify novel immune modulatory ligands on tumor cells. 
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Figure 6. Identification of immune-modulatory tumor genes. (A) Principle behind hit identification using 
differential score calculation between without CTL and with CTL condition (black bar and white bar, 
respectively). MCF7 cells were transfected with siRNAs against immune-suppressive PD-L1 and immune-
activating CASP3 and challenged with or without CTLs and bsAb in Luc-CTL assay. For each condition, the 
luciferase activity was normalized to that of the control treatment and is shown here. (B) Heat map 
representation of differential scores used to identify positive immune modulators (yellow), i.e. the knockdown of 
which enhance CTL mediated cell killing and negative immune modulators (blue), i.e. the knockdown of which 
reduce CTL mediated cell killing are depicted for all genes tested in the 3 different screens. Differential scores 
prior to filtering are shown (see methods). Selected representative clusters of high-confidence hits are displayed 
herein. (C) Correlation between the toxicity scores across the three screens as evaluated using the Pearson’s 
correlation test. 
4.7 Validating potential immunosuppressors in the re-run of the primary assay 
Next, based on the overlap between the three screens and the exhibited immunosuppressive 
strength (Figure 6B, Supplementary Figure 1), selected hits (CCR9, GHSR and CCRL1) were 
repeated in the Luc-CTL assay for first round of validation. This was performed at least thrice 
with individual deconvoluted as well as the pooled siRNAs to reproduce the results obtained 
from the primary screens and to refine the candidate hit-list for further validation studies. As 
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shown in Figure 7A, the identified gene hits were compared for their impact on CTL-
mediated tumor lysis based on the range set by control siRNA on one hand and the PD-L1 
siRNA on the other hand. As a control for the selectivity of the RNAi screen, PTGER3 which 
was not identified as an immunosuppressive hit was also included in the assay re-run. Cell 
viability assay was performed to rule out the siRNA sequences that impacted cell viability 
(Figure 7B). Both GHSR and CCR9 exhibited a strong suppression on the CTL-mediated 
tumor lysis, comparable to that observed with PD-L1, without affecting cell viability per se. 
For CCRL1, s2 and s3 siRNA sequences resulted in an increase in tumor lysis, however they 
also showed a commensurate impact on cell viability. Based on the strength of 
immunosuppression observed in the screens as well as in the re-run assays, CCR9 was chosen 
for further validation studies. Interestingly, its role in immune modulation has never been 
reported before. 
 
 
 
Figure 7. Pre-validation of the identified hits using primary assay re-runs. (A) Luc-CTL assay was 
performed with the deconvoluted siRNAs against the indicated target genes in MCF7luc cells using the PBMC-
derived, pre-activated CTLs and bsAb at 10:1 (E:T) ratio. PD-L1 was used as the positive immunosuppressive 
control along with the negative control siRNA. (B) CTG cell viability assay was performed with the individual 
siRNAs transfected in MCF7luc cells. Mean +SEM are plotted herein; n=4. Data presented here is representative 
of at least three independent experiments. 
4.8 Knockdown of CCR9 sensitizes the breast cancer cells towards immune lysis 
C-C chemokine receptor 9 (CCR9) is a surface bound receptor which binds to the chemotactic 
ligand CCL25 and is involved in the trafficking of a subset of immune cells to the intestinal 
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mucosa and thymus (120). To validate the role of CCR9 in suppression of anti-tumor immune 
response, correlation between the knockdown efficiency and the immunosuppressive 
phenotype of the individual siRNAs from the CCR9-targeting siRNA pool was first 
evaluated. CCR9’s mRNA and protein estimation in the MCF7 cells after knockdown with 
individual siRNAs revealed s1 and s2 siRNA sequences to induce the strongest knockdown, 
which correlated well with their functional effect on the CTL-mediated cytotoxicity (Figure 
8A, B). Since at least two different CCR9 siRNA sequences, amongst four, exhibited both 
knockdown as well as functional phenotype on CTL-mediated lysis, with CCR9 s1 siRNA 
being the strongest, it was reasonable to assume the direct involvement of CCR9 in immune-
suppression rather than an off-target effect. None of the siRNAs by themselves impacted on 
cell viability as determined in the CTG assay (Figure 8C). Furthermore, CCR9 s1 siRNA was 
also found to reduce the surface expression of CCR9 receptor on MCF7 cells in the flow 
cytometry staining (Figure 8D). Therefore, s1 siRNA sequence was chosen as the model 
siRNA for further studies. Knockdown of CCR9 using the s1 siRNA sequence markedly 
increased the tumor lysis of breast cancer cell lines MCF7 and MDA-MB-231 by survivin-
specific CTLs in the secondary independent chromium-release assays (Figure 8E, F), 
validating its role in tumor-mediated immune-inhibition. Impact of CCR9 knockdown on 
CTL-mediated cytotoxicity was found to be comparable to or even better than PD-L1 
knockdown (Figure 8B and E). 
 
 
 
 
Figure 8. CCR9 knockdown sensitizes breast tumor cells to immune attack. (A) MCF7 cells were 
transfected with the described siRNA sequences for estimating the mRNA and protein levels using RT-PCR 
(left) and western blot (right) analysis respectively. GAPDH and beta-actin were used as controls for RNA and 
protein normalization respectively. (B) Luc-CTL cytotoxicity assay with PBMC-derived CTLs as effector 
population and MCF7 as target cells, which were transfected with individual (s1-s4) or pooled CCR9 siRNA 
sequences. PD-L1 and non-specific control siRNAs were used as positive and negative controls respectively for 
CTL-mediated cytotoxicity. (C) CTG viability assay with MCF7 cells upon CCR9 knockdown using the 
described siRNAs, along with lethality control (UBC) and negative non-specific control siRNA. (D) Flow 
cytometry staining for CCR9 surface expression on MCF7 cells after 72h of knockdown with control or CCR9 
s1 siRNA. Shift in the CCR9+ population can be seen in CCR9 siRNA treated samples. Gates were set based on 
the isotype antibody control. (E, F) Cr-release assay showing % specific lysis of MCF7 (E) or MDA-MB-231 
(F) breast cancer cells by survivin-specific T cells at different ratios upon CCR9 knockdown and in comparison 
to the positive control PD-L1 (□) or non-specific control siRNA (■). 
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4.9 Overexpression of CCR9 on breast cancer cells inhibits immune lysis 
Next, to investigate whether overexpression of CCR9, which is observed in many tumor 
entities, correlated with poor immune response, breast cancer cells were transfected with 
histidine-tagged CCR9 expression plasmid. Since CCR9 is a 7-transmembrane receptor, the 
efficacy of the exogenously introduced CCR9 to be expressed and targeted to the cell surface 
was first assessed. Easily transfectable HEK 293T cells showed a marked upregulation of 
CCR9 expression on the cell surface upon transfection with the CCR9 vector compared to the 
control vector in the flow cytometry staining (Figure 9A). Similar increase in cell surface 
expression of CCR9 was also noted in MCF7 cells transfected with the overexpression 
construct. Importantly, overexpression of CCR9 resulted in a clear decrease in antigen-
specific lysis of MCF7 cells by the survivin-specific CTLs (Figure 9B), indicating that cell-
surface bound CCR9 inhibits immune-recognition and lysis of the protected tumor cells. 
 
A B
 
 
Figure 9. CCR9 overexpression inhibits immune lysis of tumor cells. (A) Flow cytometry staining for CCR9 
surface expression in HEK 293 cells transfected with control or histidine-tagged CCR9 (CCR9-His) 
overexpression vector. Gates were set based on isotype control. (B) Cr-release assay showing % specific lysis of 
MCF7 cells by survivin-specific T cells. MCF7 cells were transfected with control vector (■) or CCR9-His 
expression vector (○) 72h prior to the assay. 
4.10 CCR9 inhibits the secretion of cytolytic enzymes and Th1 cytokines  
Cytotoxic T cells upon antigen encounter and engagement secrete effector cytokines such as 
interferon-gamma (IFN-γ), interleukin-2 (IL-2) and cytolytic enzymes such as perforin and 
granzyme B that bring about tumor lysis (121). Tumor-specific CCR9 inhibits this anti-tumor 
immune response by inhibiting the secretion of these immune mediators as seen in the IFN-γ 
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and granzyme B ELISpot assays. siRNA-mediated knockdown of CCR9 in MCF7 cells 
significantly increased the secretion of IFN-γ and granzyme B by survivin-specific T cells as 
shown in Figure 10A and B. Furthermore, luminex analysis of the tumor/TC co-culture 
supernatant revealed that CCR9 also selectively inhibited the secretion of T-helper-1 (Th1) 
cytokines, such as IL-2 and tumor necrosis factor-alpha (TNF-α), as well as IL-17, but 
increased the secretion of the immunosuppressive cytokine IL-10 (Figure 10C). Together, 
these data indicate that tumor-associated CCR9 impedes the anti-tumor, Th1 cytokine-based 
immune response. 
 
 
 
Figure 10. Tumor-specific CCR9 impedes Th1-type immune response. (A, B) ELISpot assay showing IFN-γ 
(A) and granzyme B (B) secretion by survivin-specific CTLs, as spot numbers, upon CCR9 knockdown (black 
bars) in MCF7 cells compared to the control knockdown (white bars). T cells (TC) only group was used to 
account for the background noise. Triplicate wells were used per sample group. (C) Luminex assay showing 
cytokine levels in the supernatant from the co-culture of survivin-specific T cells (TC) with either CCR9- MCF7 
(transfected with CCR9-specific siRNA) or CCR9+ MCF7 (transfected with control siRNA) cells. Error bars 
denote SEM. Statistical differences between the control siRNA and CCR9 siRNA treated groups were calculated 
using two-sided student’s t-test: * = p<0.05, ** = p<0.01, *** = p<0.001. 
4.11 CCR9 expression in melanoma inhibits the anti-tumor reactivity of TILs 
After validating the immunosuppressive role of CCR9 in breast cancer setting, its influence 
on anti-tumor immunity in other tumor entities was investigated next. For this, primary 
melanoma cells (termed as M579 cells) isolated from a metastatic melanoma patient were 
used. M579 cells were additionally stably co-transfected with an HLA-A2 expression 
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construct and luciferase-expressing plasmid (M579-A2-luc). At the same time, tumor 
infiltrating lymphocytes (termed as TIL 412) were isolated from a sygeneic metastatic 
melanoma patient and expanded in vitro using the modified Rosenberg’s rapid expansion 
protocol. TIL 412 consists of CD8 (43%) as well as CD4 (55%) T cells as shown in the flow 
cytometry staining of Figure 11A. Amongst the CD8+ T cell compartment, almost half 
express PD-1, around 34% express TIM-3 and ~17% express both the exhaustion markers, 
underscoring the exhausted state of the tumor infiltrating T cells in this melanoma patient 
(122, 123) (Figure 11A). Since M579-A2 cells were also found to express CCR9, the next 
question therefore was whether CCR9 inhibition could alleviate the anti-tumor immune 
reactivity of the exhausted TIL 412 cells as well. Indeed, knockdown of CCR9 in M579 cells 
resulted in a marked increase in tumor lysis by TIL 412 cells in both Luc-CTL and Cr-release 
cytotoxicity assays, performing even better than PD-L1 inhibition (Figure 11B, C). 
  
 
 
 
Figure 11. CCR9 inhibition induces anti-tumor reactivity of melanoma patient-derived exhausted TILs. 
(A) Flow cytometry staining showing the percentage of CD8 and CD4 T cells amongst CD3 T cells (left) and the 
percentage of PD-1 and TIM-3 positive T cells amongst CD8 T cells (right) in the melanoma patient-derived TIL 
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412 T cell culture. Gates were set based on the isotype controls. Stainings were performed by Tillmann Michels. 
(B, C) Luc-CTL (B) and Cr-release (C) cytotoxicity assays showing lysis of M579-A2-luc cells upon siRNA-
mediated CCR9 knockdown by TIL 412 cells. Error bars denote +/- SEM. 
4.12 CCR9 suppresses the tumor lysis potential of TILs in pancreatic adenocarcinoma 
Next, the influence of CCR9 expression upon anti-tumor immune response in pancreatic 
adenocarcinoma (PDAC) was assessed. PDAC results from the malignant neoplasm arising in 
the exocrine component of the pancreas and has an extremely poor prognosis with the 5-year 
survival rate as low as 6% (124). Tumor infiltrating lymphocytes, although present in PDAC 
patients, are known to be subjected to systemic and local immune suppression (125). 
Accordingly, an exhausted immune phenotype, based on the PD-1 and TIM-3 surface 
staining, was noted in TIL 34 and TIL 53 T cell cultures which were isolated and established 
from two poorly differentiated PDAC male patients (Figure 12A). TIL 34 is a CD8/CD4 
mixed T cell culture, whereas TIL 53 consists primarily of the CD8+ T cells (Figure 12A). 
Upon siRNA-mediated knockdown of CCR9 in PANC-1 pancreatic tumor cell line, a 
remarkable two-six fold increase in the tumor lysis capacity of both these exhausted TILs was 
noted in the Luc-CTL and Cr-release cytotoxicity assays (Figures 12B, C). Additionally, 
polyclonal CD8+ T cells derived from the peripheral blood of healthy donors also showed an 
enhanced IFN-γ secretion when co-cultured with CCR9 knocked down PANC-1 cells 
compared to the control knockdown cells (Figure 12D). 
 
Taken together these data indicate that CCR9 mediates immunosuppressive effect in a broad 
variety of tumors with a clear clinical impact on the tumor lysis capacity of the infiltrating 
lymphocytes. 
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Figure 12. CCR9 mediates immune suppression in pancreatic cancer. (A) (left) CD8 and CD4 T cell 
population distribution amongst the TIL 34 and TIL 53 lymphocyte culture as determined by flow cytometry; 
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(right) PD-1 and TIM-3 expression on CD8+ T cells of TIL 34 and TIL 53 culture as analysed by flow cytometry 
(grey histogram: anti-PD-1 or anti-TIM-3 staining, white histogram: isotype Ab). Stainings were performed by 
Antonio Sorrentino. (B, C) Increase in TIL 34 (B) or TIL 53 (C) mediated lysis of PANC-1 cells upon CCR9 
knockdown as determined by the Luc-CTL (B) or the Cr- release assay (C). (D) ELISpot assay showing IFN-γ 
secretion by polyclonal CD8 T cells upon co-culture with control or CCR9 knocked down PANC-1 tumor cells 
in the presence of anti-CD3 x EpCAM bi-specific antibody. Only T cells or PANC-1 cells were used as controls 
to account for the background signal. Error bars denote +/- SEM; statistical difference between control siRNA 
and tested siRNA groups are highlighted herein whereby * = p<0.05, ** = p<0.01, *** = p<0.001. 
4.13 Tumor-specific CCR9 does not impair the activation of the T cell receptor 
signaling complex 
To explore whether the immunosuppressive effect of CCR9 on T cells is mediated by the 
impairment of the T-cell-receptor (TCR)-based signaling events, survivin-specific CTLs were 
co-cultured with either control siRNA-transfected (denoted as CCR9hi) or CCR9 siRNA-
transfected (CCR9lo) MCF7 cells. The activation status of the TCR-associated signaling 
complex in these CCR9hi or CCR9lo treated TCs was then assessed at different time-points 
using the phospho-plex assay. Early TCR signaling events, upon antigen recognition and 
binding, involve the tyrosine phosphorylation of the cytosolic tyrosine kinase Lck, which 
phosphorylates ITAM (immunoreceptor-tyrosine based activation motifs) on the CD3 
subunits. This leads to the phosphorylation of ZAP-70 and subsequently of the 
transmembrane adaptor protein LAT, which in turn recruits a broad range of signaling 
molecules in the T cell. As shown in Figure 13A and B, tumor-specific CCR9 did not alter the 
magnitude or the kinetics of the TCR activation and associated downstream signaling in the 
survivin-specific T cells upon antigen encounter. This indicates that CCR9-mediated immune 
suppression occurs via an alternate pathway in T cells that makes them unresponsive to tumor 
targets despite the presence of a sound and effective TCR signaling complex. 
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Figure 13. CCR9 does not impair TCR activation and signaling. (A-B) Phospho-plex analysis of the 
activated T cell receptor signaling complex in survivin-specific T cells (TC) that were co-cultured with MCF7 
cells transfected with control (CCR9lo) or CCR9-specific siRNA (CCR9hi). Log2 ratio of mean fluorescent 
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intensity (MFI) of specified phospho-proteins to the unstimulated survivin-specific TCs are depicted for all the 
studied analytes after 5 mins of co-incubation (A) or individually for all the analytes after 1 min, 5 min and 20 
mins of co-culture (B). TCs stimulated with PMA and ionomycin were used as positive control. Experiments 
were performed in triplicates and are representative of atleast three independent repeats. Mean +/- SEM are 
plotted herein. 
4.14 CCR9 impedes STAT signaling in antigen-specific T cells 
An alternative route of T cell activation is the STAT (signal transducer and activator of 
transcription) family of transcription factors which regulate the expression of cytokines in T 
cells (126). Since an impediment in Th1 cytokine production by T cells in response to CCR9+ 
tumor targets was already observed (Figure 10C), it was next sought to assess the impact of 
CCR9 on the activation status of STAT signaling in the encountered TCs. To analyze STAT 
signaling exclusively in the T cells after co-culture with the tumor cells, we exploited the 
preferential expression of EpCAM antigen on the surface of epithelial MCF7 tumor cells, and 
its lack thereof on the endothelial T cells, for separating the two cell populations (Figure 
14A). Using anti-EpCAM antibody-coated magnetic beads, which effectively bound only 
EpCAM+ve MCF7 tumor cells, EpCAM-ve T cells were separated from the co-culture with 
more than 95% purity as assessed by the CD3 surface staining on the purified TCs (Figure 
14B). Time-course based analysis of STAT activation in CCR9hi and CCR9lo treated TCs 
revealed a significant decrease in STAT1 signaling, along with decrease in STAT2 and 
STAT5a/b signaling, in survivin-specific T cells mediated by CCR9 (Figure 14C, D). This 
impairment in STAT1 signaling could also be verified on western blot using phospho-specific 
STAT1 antibody, indicating that tumor-derived CCR9 impairs STAT signaling, especially 
STAT1, in the encountering TCs (Figure 14E). Taking together the observations from the 
cytokine and phospho-STAT analysis, it can be concluded that tumor-specific CCR9 impedes 
Th1-type immune response via differential regulation of the STAT pathway. 
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Figure 14. CCR9 impairs STAT activation in T cells. (A) Flow cytometry staining showing EpCAM 
expression on MCF7 and survivin T cells before co-culture. After 2h of co-culture they were separated using 
EpCAM-Ab-coated magnetic beads. EpCAM and CD3 staining on the bead-free cell suspension is shown at the 
extreme right. Cells were gated based on the isotype control. (B) Phospho-plex analysis showing the activation 
of STAT signaling in survivin-specific TC upon encountering CCR9lo MCF7 cells (CCR9-siRNA transfected) 
compared to CCR9hi MCF7 cells (control siRNA transfected). (C) Time-course based phosphorylation of 
STAT1 in survivin-specific T cells (TC) that were co-cultured with CCR9hi or CCR9lo MCF7 cells for the 
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indicated time points. Log2 ratio of mean fluorescent intensity (MFI) to the unstimulated TCs are plotted in B 
and C. (D) Western blot analysis of phospho-STAT1 protein levels in the respective TC samples. Beta-actin was 
used as the loading control. All experiments were performed in triplicates. Error bars denote +/- SEM. * = 
p<0.05, ** = p<0.01, *** = p<0.001, as calculated by two-sided student’s t-test. 
4.15 Role of CCL25 in CCR9-mediated immune-suppression 
CCL25 is the only known interacting partner and ligand for CCR9 and was also found to be a 
weak immune-inhibitory hit in the first two screens (Supplementary Figure 1). Therefore, 
CCL25’s involvement in tumor immune-suppression and its role in defining CCR9’s 
tolerogenic phenotype were characterized next. Firstly, CCL25 was found to be produced by 
all the studied tumor cell lines, although at varied levels, as determined by ELISA (Figure 
15A). Interestingly, shRNA-mediated stable knockdown of CCR9 did not affect CCL25 
production by MCF7 breast cancer cells (Figure 15A). Next, inhibition of CCL25 using 
siRNAs or blocking antibody showed no effect on antigen-specific lysis of MCF7 or PANC-1 
cells by the respective antigen-specific T cells, au contraire to the CCR9 knockdown (Figure 
15B-D). Although, stronger responses were observed in IFN-γ and granzyme B secretion by T 
cells upon CCL25 knockdown in MCF7 cells (data not shown). In case of M579 melanoma 
cells, which secreted higher levels of CCL25 (Figure 15A), knockdown of CCL25 resulted in 
a significant increase in tumor lysis by TIL 412 (Figure 15E). Conversely, the addition of 
recombinant CCL25 protein to the tumor/TC co-culture led to a slight decrease in IFN-γ 
production as measured by ELISA (Figure 15F), which was not noted for the other cell lines. 
Thus, based on the current data, CCL25 does not seem to play a driving role in immune 
suppression of breast or pancreatic tumors, but might be crucial for melanoma cells. Further 
investigations would be required to clarify CCL25 as an immunosuppressive entity. 
 
 
Figure 15. Role of CCL25 on immune-suppression of antigen-specific T cells. (A) ELISA showing CCL25 
expression in cell lysates from indicated cancer cell lines. rhuCCL25 and rhuPD-L1 were used as positive and 
negative controls respectively for CCL25 detection by anti-CCL25 antibody coated ELISA plates. (B-E) Cr-
release assay showing % specific lysis of MCF7 (B, C), PANC-1 (D) or M579-A2 (E) cells by survivin TC (B-
C), TIL 53 (D) or TIL 412 (E) upon CCL25 inhibition using either specific siRNAs (B, D, E) or blocking 
antibody (C). Unspecific siRNAs or isotype antibodies were used as controls in the respective experiments. (F) 
ELISA showing HLA-A2-restricted IFN-γ production by TIL 412 cells in response to HLA-A2 positive M579-
A2 cells or HLA-A2 negative MaMel 33 melanoma cells upon addition of rhuCCL25 protein to the co-culture. 
Error bars denote SEM; n=3. Parts of the experiments were performed by Tobias Speck and Tillmann Michels. 
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4.16 CCR9-mediated immune suppression requires direct cellular contact with T cells 
It is possible that CCR9 mediates its immune-suppressive effect via other soluble ligands or 
mediators. To examine this possibility, survivin-specific T cells were treated with the cell 
culture supernatants from either the knocked down (CCR9lo) or control (CCR9hi) MCF7 
tumor cells overnight and then challenged against CCR9hi or CCR9lo MCF7 cells in the 
cytotoxicity assay. Against the same tumor target, neither of the supernatant treated T cells 
showed any difference in their recognition and lytic capacity. The difference in lysis between 
the different groups depended entirely upon CCR9’s expression on the tumor targets rather 
than on the TC treatment (Figure 16A). This clearly indicated that soluble mediators released 
by the tumor cells, including CCL25, are not involved in defining CCR9’s 
immunosuppressive capacity. Rather direct cellular contact between the CCR9-bearing tumor 
cells and the T cells is essential for the observed immunosuppressive effect. To further assess 
whether cytoplasmic signaling mediated by the surface-bound CCR9 in tumor cells plays any 
role in immunosuppression, pertussis toxin (PTX) was used. PTX irreversibly inhibits and 
uncouples the Gαi family of proteins from binding to the GPCRs and thereby blocks the 
downstream GPCR signaling. Treatment of CCR9+ve MDA-MB-231 tumor cells with PTX 
inhibited its migration towards the chemotactic stimuli of CCL25 in a transwell migration 
assay, proving the effectiveness of pertussis toxin in blocking CCR9’s downstream signaling 
that is responsible for its chemotaxis (Figure 16B). However, inhibition of intracellular CCR9 
signaling by PTX failed to elicit elevated tumor lysis by antigen-specific T cells, when 
compared to the CCR9 gene knockdown, indicating that CCR9-mediated immune suppression 
on T cells is independent of its intracellular signaling in the tumor cells (Figure 16C). 
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Figure 16. Direct cellular contact is essential for CCR9-mediated immunesuppression. (A) MCF7 cells 
were transfected with control or CCR9-specific siRNAs and 48h later the respective supernatants (CCR9lo or 
CCR9hi SSN) were used to culture survivin TCs overnight. Supernatant treated TCs were then used as effector 
cells against CCR9lo or CCR9hi MCF7 tumor cells in the Cr-release assay along with wild type MCF7 cells. (B) 
Migration of MDA-MB-231 tumor cells in response to rhCCL25 protein with or without pertussis toxin (PTX) in 
24-well transwell migration assay. Migrated cells were fixed and stained with CTG dye and luminescence was 
used to score the migration capacity. ***= p <0.001 (C) Cr-release assay showing % specific lysis of MCF7 
cells pre-treated with or without pertussis toxin, along with CCR9 knockdown MCF7 cells as positive control. 
Error bars denote SEM. 
4.17 CCR9 induces immune-suppressive gene signatures in encountered T cells 
To better understand the mode of CCR9-mediated immunosuppression in T cells, global gene 
expression study was performed to compare the changes in the transcriptome of the T cells 
that encounter CCR9hi versus CCR9lo MCF7 tumor cells. Microarray analysis comparing 
these two populations revealed a list of differentially up and down regulated genes in the 
CCR9lo treated T cells compared to the CCR9hi treated T cells which is represented in the 
volcano plot of Figure 17A and listed in the associated heatmap of Figure 17B. Immune 
response-related genes such as LTA, IL2RA, CISH were found to be upregulated; whereas 
genes that inhibit T cell maturation and effector function such as CD24, EFNA1, ID1, TOB1 
were downregulated in the CCR9lo treated T cells, which was found to be in accordance with 
the increased cytotoxicity observed before. Gene-annotation/ontology (GO) analysis of the 
top up-regulated genes revealed an significant enrichment of genes involved in the positive 
regulation of immune response, while genes involved in lymphocyte maturation and apoptosis 
were found to be significantly enriched in the downregulated list (Figure 17C). Next we 
wondered if these gene signatures associated with the re-activated T cells upon tumor-specific 
CCR9 knockdown overlap with the gene signatures generally associated with an activated T 
cell population. Using a publically available gene expression study comparing the 
unstimulated CD8+ T cells to activated T cells (105), overlapping gene signatures in the 
upper quartile could be identified that were present in both the studies (Figure 17D). Taken 
together, these data underscore CCR9’s role in keeping the anti-tumor T cells in a suppressed 
and relatively immature phase, which can be reprogrammed to an effector phenotype upon 
successful inhibition of tumor-specific CCR9. 
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Figure 17. CCR9 knockdown on tumor cells reprograms the T cells towards an immune effector 
phenotype. MCF7 cells transfected with control siRNA (CCR9hi) or CCR9 siRNA (CCR9lo) were co-cultured 
with survivin TCs for 12 h. Gene microarray was performed with the total RNA extracted from purified T cells 
after the co-culture. (A) Volcano plot illustrating fold change (FC; log2) in gene expression intensities compared 
with p-value (-log2) between CCR9hi and CCR9lo treated TCs. Horizontal bar at y = 4.32 represents a statistical 
significance of p=0.05 (genes in grey below this line did not reach significance). LogFC cut-off at ± 0.5 is 
represented by the vertical lines. (B) Heatmap representation of the top upregulated (LogFC>0.5) and 
downregulated (LogFC<-0.85) genes with p≤0.05. Individual replicates per sample group are shown herein. (C) 
GO categories of differentially expressed genes in CCR9lo TCs as determined by DAVID. Percentages of genes 
within the differentially regulated gene list that are attributed to a certain GO category are represented here with 
only statistically significant enrichment terms being plotted. (D) Differentially regulated genes overlapping in 
the presented microarray study and a published study comparing gene expression changes in CD8 T cells before 
and after activation (GSE7572; refer to methods for details) is represented. Significantly up and down regulated 
genes (top 30%) in both the studies were compared and few of the common gene signatures are summarized in 
brief. 
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4.18 Synergistic blockade of immune modulatory pathways: CCR9, PD-L1 and 
CEACAM-6  
Combinatorial inhibition of multiple immune-checkpoint molecules is currently being 
investigated in the clinics to further strengthen the magnitude of the anti-tumor T cell 
responses in cancer patients. This study therefore investigated whether any synergy exists 
between the immune-modulatory pathways mediated by CCR9 and those of other immune-
checkpoint molecules, namely PD-L1 and CEACAM-6, so that co-inhibition could result in 
even heightened immune response against target tumor cells. For this, CCR9 and PD-L1 or 
CCR9 and CEACAM-6 were co-inhibited in the MDA-MB-231 or PANC-1 tumor cells, 
respectively, and evaluated for impact on CTL-mediated tumor lysis. Antibody-mediated 
blockade of PD-L1 or CEACAM-6 on the surface of CCR9 knocked down tumor cells 
showed no striking additive effect on the anti-tumor T cell responses, however individual 
blocking of both these immune-checkpoint entities was successful in elevating the cytotoxic 
potential of the tumor-specific CTLs (Figure 18A, B). 
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Figure 18. Synergy between CCR9 and PD-L1 or CCR9 and CEACAM-6 mediated immune-suppressive 
pathways. (A-B) Cr-release cytotoxicity assay showing % specific lysis of MDA-MB-231 cells by survivin-
specific CTL (A) or PANC-1 tumor cells by TIL 53 (B) upon CCR9 knockdown along with PD-L1 (A) or 
CEACAM-6 (B) inhibition. Anti-PD-L1 and anti-CEACAM-6 blocking antibodies, along with respective isotype 
controls, were used for PD-L1 and CEACAM-6 inhibition on tumor cells. Curve represents the mean and error 
bars denote +/- SEM. 
4.19 Tumor pathways modulated by CCR9 
For rational designing of efficient combinatorial therapies for cancer treatment, it is essential 
to identify whether redundant or divergent signaling pathways underlying the potential 
immune modulatory function of CCR9 and other immune-checkpoint entities exist, which 
could then be synergistically targeted. Although intracellular signaling mediated by CCR9 
was not found to be critical for its immunosuppressive effect on the T cells, it might still be 
relevant for its impact on other tumor immune-modulatory pathways and therefore relevant 
for the design of synergistic approaches. As a preliminary approach in this direction, signaling 
pathways downstream of CCR9 were characterized using the phospho-protein analysis of 
major transcription factors in WT versus CCR9 knockdown MCF7 cells. Knockdown of 
CCR9 resulted in a significantly reduced signaling via Akt and S6-kinase, whereas a 
potentially compensatory upregulation in the ERK kinase pathway was noted, indicating their 
involvement in the downstream CCR9 signaling (Figure 19).  
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Figure 19. Altered signaling cascades in MCF7 tumor cells upon CCR9 knockdown. MCF7 cells were 
reverse transfected with control or CCR9-specific siRNA and after 72h protein lysates were used for phopho-
plex analysis of the major transcription factors indicated on x-axis (studied phopho-sites are indicated in 
brackets). Statistical differences between the two groups were analyzed using student’s two-sided t-test, n=3. 
Error bars represent SEM. 
4.20 Blocking antibody for inhibiting CCR9’s immunosuppressive effect 
Therapeutic targeting of the classical immune-checkpoint nodes such as CTLA4, PD-L1 or 
PD-1 has gained clinical success owing to the generation of effective blocking antibodies that 
inhibit the interaction of these negative immune-checkpoint receptors with their respective 
counterparts on the tumor or T cell surface. Therefore it was next assessed whether any of the 
commercially available anti-CCR9 monoclonal antibodies could inhibit the tumor immune-
resistance phenotype imposed by CCR9 expression. Antibody blockade of CCR9 on MCF7 
cells using the two different antibody clones from R&D and Abcam manufacturers failed to 
induce tumor lysis or IFN-γ secretion by survivin-specific CTLs, irrespective of the dosage 
(Figure 20A-C). However, the reported blocking properties of the R&D anti-CCR9 antibody 
clone could not be verified in the transwell migration assay, where the addition of anti-CCR9 
antibody did not inhibit the migration of CCR9+ve MDA-MB-231 breast cancer cells towards 
the chemotactic gradient of the recombinant CCL25 protein (data not shown), leaving open 
the search for a function blocking CCR9 antibody that could also inhibit its 
immunosuppressive property. 
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Figure 20. antibody-mediated blockade of CCR9. (A-B) Cr-release assay showing % specific lysis of MCF7 
tumor cells by survivin TCs upon CCR9 inhibition using commercial blocking antibodies from R&D systems 
(A) or Abcam (B) along with the respective isotype controls. Tumor cells were incubated with the respective 
antibodies for 30 min on ice before being used as target cells in the cytotoxicity assays. (C) ELISpot assay 
showing IFN-γ secretion by survivin TC as spot numbers in response to MCF7 cells upon CCR9 inhibition using 
anti-CCR9 Ab (R&D systems) or isotype control Ab. Only T cells (TC) were used as control for unspecific 
background IFN-γ secretion. Mean ±SEM are indicated herein. 
4.21 CCR9 inhibition results in delayed tumor growth in vivo upon adoptive T cell 
transfer in xenograft NSG mouse model 
To evaluate the in vivo relevance of CCR9 as a tumor-associated immunosuppressive entity, 
stable CCR9 knockdown variants of the PANC-1 tumor cell line were created which also 
expressed the luciferase reporter to allow in vivo bioluminescent imaging. Figure 21A shows 
the knockdown efficiency of the lentivirally transduced PANC-1-luc cells using the non-
targeting shRNA (NTS) or the CCR9-specific shRNA (shCCR9). As expected, stable CCR9 
knocked down cell variants were more susceptible to immune lysis than their counterparts in 
the in vitro chromium release assay (Figure 21B). 
 
For the preliminary in vivo analysis, 4x105 cells each of PANC-1-luc-NTS (CCR9+ve) and 
PANC-1-luc-shCCR9 (CCR9-ve) tumor cell lines were subcutaneously implanted in the left 
and the right flank respectively of the NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) 
immunodeficient mice, which lack mature T, B and NK cell compartments (scheme in Figure 
21C). These mice then received intravenous injection of 1x107 pancreatic tumor infiltrating 
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lymphocytes (TIL 53) at day 2 and day 9. Tumor growth was followed using bioluminescent 
imaging via intraperitoneal injection of the luciferin substrate until day 35 (Figure 21D). As 
shown in Figure 21E, in the early phases of the tumor growth, CCR9-ve PANC-1 tumors 
grew much slower in response to the adoptive T cell transfer than the CCR9+ve tumors, 
indicating that CCR9 suppresses the anti-tumor activity of the transferred T cells in vivo as 
well. Differences in the tumor growth upon T cell therapy remained statistically significant at 
d35 (Figure 21F). However, towards the later stage, a difference in the tumor growth kinetic 
between the CCR9+ve and the CCR9-ve tumor cells was also observed in mice that received 
no T cell transfer, indicating that long term knockdown of CCR9 in itself might confer some 
growth disadvantage to the growing tumors (Figure 21G). Therefore, this argues for a 
cautious interpretation of the results. Nevertheless, adoptively transferred human T cells could 
be detected in the spleen and the tumors of the treated mice even after day 35 as assessed by 
the CD3/CD45 based flow cytometric analysis of the respective tissue samples (Figure 21H 
and I). Relative frequency of the detected CD3+ CD45+ TILs was found to be significantly 
higher in the tumor bed than in the spleen (Figure 21J), out of which majority of them were 
CD8+ T cells (Figure 21K). This distribution was consistent with the ratio of CD8 and CD4 T 
cells in the TIL 53 culture before transfer (~ 85% CD8+ and ~ 8.5% CD4; Figure 12A). 
 
Taken together, these results give a preliminary indication of the in vivo relevance of targeting 
CCR9 as an immune-checkpoint node for application in cancer immunotherapy. These 
findings need to be replicated for reproducibility with additional improvements implemented 
to the tumor model. 
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Figure 21. In vivo inhibition of CCR9 for adoptive T cell transfer therapy. (A) Immunoblot analysis 
showing stable knockdown of CCR9 in PANC-1 tumor cells transduced with lentiviral construct coding either 
CCR9-specific shRNA (sh6) or the non-targeting shRNA (NTS). Immunoblot was probed for beta-actin as 
control for equal protein loading. (B) Cr-release assay showing TIL 53-mediated lysis of PANC-1 tumor cells 
upon stable knockdown of CCR9 (CCR9-ve) compared to the control knockdown (CCR9+ve). Mean ±SEM are 
plotted herein, n=3. (C) Scheme for the in vivo mouse experiment involving the s.c. injection of CCR9+ve or 
CCR9-ve PANC-1-luc tumor cells in the left and right flank, respectively, of the NSG mice at the beginning of 
the experiment (d0). Following this, at d2 and d9, mice received i.v. injection of TIL 53 cells (n=5) or no T cells 
at all (control group for tumor growth; n=3). Mice were imaged for bioluminescence twice every week until d35 
to monitor tumor growth upon treatment or without. After d35, mice were sacrificed and organs were harvested 
for flow cytometric analysis. (D) Representative bioluminescence imaging showing the growth of CCR9+ve and 
CCR9-ve tumors at d35 of TIL-treated mice. (E) Individual tumor growth per mice (in terms of luciferase units; 
RLU) is plotted for the first 25 days where maximum immune control of tumors is expected. (F) Mean ±SEM of 
tumor growth in terms of luciferase intensity is represented herein for CCR9+ve and CCR9-ve PANC-1 tumors 
in mice that received adoptive TIL transfer. n=5. (G) Tumor growth curve showing mean± SEM of CCR9+ve or 
CCR9-ve tumors in non-TIL treated mice. n=3. Statistical difference was calculated using paired student’s t-test. 
(H-K) Representative dot plots showing the gating strategy to identify CD3+ and CD45+ human T cells in the 
spleen (H) and tumor (I) of TIL-treated (or non-treated control) mice after d35. Individual frequency of 
CD3+CD45+ T cells in spleen, CCR9+ve and CCR9-ve tumors of each mice are cumulatively shown in J. 
Percentage of CD4 and CD8 T cells amongst the CD3+CD45+ T cells are representatively shown on the extreme 
right in the dot plots (H and I) and the cumulative data is shown in K. Tumors were harvested from 3 mice 
whereas all 5 mice were used for FACS staining of the spleen. Statistical differences between the test groups 
were assessed using the paired student’s t-test. Experiments were designed and supervised by me and executed 
by Tobias Speck as a part of his Masters thesis. 
4.22 Extension of the screening methodology to additional tumor entities 
Given that tumors are heterogeneous entities, even in their immune-modulatomic profile, it 
would be essential to elaborate this screening methodology to other tumor entities in order to 
find tumor-specific immune-modulators that could be targeted for individual cancer types or 
to find common checkpoint nodes for broader applicability and therapeutic development. 
Colorectal cancer (CRC) is the third most common cause of cancer worldwide and represents 
an urgent need for successful translation of immunotherapeutic approaches for better 
treatment options for patients (127). Therefore, to extend the screen to CRC setting, HLA-A2 
positive SW480 colorectal cancer cell line was chosen. Reverse transfection of lethal siRNAs 
(targeting UBC and PLK-1) using RNAiMAX as the transfection reagent led to a strong 
decrease in viability of the SW480 cells as demonstrated by the Hoechst dye staining in 
Results 
Page 90 
 
Figure 22A-B. Thus SW480 cells could be used for the siRNA-based screening strategy using 
RNAiMAX as the transfection reagent. For applicability of the SW480 cells in the Luc-CTL 
assay, plasmid transfection efficacy of these cells was next tested using the pEGFP-Luc 
plasmid and different transfection reagents. Remarkably, plasmid transfection with Trans-IT, 
which worked well for the MCF7 cells (Figure 2D), failed to induce luciferase expression in 
the SW480 cells (Figure 22C). Nevertheless, Lipofectamine LTX-PLUS and GeneJammer 
transfection reagents could successfully deliver the GFP-Luc plasmid to the SW480 cells as 
determined by the luciferase activity upon plasmid transfection (Figure 22C). SW480 cells 
were next tested for whether they could be recognized and lysed by the already established T 
cell cultures. Both survivin-specific T cell clone and pancreatic cancer derived TIL 53 could 
recognize and lyse SW480 cells in the chromium-release cytotoxicty assay in a dose-
dependent manner, with survivin TCs exhibiting higher cytotoxicity against SW480s. It is 
indeed known that colorectal cancer in general and SW480s in particular express higher levels 
of the survivin antigen (128), supporting the observed effect. Both these T cell populations 
could therefore be used as effector cells against SW480s in an siRNA-based immune screen 
to uncover CRC-associated immune-modulators. 
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Figure 22. Establishing SW480 colorectal cancer cells for the immune RNAi screen. (A-B) SW480 
colorectal cancer cells, seeded at two different concentrations, were reverse transfected with the described 
control (H2O blank, RLuc) or lethal (UBC, PLK1, COPB2) siRNAs in 384 well plates using RNAiMAX as the 
transfection reagent. Loss in cell viability was readout 72h later using Hoechst staining with light green 
representing viable cells and dark green indicating loss in viability (A). Total cellular intensities upon siRNA 
transfection are enumerated in B. (C) Luciferase activity of SW480 cells upon transfection with pEGFP-Luc 
plasmid with the indicated transfection reagents. Mock represents addition of no transfection reagent. (D) Cr-
release cytotoxicity assay showing % specific lysis of SW480 cells using survivin-specific T cells (○) or 
pancreatic cancer-derived TIL 53 cells (■) as effector CTLs at titrating E:T ratio. Error bars denote +/- SEM. 
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5. Discussion 
5.1 High-throughput screening for immune modulatory genes 
One of the major challenges for the systematic discovery of novel immune modulators has 
been the lack of a robust and relevant immune-based assay that is suitable for scale up to 
high-throughput needs. This thesis addresses this problem by establishing and implementing a 
screening assay which overcomes the current limitations and subsequently proves its efficacy 
by successful validation of the identified hits. Previous screening strategies to uncover 
immune modulators have relied on the release of IFN-γ as an indicator of anti-tumor immune 
cell reactivity (103, 129). However, IFN-γ secretion alone by immune cells does not always 
correlate with cellular cytotoxicity (130, 131). This could be partly due to the fact that certain 
tumor cells (for example, LNCaP prostate cancer cells) lack the expression of IFN-γ receptor 
or have defects in the downstream JAK-STAT signaling pathway, making them insensitive to 
IFN-γ in the in vitro assays (132). This is further reiterated from the observations in the field 
of viral immunology, where HIV vaccines that predicted T cell responses based on  IFN-γ 
secretion failed to reduce the viral load in infected patients (133). Therefore, in this study 
direct tumor cell lysis by the T cells was set out as the end-point of the assay readout. 
5.1.1 Assessment of cytotoxicity 
Quantification of target cell lysis by immune cells has classically relied on the chromium 
(51Cr)-release based cytotoxicity assay which involves the tagging of target cells with a 
radioactive salt of chromium, sodium chromate (Na251CrO4) (113). However, the short half-
life and the radioactive nature of the assay itself make this assay unsuitable for an RNAi-
based immune screen. Alternatives to the 51Cr-release assay for quantifying immune-mediated 
cytotoxicity can be broadly classified into the following genres: 
 
1. Fluorescent dye-based assays: These employ tagging of the tumor cells with 
fluorescent dyes such as calcein (134), BCECF (135), CFSE (136), MUH (137) etc. 
However, not all target cells take up and retain fluorescent dyes with equal ease and 
higher spontaneous release of dyes leads to low signal to noise ratio (134). 
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2. Flow cytometry-based assays: These employ the detection of apoptosis markers, such 
as annexin V (138), caspase 3 (139), 7-AAD (140), on the target cells at single cell 
level upon co-culture with immune cells. However, this requires efficient separation of 
the target and immune cell populations in the flow cytometric set-up, making data 
analysis time and labor-intensive, along with the requirement for automated 
acquisition dashboard for flow cytometers for batch sample processing. Moreover, 
apoptosis marker analysis using flow cytometric staining only captures the cells 
undergoing apoptosis at the time of staining. This overlooks the impact of immune-
mediated lysis during the initial hours of the tumor-T cell co-culture.  
 
3. Reporter enzyme-based assays: These require the tagging of tumor cells with 
exogenous reporter enzymes, such as luciferase (firefly or renilla), beta-galactosidase 
or lactate dehydrogenase (LDH), before the co-culture with T cells (111, 134, 141). 
Tumor cell viability can then be estimated based on the loss or residual enzyme 
activity. For example, luciferase activity can be quantified by measuring the emitted 
bioluminescence resulting from the oxidative catalysis of luciferin substrate to 
oxyluciferin by the tumor-derived luciferase enzyme. Such systems offer the ease of 
readout desirable for a high-throughput screening approach. 
 
Keeping the above caveats in mind, this study adapted the luciferase-based readout assay 
from Brown et al (107), combined it with the RNAi approach and successfully tested the 
resulting screening system to identify known as well as novel immune modulators which 
could be further validated in independent assays. Besides being non-radioactive, the 
luciferase-based cytotoxicity assay, termed as the Luc-CTL assay in this study, also exhibits: 
high sensitivity, high signal-to-noise ratio, ease of readout, simplified data analysis and allows 
batch processing of samples using standard robotics. All of this makes the Luc–CTL assay, in 
comparison to the other alternatives above, the most suitable assay for high-throughput 
immune screening needs. Notably, the Luc-CTL assay is based on the detection of the 
luciferase activity in the leftover live tumor cells upon removal of the dead cells from the 
culture wells, which assumes the efficient removal of the dead cells upon aspiration of the cell 
culture supernatant. However, this needs to be controlled and monitored for individual tumor 
cell lines which might differ in their adhesion properties to the surface of the wells. 
Accordingly, the Luc-CTL assay would be unsuitable for screening purposes in the 
suspension cell lines. Besides screening for tumor-associated gene modifiers of CTL 
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responses, luciferase-based cytotoxicity assay could also be applied to screen for modulators 
of NK (natural killer) cells, NK-T cells, cytotoxic CD4+ T cells and interferon-producing 
killer DC (IKDC) using the same principle as above. 
5.1.2 Gene knockdown for high-throughput approaches  
Both siRNA as well as shRNA based formats have been widely employed for high-throughput 
RNAi screens. Given that the tumor cell lines are generally amenable to transfection with 
siRNAs and that it doesn’t require specialized bio-safety hoods that are necessary for virus-
based transductions, this study employed the siRNA-based screening library for its purpose. 
RNAi screens based on synthetic siRNA duplexes make use of arrayed and pre-spotted 
siRNAs in individual wells of 384- or 96-well microtiter plates. These, when complexed with 
RNAi transfection reagent, could reverse transfect the overlaid cells to induce transient gene 
knockdowns. However, at this stage the right choice of transfection reagent which could 
successfully deliver the siRNAs to the cells is critical, as not all reagents do the job similarly 
for all the cell lines and therefore this needs to be carefully optimized for a given cell line. 
Cationic lipid based transfection of siRNAs is generally employed for successful siRNA 
delivery in arrayed cell culture systems. Cationic lipids, consisting of positively charged polar 
head group linked to apolar alkyl chains, interact with the negatively charged phosphate 
backbone of nucleic acids forming a complex which fuses with the negatively charged cell 
membrane. The transfection complex enters the cells via endocytosis and once inside, the 
siRNA diffuses through the cytoplasm, where it is recognized by the cellular RISC machinery 
and targeted for mRNA inhibition. siRNA duplexes in the endosomes could also be 
recognized by RNA-sensing Toll-like receptors (TLR), especially TLR-3, -7 and -8; however 
chemical modifications of nucleosides, such as 2'-O-methyl, are nowadays employed to 
suppress the immunerecognition of siRNAs (142). Nevertheless, there are numerous cell types 
and lipid structure that influences the transfection efficiency, case in point being RNAiMAX 
which could efficiently deliver siRNAs to MCF7 cells but not to KS cells (Figure 2A). This 
emphasizes the necessity for pre-optimization of siRNA delivery for individual cell types 
while conducting patient-specific rapid RNAi screening protocols. 
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5.1.3 T cell recognition format for high-throughput assays 
With regard to the nature of the tumor and T cell interaction used for the screen, both antigen-
unrestricted as well as antigen-restricted systems were successfully employed. This was done 
for several reasons. Firstly, this study sought to uncover robust immune modifiers that were 
not biased based on the use of T cells derived from a single donor. Establishing multiple T 
cell clones from different donors with the same antigenic specificity is technically challenging 
and time intensive. Whereas, polyclonal T cells could be easily isolated and expanded from 
the peripheral blood of multiple donors and used as effector T cells for the screen. Secondly, a 
genome-wide RNAi screen for immune-modulators would typically require one to ten billion 
T cells - a number which is difficult to obtain from the expansion of antigen-restricted clones 
compared to the polyclonal T cells from the peripheral blood. Thirdly, the antigen-
unrestricted system using the bi-specific antibody helps to additionally uncover those tumor-
associated immune modulatory targets that can be synergistically inhibited to increase the 
clinical efficacy of the bsAb-based therapy (143). Fourthly, the antigen-restricted system 
recapitulates the real supramolecular complex structure of the immune synapse involving the 
TCR-peptide-MHC interaction and the resulting co-stimulatory signals, which is missing 
from the CD3-mediated activation of the polyclonal T cells. Taking these caveats into 
consideration, both T cell formats were used so that TCR signaling-dependent as well as -
independent immune modifiers could be identified by comparing the two approaches. Indeed, 
55% overlapping immune-inhibitory hits from all the three screens were found to be common 
between the antigen-unrestricted (either of the two screens) and the antigen-restricted screen.  
 
One of the attractive approaches to customize the antigen-specificity of a T cell is by 
introducing transgenic TCRs which could alleviate the problem of isolating low frequency 
antigen-specific T cell clones from the patients. However, an important parameter to keep 
under consideration with the antigen-specific T cell clones is the affinity of their T cell 
receptor (TCR). High affinity TCR-transgenic T cells bind strongly to their pMHC partners 
on the tumor targets, but they represent an unlikely and small proportion of the natural 
repertoire of anti-tumor T cells, since high affinity TCR-bearing T cells that are reactive to 
tumor-associated antigens (which are mostly dysregulated self-antigens) are subjected to 
peripheral tolerance mechanisms (144). In accordance with this, it has been observed that 
most of the naturally occurring anti-tumor T cells isolated from cancer patients bear low-
affinity TCRs which possibly escape the strong tolerance mechanism to persist in the 
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circulation and are favored over the high affinity effector T cells by the tumors themselves 
(145, 146). Therefore, to keep the in vitro RNAi screen as close to the in vivo patient scenario 
as possible, it would be recommended to use low-affinity, naturally occurring anti-tumor T 
cells rather than strong affinity engineered T cells. The survivin-specific T cell clone used in 
this study was isolated from the peripheral blood of an HLA-matched (to limit alloreactivity) 
breast cancer patient bearing a relatively low affinity TCR. In the peptide titration assay, 
10−7–10−6 M concentration of survivin95−104 peptide loaded onto T2 cells resulted in the half-
maximum of IFN-γ secretion by survivin-specific T cells, proving the mild affinity of its TCR 
(108). Importantly, the inhibition of the identified immune modulatory targets on tumor cells, 
as shown in the post-validation studies, could enhance the anti-tumor response of even these 
low-affinity survivin T cells. Additionally, it is important to note that performing a high-
throughput genome-wide RNAi screen with antigen-specific CTL clones might also result in 
true hits being masked or false hits to pop up given that the genes involved in regulating the 
antigen expression and/or processing itself might be targeted. In such a scenario, post-screen 
validations with CTL clones of different antigenic specificity than the one used for the initial 
screen could bypass the problem. 
5.1.4 Performance and interpretation of the high-throughput screen 
Performance of the established high-throughput screening methodology is reflected by its 
sensitivity to identify the already established immune-inhibitors (PD-L1, Gal-3, RCAS-1) and 
immune activators (CXCL9). However, a certain degree of heterogeneity in the performance 
of the individual genes was noted across the first two screens (e.g., 23 common hits out of the 
54 overall hits), as well as in comparison to the third screen. This was expected given their 
different biological set ups, not only with regard to the different CTL source, but also with 
regard to the use of genetically engineered MCF7luc cells or wild-type MCF7 cells transiently 
expressing luciferase. Even though technical replicates within each screen were in the 
acceptable quality range, more biological replicates would be required to be certain that the 
observed heterogeneity between the different screens does not represent a technical pitfall, but 
rather has a biological meaning. On the same note, it is interesting to note the observations 
from the three different yet similar RNAi screens in which the investigators in each study 
infected siRNA-transfected HeLa (147, 148) or HEK (149) cells, that expressed HIV receptor 
CD4, with HIV-1 virus in order to determine the host genes essential for virus replication. 
Each of these studies yielded more than 200 filtered hits, but when compared to each other, 
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showed a mutual overlap of only 13-15 genes (150). This limited overlap in rather similar 
screens emphasizes the importance of doing a biologically mixed screening asking the same 
question in order to identify high-confidence hits.  
 
Surface-bound immune modulators are easy targets for therapeutic antibody development. G-
protein coupled receptors (GPCRs), which represent a sizeable fraction of the surface-bound 
molecules, were screened in this focused study as a proof-of-concept of the screening 
methodology. Extension of this approach to all surface-related entities would be an essential 
step forward for future screening approaches. Unfortunately, none of the current commercial 
siRNA libraries are uniquely dedicated to the cell surfaceome coverage, therefore custom-
designed libraries would need to be produced. With regard to GPCRs, they have been well 
described to be involved in metastasis, angiogenesis, proliferation and survival among other 
functions (151). Therefore, it is not surprising that they hold more than 30% of the market 
share for FDA-approved drugs currently (152). However, the involvement of GPCRs, 
including the chemokine and chemokine-receptor sub-family, in immune regulation hasn’t 
been investigated in depth before. This study sheds a new light on the role of GPCRs in 
immune regulation of cancer progression which merits further investigation. 
 
Considering the use of a focused siRNA library in this study, a hit rate of ~10% was noted for 
identifying potential immune inhibitors. When put in the context of genome-wide screens, this 
discovery rate might appear high and therefore warrants careful functional validation of the 
individual candidates. Off-target effects are not uncommon in RNAi-based screenings and 
could lead to the discovery of false hits (153). They might occur if an siRNA sequence in 
addition matches to an unintended mRNA sequence, leading to its degradation and creation of 
a mixed phenotype which might be construed as a false-positive hit (153). Additionally, 
partial sequence similarity of the seed region of an siRNA to the 3’ untranslated region (UTR) 
of an unrelated mRNA might cause the translational repression of the unintended mRNA, 
leading to the same consequence as above. Finally, sequence-independent recognition of 
siRNA duplexes by the cellular sensors, such as Toll-like receptors which can activate type-I 
interferon signaling, might interfere with the appropriate interpretation of readout assays 
leading to false-positives (154). Consequently, commercial companies selling siRNA libraries 
are on a constant look out for unintentional complementarities for their siRNA sequences that 
are omitted from their databases on a continuing basis. However, it is also plausible that this 
high discovery rate might indeed represent the complex regulatory networks that govern the 
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peripheral immune surveillance. Immune response-related genes represent a major proportion 
of the genome, out of which cell surface signaling proteins, which were already enriched in 
this study, play a pivotal role in immune modulation (155). Moreover, a previous screen for 
tumor ligands that modulate NK cell function also revealed a high number of immune-
modulatory candidates (103), indicating the complex nature of immune surveillance that 
possibly involving multiple players. 
 
Besides for CCR9, preliminary experimental validations have been performed for few of the 
other identified immunosuppressive hits, including GHSR, TRHDE, OR51E2, HTR1D, IL8 
and IL8RA. Strong immunosuppression in both luciferase as well as Cr-release based 
cytotoxicity assays could be demonstrated in breast cancer cell lines using the survivin-
specific T cells for GHSR, TRHDE and OR51E2, with mild effects observed for IL8 and 
IL8RA (preliminary findings, not presented here). Further repetitions and additional analysis 
of the T cell effector functions (such as cytokine and cytolytic enzyme production) upon 
target gene knockdown would be required to confirm the immune modulatory role of these 
candidate genes. Nevertheless, successful validation of these candidate genes in the primary 
Luc-CTL and the secondary Cr-release assays stresses the robustness of the screening 
methodology which appears to have a low false-positive hit rate. 
 
Both PD-L1 and CEACAM-6, which were intended as immunosuppressive controls, could be 
successfully identified as negative modulators of anti-tumor immunity in the RNAi screen. 
Although PD-L1 is known to mediate immune suppression in breast cancer setting (65), 
CEACAM-6’s involvement in immune modulation of breast cancer has never been reported 
before. Interestingly, CEACAM-6 is overexpressed on a majority of human breast cancers 
with expression being correlative to poor prognosis (156). Although not presented here in 
detail, CEACAM-6 was further validated as a potent immunosuppressor in breast cancer as a 
sub-project of the presented thesis. CEACAM-6 expression on multiple breast tumor cell lines 
was found to inhibit antigen-specific tumor lysis by reactive T cells. Moreover, therapeutic 
inhibition of CEACAM-6 with function-blocking antibody could slow down tumor growth 
upon adoptive T cell transfer in a breast cancer xenograft mouse model, indicating the 
therapeutic relevance of targeting CEACAM-6. Notably, the detection of such a valid immune 
suppressor as a part of the screening methodology further strengthens the biological 
sensitivity of the screening approach.  
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5.2 Functional validation of the high-throughput screen 
5.2.1 C-C chemokine receptor 9 (CCR9) 
CCR9 (previously known as GPR-9-6) is a 42 kDa member of the beta-chemokine receptor 
family containing the C-C motif. Like most other G-protein coupled receptors, CCR9 is also a 
seven transmembrane protein with a short extracellular domain. The CCR9 gene is mapped to 
the chromosome 3 on the p21.3 locus and transcribes two spliced variants: one of which lacks 
12 amino acid residues at the N-terminal end (157). Expression of CCR9 is restricted to the 
intraepithelial lymphocytes (IELs) and to a small subset of the beta7+ T cells in the 
circulation (158). Along with integrin α4β7 (or LPAM), CCR9 is one of the key homing 
receptors of effector T cells, regulating their migration to intestinal mucosa in response to the 
chemotactic stimulus provided by its ligand CCL25, which is constitutively expressed by the 
epithelial cells of the intestine (120) (Figure VIII). CCR9 knockout mice show no major effect 
on the intrathymic T-cell development; however a reduction in the intraepithelial γδ T cells is 
noted (159). In cancer, CCR9 has been shown to be overexpressed in breast, ovarian, 
pancreatic and prostate cancer, aiding in tumor cell migration and invasion (160-162). Its 
expression positively correlates with the histopathological state of the tumor (162). Recently, 
CCR9 expression has been shown to mark the tolerogenic plasmacytoid DCs that are capable 
of suppressing acute graft-versus-host disease (163). However, the exact functional role of 
CCR9 in defining the tolerogenic phenotype was never elucidated. This study is the first one 
to point out the functional role of CCR9 in actively suppressing anti-tumor immunity. 
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Figure VIII. Role of CCR9 in the homing of IELs. Integrin α4β7’s expression on the CCR9+ T cells facilitate 
its attachment to mucosal vascular addressin cell adhesion molecule-1 (MadCAM-1) expressed on the small 
intestinal vascular endothelial cells (a-b). This is followed by the migration of the T cells into the lamina propria 
in the direction of the CCL25 gradient, expressed constitutively by the intraepithelial cells (c). Adapted from 
Agace, 2008 (164). 
 
 
CCR9 was found to be strongly immunosuppressive in all the three screens. Subsequent 
validation studies effectively showed that tumor-specific expression of CCR9 inhibited tumor 
lysis as well as effector Th1 cytokines production by antigen-specific T cells, making 
CCR9+ve tumors highly immune-resistant. Previous studies have demonstrated that triplet 
production of IFN-γ, IL-2 and TNF-α cohort by virus-specific CD8+ T cells correlates with 
improved virus control in vitro as well as in vivo (165, 166). The same has been shown for 
anti-tumor CTL responses whereby secretion of these poly-cytokines is known to be tightly 
associated with higher peptide sensitivity and superior tumor recognition by antigen-specific 
CTL clones (167). Similar cytokine release pattern was observed upon CCR9 knockdown 
which would explain the pro-tumor attack environment generated by disarming the tumor 
cells of CCR9 expression. Additionally, IL-10, which is known to mediate immune 
suppression by selectively inhibiting the CD28 co-stimulatory pathway in antigen-specific T 
cells, was also downregulated upon CCR9 knockdown (168).  
 
Of note, CCR9-mediated immune suppression was found to be comparable, or even stronger 
in some instances, to PD-L1, making one speculate whether it overtakes and replaces PD-L1 
as one of the major immunosuppressive pathway in certain tumors. One reason for the 
observed effect might be that MCF7 cells, compared to the MDA-MB-231 breast cancer cells, 
are believed to express lower levels of surface-bound PD-L1 (65). However, even in the 
MDA-MB-231 cells CCR9 was found to mediate comparable levels of immune suppression 
as PD-L1 (Figure 18A). CCR9-mediated immunosuppression was noted not only in breast 
cancer but also in multiple tumor entities, stressing its importance as a key immune regulator. 
However, the lack of autoimmune phenotype in CCR9 null mouse limits its claim as an 
important player in the central immune tolerance. Rather, it appears that the deregulated 
expression of CCR9 is exploited by the tumors to mediate pro-tumor pathways including 
immunosuppression. 
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Importantly, this study found out that tumor infiltrating lymphocytes (TILs) derived from 
melanoma and pancreatic cancer patients are susceptible to CCR9-mediated 
immunosuppression. Cellular therapy involving isolation, ex vivo expansion and autologus 
adoptive transfer of patient-specific TILs has been shown to induce tumor regression in 
metastatic melanoma patients with overall response rate of 40-60% (169). But only a fraction 
of them show durable responses and therefore one of the major challenges that remains to be 
tackled is to increase the frequency of these durable responses. Two of the doctoral students 
in our lab (Tillmann Michels and Antonio Sorrentino) have established the ex vivo culture and 
expansion protocol for TILs derived from melanoma and PDAC patients (TIL 412 and TIL 
34, TIL53; respectively) and have characterized their exhausted phenotype in culture based on 
PD-1 and TIM-3 double-positive surface expression. Given, the immune-exhausted phenotype 
of these TILs in the tumor microenvironment, further enablement of the T cell effector 
function by targeting the immune-checkpoint nodes would be a promising approach to 
strengthen the TIL-based therapy. This is even more critical for PDAC-derived TILs, which 
are known to be less tumor-reactive (170), with TIL 53 showing a weak basal killing of 
around 10% against syngeneic tumor cell line at 100 to 1 E:T ratio. Additionally, it would be 
interesting to see whether tumor-specific CCR9 blockade, which reactivates these exhausted 
TILs to kill again, induces a durable imprinting on the T cells or not. 
 
TCR downstream signaling has been shown to be inhibited upon the engagement of PD-1 
receptor on the activated T cells with PD-L1 and is defined as the mode of action of PD-L1 
mediated immunosuppression (171). CCR9, however, seemed to act independent of its effect 
on the TCR signaling, as the level of T cell activation was found to be similar irrespective of 
tumor’s CCR9 expression and even comparable to the superantigen stimulated TCs. This 
might suggest that a threshold level of activation is already achieved when survivin TCs 
interact with antigen-bearing MCF7 tumor cells and further fluctuations in TCR signaling 
upon manipulation of CCR9 expression might be unfeasible. This doesn’t come as a surprise 
as CCR9 was found to mediate strong immunosuppression even in the antigen-unrestricted 
screen which lacked the TCR interaction. Nevertheless, CCR9 was found to impair the 
activation of STAT-1 pathway in the encountering T cells. STAT-1 is typically activated upon 
interferon signaling (especially IFN-γ), following which phospho-STAT dimers translocate to 
the nucleus and bind to the interferon-stimulated response elements (ISRE) in the promoter 
region of the target genes (such as CD80, CD40, IL-12, CDKN1A) inducing their expression 
(126). In accordance with this finding, a previous study has also demonstrated a similar 
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enhancement in STAT-1 phosphorylation levels upon inhibition of PD-1 signaling in T cells 
isolated from the HCV-infected patients (172). Moreover, intratumoral exhausted T cells in 
follicular lymphoma patients also exhibit lower STAT1 signaling upon stimulation compared 
to the non-exhausted counterparts (173). Given that Stat1-/- mice fail to reject immunogenic 
tumors and their T cells lack cytolytic function (174), inhibition of STAT-1 signaling in CTLs 
by tumor-specific CCR9 represents an important aspect of its immunosuppressive mechanism. 
CCR9 inhibition also led to a significant increment in the STAT-2 and slight increases in the 
STAT-5 signaling. Role of STAT2 in anti-tumor immunity, particularly in CTLs, has been 
poorly defined. However, it is reported to act along with STAT1 as a part of the heterodimer 
(175), which might explain its commensurate activation with STAT1 upon CCR9 inhibition. 
Activated STAT5 signaling, on the other hand, has been clearly shown to correlate with 
prolonged CTL survival and in vivo tumor rejection (176). Taken together, these findings 
implicate the involvement of deregulated STAT signaling as a part of CCR9’s 
immunosuppressive pathway, but whether they are causally linked to CCR9-mediated 
immunosuppression remains to be clarified. 
 
Genome-wide transcriptomics analysis in CCR9lo encountering CTLs revealed a distinct 
pattern of gene signature changes that are mediated by CCR9. Analysis revealed that CCR9-
mediated signaling events in the T cells inhibit the expression of genes involved in the gain of 
T cell effector functions (such as ITGA2, IL2RA, LTA, SOCS1, CISH); whereas on the other 
hand it upregulates genes that either inhibit effector functions (such as ID1, TOB1) or induce 
immature T cell phenotype (such as CD24, EFNA1).  
 
Integrins are α/β heterodimeric transmembrane receptors that facilitate cell-to-cell interaction 
by binding to proteins in the extra cellular matrix (such as collagen), thereby inducing a two-
way signaling cascade. Integrin alpha-2 (ITGA2 or CD49b), in heterodimeric interaction with 
integrin beta-1 (CD29), forms the VLA-2 receptor which mediates the adhesion of activated T 
lymphocytes to collagen type I in the extracellular matrix (177). VLA-2 (α2β1) signaling in T 
cells acts as a costimulatory signal and augments IFN-γ production (178). Moreover, in a 
previous study in neuroblastoma it has been demonstrated that upon cell-based vaccination 
CD49b gets upregulated on activated CD8+ T cells and that CD49bhi CTLs are far more 
effective in tumor control in vivo than the CD49blo counterparts, making CD49b expression a 
marker for superior anti-tumor effector CTLs (179). IL-2 receptor alpha (IL2RA) and IL-2 
signaling are known to be required for the differentiation of CD8+ T cells to cytotoxic 
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phenotype, as IL2RA-deficient CD8+ T cells lack peforin and granzyme B expression in vivo 
and they prematurely express the terminal memory markers CD62L and BCL6 (180). 
Interestingly, in accordance with the above report, this study also observed a downregulation 
of BCL6 transcript levels along with IL2RA upregulation in CCR9lo encountering T cells. It 
would therefore be interesting to assess whether long-term exposure to CCR9 leads to a 
premature terminal differentiation of the encountering T cells as one of the possible routes to 
abrogate effective anti-tumor immunity. Fasciculation and elongation protein zeta 1 (FEZ1) 
was also one of the top upregulated genes found in this study. It is a cytoskeletal transport 
protein that is involved in axonal guiding. Role of FEZ1 in immune effector functions has not 
been investigated before, but recent studies have linked the expression of FEZ1 in cultured 
cells to resistance against viral infection (HIV-1 and MLV) (181), as well as its expression in 
cancer is known to regulate mitosis (182). It is possible that immune synapse formation might 
require the involvement of microtubule-associated FEZ-1 in immune cells, a speculation that 
merits further investigation. Other markers which are typically associated with effector 
function or prolonged survival of T cells were also found to be upregulated in CCR9lo 
encountering T cells, for example CISH (183), LTA or TNF-beta (184), SLAMF1 (185). 
Importantly, many of these upregulated genes, such as CISH, CCND2, IL2RA, SOCS1, IL13, 
were linked to the JAK-STAT signaling pathway (analyzed via KEGG pathway mapping 
tool), which was found to be in consistence with the observed upregulation of the phospho-
STAT levels upon CCR9 knockdown. Given that many of these gene expression changes 
noted above correlate with reported enhancement in T cell functionality, it would be 
interesting to exploit them as functional markers for identifying more effective CTLs that are 
resistant against immunosuppressive tumors in clinical studies.  
 
Conversely, CCR9 inhibition in tumors resulted in the downregulation of gene signatures 
associated with immature T cell phenotype, such as KLF4 and ID1 whose expression is 
known to inhibit the T cell lineage commitment, impair the generation of functional memory 
CD8+ T cells and induce apoptosis by lowering the threshold for TCR activation (186-188). 
Additional molecules that are known to directly inhibit T cell effector responses or IL-2 
mediated signaling, such as TOB1 (189) and EFNA1 (190, 191) were also found to be 
significantly downregulated in the CCR9lo encountering CTLs. Notably, no significant 
upregulation in the transcript levels of cytolytic enzymes such as perforin or granzyme B was 
observed. However, an increase in the lytic enzyme secretion was already detected at protein 
level in the ELISpot assays 12 hours post target cell and T cell co-culture (Figure 10), which 
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is the same time-point that was used for the gene-expression analysis. So it is possible that the 
transcript upregulation for these cytolytic enzymes might have preceded the studied time-
point. Consistent with this, an increase in expression of genes that control TCR signaling was 
also noted at this time-point, such as CEACAM1 (192) and SOCS1 (193), which are generally 
expressed only in the activated T cells as a fail-safe switch to fine tune the intensity of 
immune response. 
 
Comparison of the observed gene signatures with another study performed by Wang et al 
(105), where they compared stimulated TCs to unstimulated TCs, confirmed a clear pattern of 
gene expression changes that correlated with activated T cell phenotype upon tumor-specific 
CCR9 knockdown. It is relevant to note here that in contrast to the unstimulated peripheral 
CD8+ T cells that were used as the control by Wang et al, this study made use of survivin-
specific T cells which are not entirely unstimulated as a threshold level of activation occurs 
upon encounter of wild type survivin-positive MCF7s. Therefore, a significant overlap of 
differentially regulated gene hits between both these studies might not be expected. However, 
above and beyond the threshold level of activation, it is encouraging to see many gene 
signatures overlapping that define activated T cells. Now the question remains that which 
amongst of these genes falls directly in the line of CCR9-mediated immunosuppressive 
pathway. Many of the observed changes, such as upregulation of lymphotoxins, shut-down 
signals or IL-2 signaling related genes, might very well represent the bystander effects of T 
cell activation upon CCR9 inhibition rather than the causal link for CCR9-mediated 
suppression. In this regard, it would be interesting to look at the non-overlapping genes 
between the CCR9lo treated TCs and the polyclonally stimulated TCs, which might represent 
genes that are unique to the CCR9-mediated pathway. Functional validation studies involving 
knockdown of these relevant gene hits in T cells would be essential to establish the causal link 
between tumor-specific CCR9 and induced immunosuppressive pathways in the interacting T 
cells. 
 
CCL25 (also known as thymus expressed chemokine, TECK) is a 16 kDa CC-chemokine that 
is primarily expressed in the thymic dendritic cells and mucosal epithelia (194). It serves as a 
chemoattractant for CCR9-expressing T cells to the mucosal sites. In addition, CCL25 has 
been shown to be expressed by various tumors, with expression being correlative with 
histological subtype and metastatic potential (162, 195). Inhibition of CCR9 expression in 
tumor cells was not found to modulate CCL25’s expression. This excluded the possibility of 
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an autocrine loop mechanism whereby immune-suppression mediated by CCR9 might act via 
the increase of CCL25 in the tumor-immune cell space as a result of CCR9-CCL25 signaling 
axis. However, it might still be possible that knockdown of CCR9 on the cell surface leads to 
increased bioavailability of CCL25 for the interacting T cells in the co-culture, as it is no 
longer occupied by CCR9, leading to the observed immunosuppressive effects. But to this 
end, no effect of CCR9 knockdown supernatant or CCL25 per se was observed on the 
suppression of anti-tumor T cell activity, except against melanoma cells which secreted higher 
levels of CCL25. Therefore, it might be possible that depending on the relative abundance in 
different tumor types, CCL25 might be involved in shaping the immune response, but whether 
it does so independently or in concert with CCR9 remains to be established. Although for 
CCR9 it is clear that its immunosuppressive effect is mediated by non-soluble entities that 
rather require direct cellular contact with the T cells. Additionally, this immunosuppressive 
effect also seems to be independent of the intracellular CCR9 signaling as functional blockade 
of the downstream signaling by pertussis toxin did not have any impact on the immune 
susceptibility of the treated tumor cells. In contrast, CCR9 knockdown which effectively 
reduces the surface receptor expression shows an impact.  
 
Together these findings indicate that surface bound CCR9, via its interaction with a putative 
corresponding ligand on the T cell surface, brings about the immune regulatory phenotype. 
However, since CCL25 is the only known interaction partner for CCR9 in functional 
interaction databases, speculating or predicting novel direct or downstream interaction 
partners seems tedious. It might also be possible that the effect is indirect, wherein CCR9 
regulates the expression of another tumor cell surface bound entity that in turn is responsible 
for relegating the immunosuppressive signals to the interacting T cells. Although such a 
regulation mediated by CCR9 could be effectively blocked upon long term pertussis toxin 
treatment (current protocol involved the tumor cell treatment with toxin for only 1 hour before 
their use in the cytotoxicity assays), it should be avoided as pertussis toxin is an unspecific 
GPCR blocker affecting other receptors as well. Perhaps stable CCR9 knockdown tumor 
variants could be employed to investigate the expression changes in the surface proteins upon 
CCR9 inhibition and assess if they share a causal link to CCR9-mediated suppressive effects 
on the T cells. 
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5.2.2 Synergy of CCR9 with other immune-checkpoint pathways 
Blockade of multiple immune-checkpoint molecules in several combinations is increasingly 
being tested in early clinical trials. The recently concluded anti-PD1 plus anti-CTLA4 
antibody trial has demonstrated a synergistic advantage (more than 40% objective response 
rate) of simultaneously targeting multiple immune-checkpoint molecules (70). In this thesis 
also, synergistic blockade of CCR9-mediated immunosuppressive pathway with other 
immune-checkpoint molecules was explored. Co-inhibition of PD-L1 or CEACAM-6 with 
CCR9 resulted in no additive effect upon T cell mediated tumor lysis, however each of these 
targets in themselves induced a strong suppression on CTL’s effector function. In this regard, 
it is interesting to note that PI3K-Akt and mTOR-S6K1 pathway has been shown to regulate 
PD-L1’s expression in APCs (196), melanoma (197), breast and prostate cancer (198). 
Inhibition of these pathways leads to a strong downregulation of PD-L1 expression (197, 
198). Interestingly, CCR9 knockdown in MCF7 breast tumor cells led to a significant 
decrease in the activation of the S6 kinase pathway as well as of the Akt pathway, which was 
in accordance with a previous study showing that CCR9 mediates PI3K/Akt-dependent 
signaling cascade in prostate cancer cells (199). Therefore, it is possible that CCR9 inhibition 
leads to the downregulation of PD-L1 expression on tumor cells via the PI3K-AKT-mTOR-
S6K pathway, thereby making them insensitive to PD-L1 blockade which might explain the 
lack of synergy between the two blockade therapies. An additional attribute of Akt activation 
upon CCR9 signaling that is worth mentioning is that tumor cells with higher, constitutive 
Akt activation have been shown to be more immune-resistant towards CTL-mediated lysis 
(200). Therefore, CCR9 inhibition on tumor cells might work partly by interfering with Akt 
activation and subsequently sensitizing them to immune destruction, although further 
experimental validation of any direct links between CCR9 expression, AKT activation and 
immune response are currently required. Similarly, possible mode of co-regulation of 
CEACAM-6 and CCR9 expression also needs to be further explored.  
 
In this regard, it is relevant to note the findings from a recently published screening strategy 
which utilized pooled shRNA library for gene knockdowns in OT-I mouse T cells to assess 
the impact on their accumulation in the tumor of B16-Ova-bearing mice (201). Such a screen 
revealed interesting immune inhibitory targets on the T cell side whose knockdown facilitated 
the proliferation and accumulation of reactive T cells in the tumor microenvironment. 
However, gene expression analysis revealed that out of the five candidate genes studied, none 
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of them induced a similar gene expression signature in the reactive TILs, indicating that 
overall enhanced TIL reactivity can be achieved via multiple and more likely complex 
intracellular routes. A deeper understanding of the underlying mechanisms of immune-
checkpoint pathways therefore becomes necessary for rationale designing of combinatorial 
therapies. The reported screening strategy on T cells investigated and thereby enriched gene 
knockdowns that facilitated prolonged T cell survival since the readout was based on the 
detection of shRNA barcodes in tumor-infiltrating T cell populations after a period of time. 
However, it is to be noted that prolonged survival, which might also result from knocking 
down cell cycle checkpoints, does not necessarily represent a gain in effector T cell function 
or better tumor control and therefore the reported hits must be carefully validated to assess 
true immune-checkpoint entities. 
5.2.3 In vivo relevance of CCR9 inhibition on anti-tumor immunity 
Therapeutic translation of new drug targets requires the proof-of-principle studies in pre-
clinical mouse or animal model systems to show their relative effectiveness and anticipated 
clinical outcome. Various mouse model systems for studying cancer exist, including the 
xenograft model system whereby human tumors (either established cell line or fresh patient-
derived primary tumors) can be implanted (orthotropically or heterotropically) in an 
immunodeficient mice. Although the lack of the immune system provides an unreal tumour 
microenvironment in these mice, the xenograft model system is time and cost effective 
allowing for simple and rapid assessment of response of patient-derived tumors to therapeutic 
regimen (202). For xenografting of human tumors into the recipient mouse host, several types 
of immunodeficient mice have been used. Athymic nude mice lack the T cell compartment 
but retain functional B cells and other immune cells which might interfere with tumor growth. 
On the other hand, nonobese diabetic/ severe combined immunodeficient (NOD/SCID) mice 
lack both T and B cell function and are therefore widely used for xenograft experiments. 
However, they overcompensate for this lack by increase in NK cell and macrophage activity 
which should be taken into account especially when interpreting the efficacy of adoptive 
immune cell-based therapy in this model system. Additional null mutation in the interleukin 2 
receptor gamma chain (Il2rg) gene of the NOD/SCID mice results in the most 
immunodeficient mice strain, called as NOD/scid gamma or NSG mice, which lacks 
functional T, B and NK cell compartment (203).  
 
Discussion 
Page 108 
 
To assess whether tumor-specific CCR9 expression interferes with and suppresses the anti-
tumor reactivity of the adoptively transferred T cells, immunodeficient NSG mice were used 
for transplantation of CCR9+ve or CCR9-ve human PANC-1 pancreatic cancer cell line and 
subsequently treated with adoptive transfer of pancreatic patient-derived TIL 53 cells. Given 
the highly immunosuppressive environment of pancreatic tumors and the exhausted state of 
the patient-derived TIL 53 cells that showed poor anti-tumor cytotoxicity in vitro, testing 
CCR9 inhibition in this setting in vivo to reactivate the anti-tumor response in TIL 53 
transferred mice constitutes the litmus test for the strength of CCR9-based therapeutics. 
Bioluminescent in vivo imaging was used for monitoring the tumor growth in mice. Besides 
early detection of small or slow growing tumors, bioluminescent imaging also reduces any 
user-based biases in tumor measurement, exhibits minimal background luminescence from 
animal tissue and embodies the 3R principle of ethical animal work by allowing non-invasive 
and frequent in vivo imaging of animals (204). To minimize inter-mouse variability, 
CCR9+ve and -ve PANC-1-luc cells were xenografted into the right and left flank of the same 
mice, respectively, thereby also effectively reducing the number of animals per test group to 
half while keeping the statistically relevant sample size. Given the high sensitivity of the 
bioluminescent imaging system, one should be aware of the possibility of signal saturation at 
later time points when tumors have grown out in size which could make comparisons between 
the test groups difficult. 
 
Adoptive transfer of pancreatic human TIL 53 cells into tumor-bearing immunodeficient mice 
led to significantly delayed growth of CCR9-ve tumors compared to the CCR9+ve PANC-1 
tumors, especially in the early stages. Anti-tumor reactivity of the transferred TILs could only 
be observed in the CCR9-ve tumors compared to the CCR9+ve tumors during this period. 
This goes in parallel with the observed poor cytotoxic capacity of TIL 53 in the in vitro assays 
whereby basal lysis of CCR9+ve PANC-1 cells was observed at maximum of 10-20% which 
effectively doubled upon CCR9 inhibition. However, the in vivo delay in tumor growth upon 
CCR9 inhibition was also noted in the non-TIL treated animal group, indicating that stable 
knockdown of CCR9 itself retards tumor growth. CCR9-mediated signaling in PANC-1 cells 
has been shown to be important for cell survival (160), possibly involving the downstream 
activation of the PI3K-Akt signaling pathway as shown in the prostate cancer cells before 
(199). This goes in parallel with the findings of this thesis whereby involvement of the Akt 
pathway in CCR9-mediated signaling was observed in the MCF7 breast cancer cells. 
Therefore, it is possible that the in vivo delay of PANC-1 tumors upon long-term inhibition of 
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CCR9 might result from defects in the PI3K-Akt pathway. The extent of CCR9’s contribution 
to this pathway and the reliance of different tumor types, such as melanoma or beast tumors, 
on this pathway for survival is still not clearly known. Preliminary studies in our laboratory 
using xenotransplantation of control or CCR9 knockdown variants of M579 melanoma cells 
in NSG mice indicated no difference in tumor growth kinetics between the two cell types 
when followed until day 35 after tumor injection. Perhaps, the melanoma xenotransplant 
system, where no growth disadvantage is conferred to tumor cells upon CCR9 inhibition, 
would be a better model to uncouple the immunosuppressive function of CCR9 from its 
proliferative function and therefore could be used to independently assess the significance of 
CCR9 as an immunomodulatory target for adoptive cellular therapy. On the other hand, 
functional blocking antibody against CCR9, which hinders its interaction with the putative 
immunosuppressive interacting partner on the T cell without disrupting its intracellular 
signaling cascade, might be a better tool to inhibit CCR9’s immunosuppressive function than 
the gene knockdown strategy. Commercially available functional blocking antibodies against 
CCR9 have so far failed to elicit immune-activating response on T cells, stressing the need for 
undertaking hybridoma panning approach to generate and test multiple antibody clones for the 
desired effect. Notably, small molecule inhibitors for CCR9 developed by ChemoCentryx 
(Vercirnon/CCX282 and CCX8037) are been clinically tested in phase III trials for 
inflammatory bowel disease to inhibit the trafficking of CCR9+ IELs to the inflamed bowels 
(205, 206). These small molecule antagonists could additionally be tested for their potential to 
inhibit immunosuppressive role of tumor-associated CCR9 in the pre-clinical mouse models.  
 
Interestingly, injected TILs could be detected in the spleen and tumors of the treated mice, 
although at low frequency, even at 26th day after the last TIL injection. This was observed 
without any co-administration of cytokines, such as IL-2 or IL-15, which are generally 
employed in adoptive T cell transfer therapies to facilitate longer persistence of T cells (207, 
208). Systemic administration of IL-2 must be cautiously employed in CCR9 inhibition-based 
therapies as IL-2 and IL-4 have been shown to trigger the internalization of the CCR9 
receptor in MOLT-4 human leukemia T cell line (209). Given that central memory T cells 
(TCM), defined as CD62L+ CCR7+, are known to proliferate and persist longer in vivo upon 
adoptive transfer compared to the effector memory T cells (TEM; CD62L
- CCR7-), it would be 
pertinent to assess the phenotype of the transferred TILs before and after adoptive transfer 
(210). Selective migration of the T cells to CCR9+ve or CCR9-ve tumors was not observed 
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when assessed at d35, indicating that both the tumors were equally susceptible to immune 
infiltrate. However, the number of mice was too less to get statistical significance between the 
two groups and should be thus replicated with larger cohorts. Additionally, time course 
kinetic needs to be performed to assess whether more TILs infiltrate CCR9-ve tumor during 
the earlier time-points after adoptive T cell transfer, given that a starker difference in tumor 
growth is observed during the early stages. It would be even more interesting to evaluate and 
compare the exhaustion status (via PD-1, TIM-3 staining) and effector functions (IL-2 and 
IFN-γ secretion capacity, CD107a degranulation marker) of the T cells infiltrating the 
CCR9+ve and CCR9-ve tumors in a time-course based study and to compare this with the 
observed tumor regression profile. Even though PANC-1 tumor cells and adoptively 
transferred TIL 53 immune cells were HLA-matched, one cannot completely exclude the 
possibility of allogenic T cell reactivity in this non-autologus system. Use of PDX tumor 
models with tumor and TIL cultures derived from the same patient could address this issue. 
Nevertheless, the single preliminary in vivo experiment presented here needs to be repeated to 
get more meaningful insights into the relevance of CCR9 as a tumor immune suppressor. 
  
Further development of CCR9 as an immunotherapeutic target for cancer treatment would 
require toxicological analysis based on the CCR9 knockout mouse model. Besides reduction 
in the γδ IELs, CCR9 knockout mouse has been reported to show no adverse side effects 
(159). However, given that CCR9 is important for the homing of effector T cells to the gut, 
systemic targeting of CCR9 would be a contraindication for gut-associated tumors. On the 
other hand, CCR9 was found to be expressed on only a small minority of survivin-specific T 
cells (~ 6%) and was undetectable on peripheral blood TCs from healthy donors. Its 
expression in other immune cell subsets and that on healthy tissue remains to be examined.  
5.3 Identification of tumor-associated immune activators by the RNAi screen 
This study primarily focused on the validation of tumor-associated negative immune 
regulators that were identified as a result of the screening strategy. An equally interesting and 
opposite side of the same coin is the discovery of the positive immune regulators from the 
high-throughput screen, such as CXC-chemokine ligand 9 (CXCL9 or MIG) that facilitate 
anti-tumor activity of the CTLs. CXCL9 is an IFN-γ-inducible T cell chemoattractant that 
binds to the chemokine receptor CXCR3 (211). CXCL9 deficient tumors, as well as CXCL9 
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knockout mice, have been reported to inhibit the activation of tumor-reactive T cells (212, 
213). Moreover, tumor-specific expression of CXCL9 has been reported to correlate with 
higher immune (CD8+ T cell) infiltrate and better prognosis in the colorectal cancer patients 
(214). Identification of such established immune activators lends support to the use of this 
screening approach for further identification of similar tumor-associated ligands that are vital 
for anti-tumor immunity. Along this line, GRM4 and GRK5 were found to be positively 
associated with the anti-tumor immunity in all the three screens.  
 
GRM4 or metabotropic glutamate receptor 4 (mGluR4) is one of the eight receptors belonging 
to the glutamate receptor family that binds to L-glutamate, a neurotransmitter, which leads to 
the inhibition of the cyclic AMP cascade. Expression of GRM4 has been reported in non-
neuronal tissues recently whereby normal epithelia of the upper respiratory tract, 
gastrointestinal tracts, breast, uterine cervix, urinary bladder and skin show GRM4 expression 
whereas thyroid, lung alveoli, liver, testis or prostate lacked any expression (215). 
Correspondingly, GRM4 expression has also been reported in colorectal cancer, malignant 
melanoma, laryngeal carcinoma and breast cancer, although expression was found to be 
associated with poor survival in CRC patients (215). Role of GRM4 in anti-tumor immunity 
has not been studied so far. However, by using GRM4-/- mice, investigators working on 
autoimmune encephalomyelitis have shown that the expression of GRM4 on conventional 
DCs is important for the IFN-γ and IL-2 secretion by WT CD4 T cells upon stimulation (216). 
Further experimental validations of the role of tumor-specific expression of GRM4 on 
effector functions of antigen-specific T cells will be necessary in order to shed more light on 
the matter. 
 
G protein-coupled receptor kinase 5 (GRK5) is a serine/threonine kinase that phosphorylates 
and deactivates GPCRs by allowing the binding of arrestin proteins that block receptors from 
activating downstream G protein pathways (217). Besides the regulation of GPCR activity, 
GRK5 has also been demonstrated to phosphorylate p53 transcription factor, inhibiting p53-
mediated apoptotic pathway (218). Lately it has also been shown to positively regulate the 
NF-kB signaling pathway by phosphorylating IκBα (inhibitory kB; which binds to and 
represses NK-kB in the cytoplasm) leading to the release of NF-kB transcription complex and 
subsequent activation of the NF-kB pathway (219). Interestingly, activated NF-kB in lung 
tumors of mice has been shown to orchestrate T-cell mediated rejection of immunogenic 
tumors and a similar correlation between the lung tumor NF-kB activity and the T cell 
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infiltration has been documented in patient tumor samples (220). Whether this activation of 
the NF-kB activity in tumor samples, which correlates with an enhanced immune 
surveillance, is dependent on GRK5 remains to be examined.  
 
Further investigations into the role and mechanism of such newly discovered immune-
activating ligands and their counterparts on the T cell side would be essential to exploit them 
as potentially suitable targets for agnostic antibody-based therapy in order to stimulate the 
anti-tumor immune surveillance in patients. 
5.4 Outlook 
In this thesis a screening methodology for uncovering novel immune modulators expressed by 
MCF7 breast tumor cell lines has been described. Given that tumors are heterogeneous, even 
in their expression of immune modulatory candidates, it would be essential to extend the 
screening approach to other tumor entities in order to identify overlapping as well as unique 
immunosuppressive signatures amongst different tumor types. As described in section 4.22, 
preliminary ground work has been laid down for replicating the screen in colorectal cancer 
using SW480 as the target cell line. Furthermore, application of the Luc-CTL assay to 
uncover immune-modulatome in metastatic melanoma and pancreatic carcinoma have been 
undertaken in our laboratory by Tillmann Michels and Antonio Sorrentino, respectively, 
under my supervision. To adapt the screen as close to the patient setting as possible, tumor 
infiltrating lymphocyte cultures, established from melanoma and pancreatic cancer patients 
(TIL 412 and TIL 53 from the respective tumor types; described in section 4.11 and 4.12), 
were used as effector cells in the RNAi screen. TILs, which directly encounter the 
immunosuppressive tumor microenvironment, represent one of the best suited models for 
studying the dependency of T cell’s cytotoxic capacity in response to tumor-specific 
expression of immune modulators. In a step further, primary melanoma cell cultures have 
been established from resected tumor of syngeneic patient and used as targets cells for the 
melanoma screen. Using siRNA libraries enriched in surface receptors and kinases that 
covered a total of 2800 gene targets, both the screens have identified a range of novel 
immunomodulatory candidates along with the well-reported immunosuppressors, such as 
JAK2 (103) and LPA (221), lending strength to the sensitivity and the detection capacity of 
the screening approach. Furthermore, CCR9 popped up as a strongly immunosuppressive hit 
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in the melanoma screen as well, while in-depth analysis of the pancreatic cancer screen is 
currently underway. Further functional validations of the novel candidate genes identified 
from both the screens are required and is being actively pursued. 
  
Systematic dissection of the rather complex immune regulatory circuit mediated by different 
tumor types offers a great promise for therapeutic translation. The possibility and feasibility 
of using patient-derived pairs of primary tumor and T cells for immune-modulatome 
screening ushers this approach to the frontline of personalized medicine. In such a setting, 
tumor samples from a post-operative patient could be screened for relevant 
immunosuppressors which affect patient-specific anti-tumor immune response and these 
could then be targeted clinically to induce durable and protective responses in the patients. 
Nevertheless, increased immune reactivity upon checkpoint blockade requires a pre-existing 
immune response. Therefore, combining checkpoint blockade with immune response-
inducing therapies, such as vaccination strategies, chemotherapy or radiotherapy that facilitate 
the mounting of T cell responses, would be an effective way for future treatments. Homing of 
the effector T cells to the tumor site might be improved by employing gene modified T cells 
(such as chimeric antigen receptor bearing T cells or CART cells expressing homing 
chemokine receptors) that are especially equipped to migrate to the tumor niche. Toxicities, 
which might be a limiting factor for the success of such immune-stimulatory approaches, 
might be restricted by considering local administration over systemic therapy, as has been 
demonstrated in the case of anti-CTLA4 antibody to control autoimmunity (222). Based on 
the above rationales, multi-combinatorial trials employing a cocktail of different therapeutic 
options are currently being tested with great vigor to maximize the therapeutic advantage for 
the patients.  
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Concluding remarks 
 
Despite the capacity of the immune system to recognize and eliminate cancerous cells, 
effective immunotherapy based on the adoptive transfer of reactive T cells is opposed by the 
immunosuppressive interactions between the tumor and the T cells. Findings from the 
presented thesis have added to the functional characterization of the immunosuppressive 
nature of the tumor cells by establishing an immune function-based RNAi screen that 
systematically uncovers the repertoire of immune modulatory surface ligands on the tumor 
cells. This could serve as a great diagnostic tool for identifying patients that are best suited to 
benefit from a particular checkpoint blockade therapy or a cocktail of it thereof based on the 
expression of the repertoire of checkpoint candidates identified as a result of this screening 
system. Personalized immune screening in the future for tumor immune modulators could be 
employed to rapidly assess the patient-specific immune-modulatome before devising 
immunotherapeutic treatment strategies. As a proof-of-principle of the screening 
methodology, the novel involvement of CCR9 - one of the top hits identified from the 
screening approach - in mediating immune suppression via differential regulation of the 
STAT pathways in antigen-experienced T cells is highlighted in this study. Given that CCR9 
is well reported to be involved in cancer metastasis and in some instances tumor growth, 
targeting it clinically would mean hitting three birds with one stone: tumor growth, tumor 
metastasis and immune-resistance, making it an attractive target for further clinical and 
pharmaceutical investigations.  
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7. Appendix 
Supplementary Table 1: Lethal siRNAs used as viability controls with reported function of their targeted genes 
siRNA Target Function 
COPB2 
Constitutes the coat of nonclathrin-coated vesicles and is essential for Golgi budding, 
vesicular trafficking. 
PLK1 
Serine/threonine-protein kinase that regulates centrosome maturation and spindle 
assembly. 
UBC 
Polyubiquitin precursor, involved in DNA repair, cell-cycle regulation, protein 
degradation. 
CHK1 Required for checkpoint mediated cell cycle arrest in response to DNA damage. 
ELMO2 Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells. 
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Supplementary Figure 1. Filtered hit-list of candidate immune modulatory genes identified from the RNAi 
screen. Genes that satisfied the screen-specific threshold criteria (detailed in text and methods) for the toxicity 
and the viability values in two screens or more were shortlisted and the sum of their loess differential score in all 
three screens was calculated. Based on this sum, genes were ranked for their immunomodulatory strength and 
defined as negative (Σloess>2.0) or positive (Σloess<-3.3) immune regulatory candidates. The individual loess 
scores of the shortlisted candidate genes across the three different screen setups are represented herein as 
heatmaps. Note the difference in the coloring scales of the individual heatmaps used for highlighting the relative 
performance of candidate genes across the three setups. 
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8. Abbreviations and definitions 
 
%  percentage 
~  approximately 
°C  degree celsius 
51Cr  radioactive chromium 
isotope 51 
7-AAD 7-amino actinomycin D 
AB  human serum type AB 
ACK  ammonium chloride 
potassium phosphate 
APC  antigen presenting cell 
ATCC  American Type Culture 
Collection 
BCECF  2',7'-bis-(2-carboxyethyl)-5-
(and-6)-carboxyfluorescein 
BD  Becton Dickinson 
bp(s)  base pair(s) 
BSA  bovine serum albumin 
bsAb bi-specific antibody 
Ca2+  calcium 
CCL25  chemokine (C-C motif) 
ligand 25 
CCR9  chemokine (C-C motif) 
receptor 9 
CD  cluster of differentiation 
cDNA complementary DNA 
CEACAM  carcinoembryonic antigen 
related cell adhesion 
molecule 
CFSE carboxyfluorescein 
succinimidyl ester 
CISH cytokine inducible SH2-
containing protein 
CLM  complete lymphoma 
medium 
cm2  square centimeter 
CO2  carbon dioxide 
CTG CellTiter-Glo 
CTL(s)  cytotoxic T cell(s) 
CTLA-4  cytotoxic T lymphocyte 
associated antigen 4 
d  day(s) 
DC  dendritic cells 
ddH2O  double distilled water 
DKFZ  German Cancer Research 
Center 
DMEM  dulbecco's modified Eagle's 
medium 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
DTT  dithiothreitol 
E. coli  Escherichia coli 
E:T  effector to target ratio 
ECL  enhanced chemiluninescent 
EDTA  ethylenediaminetetraacetic 
acid 
EFNA1 ephrin-A1 
EGFP  enhanced green fluorescent 
protein 
ELISpot  enzyme-linked immunospot 
assay 
env  envelope proteins gene 
EpCAM  epithelial cell adhesion 
molecule 
et al.  Latin “et alii”, - “and others” 
FACS  fluorescence activated cell 
sorting/flow cytometry 
FCS  fetal calf serum 
FDA  Food and Drug 
Administration 
Fluc  firefly luciferase 
Foxp3  forkhead box P3 
g  gram(s) 
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G protein  guanosine nucleotide 
binding proteins 
G418  geneticin sulfate 
gag  group antigens gene 
GM-CSF  granulocyte macrophage 
colony-stimulating factor 
gp100  glycoprotein 100 
GPCR  G protein-coupled receptor 
h  hour(s) 
HEPES  2-[4-(2-
hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid 
HLA-A2  human leukocyte antigen A2 
HRP  horseradish peroxidase 
HRP  horseradish peroxidase 
hu  human 
i.v.  intraveneous 
ID1 inhibitor of DNA binding 1 
IDO  indoleamine 2,3 
dioxygenase 
IFN  interferon 
IgG  immunoglobulin G 
IL  interleukin 
IL2RA Interleukin-2 receptor alpha 
ITGA2 integrin, alpha 2 
IVC  individually ventilated cages 
kb  kilobase 
kd  knockdown 
kDa  kilodalton 
L  liter 
LAG3  lymphocyte-activation gene 
3 
LTA Lymphotoxin alpha 
luc  luciferase 
M  molar 
mA  milliampere 
mAb(s)  monoclonal antibody(ies) 
MART-1  melanocytic differentiation 
antigen 
MDSC  myeloid-derived suppressor 
cells 
mg  milligram 
Mg2+  magnesium 
MHC  major histocompatibility 
complex 
min  minute(s) 
miRNA micro-RNA 
ml  milliliter 
mm  millimeter 
mM  millimolar 
mRNA  messanger RNA 
MUH 4-Methylumbelliferyl 
heptanoate 
n  number 
NEAA  non-essential amino acid 
NF-kB nuclear factor 'kappa-light-
chain-enhancer "of activated 
B-cells) 
NK  natural killer 
nm  nanometer 
NOD  non-obese diabetic 
ns  not significant 
NSG  NOD scid gamma 
nt  nucleotides 
OKT-3  Muromonab-CD3 
p  p-value 
P/S  penicillin/streptomycin 
PAGE  polyacrylamide gel 
electrophoresis 
PBMC  peripheral blood 
mononuclear cells 
PBS  phosphate buffered saline 
PBS-T  PBS-Tween 
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PCR  polymerase chain reaction 
PD-1  programmed cell death 1 
PD-L1  programmed cell death 1 
ligand 1 
PerCPCy5.5 
5.5 
peridinin-
chlorophyllprotein- 
complex-cyanine 
pH  Latin “potentia hydrogenii” 
pol  reverse transcriptase, RNase 
H and integrase gene 
PTX pertussis toxin 
PVDF  polyvinylidene difluoride 
r  recombinant 
RFP  red fluorescent protein 
RLU  relative luminescence units 
RNA  ribonucleic acid 
RNAi RNA interference 
rpm  rounds per minute 
RPMI  Roswell park memorial 
institute 
RT  room temperature 
s.c.  subcutaneous 
S.O.C. super optimal broth medium 
with catabolite repression 
SCID  severe combined 
immunedeficient 
SDS  sodium dodecyl sulfate 
SEM  standard error of the mean 
shRNA  short hairpin RNA 
siRNA  small interfering RNA 
SOCS1 suppressor of cytokine 
signaling 1 
STAT signal transducers and 
activators of transcription 
TAE  Tris-Acetate-EDTA 
TAP  transporter associated with 
antigen processing 
TCR  T cell receptor 
TH1  T helper type-I 
TIL(s)  tumor infiltrating 
lymphocyte(s) 
TOB1 transducer of ERBB2, 1 
TRAIL  TNF-related apoptosis 
inducing ligand 
Treg  regulatory T cells 
U  unit 
UV  ultraviolet 
V  volt 
VEGF  vascular endothelial growth 
factor 
VSV-G  vesicular stomatitis indiana 
virus-G protein 
w/v  weight/volume 
WB  western blot 
WHO  World Health Organization 
wt  wild type 
X  x-fold 
α  alpha 
β  beta 
γ  gamma 
µg  microgram 
µm  micrometer 
 
